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Abstract 
 
The role of the Aurora B kinase in mediating cellular functions outside 
mitosis was investigated. A SILAC-based approach was used to show that 
Aurora B interacts with proteins implicated in gene regulation and chromatin 
organization in G1 activated B cells. Among these interactors, I identified the 
PRC1 component Ring1B as a new partner of Aurora B. Both proteins are bound 
to the promoters of highly expressed genes in resting B and T lymphocytes. 
Quiescent resting B cells require the maintenance of a transcriptional programme 
that keeps the cells viable and ready to proliferate upon encounter with a specific 
antigen. Aurora B and Ring1B physically co-occupy the same promoters in 
resting B cells but, upon activation, Aurora B is replaced by MSK1 on its target 
genes, whereas Ring1B binding is preserved.  
Analysis of the active promoters in resting B cells shows that other PRC1 
components, such as Cbx7 and Bmi1, and the histone deubiquitinase USP16, 
together with Aurora B and Ring1B, bind almost exclusively to the regulatory 
elements of active promoters and are not found at repressed genes. Binding of 
PRC2 components and deposition of the H3K27me3 and H2Aubq marks are 
largely confined to silent genes. By employing conditional knockout mouse 
models, I showed that removal of either Aurora B or Ring1B results in a global 
reduction in the binding of unphosphorylated and serine 5-phosphorylated RNA 
Polymerase II to active promoters. This phenomenon is also accompanied by a 
reduction in the production of transcripts from Aurora B and Ring1B target genes 
and reduced cell viability. Aurora B is also required to maintain high levels of 
phosphorylated H3S28 and low levels of the repressive H2Aubq mark at active 
promoters. These results identify a new role for both Aurora B and Ring1B in the 
regulation of active transcription in quiescent lymphocytes. 
  5 
 
List of Contents 
Declaration of originality 2 
Copyright Declaration 3 
Abstract 4 
List of Contents 5 
List of Figures 12 
List of Tables 16 
Supplementary Tables 17 
Abbreviations 18 
Acknowledgements 29 
Chapter 1 - Introduction 30 
1.1 Overview 30 
1.2 Quiescence 30 
1.2.1 Quiescence as an adaptive mechanism 30 
1.2.2 Quiescence as a developmental stage 33 
1.2.3 The requirements for resting lymphocytes survival 34 
1.2.4 The molecular mechanisms of cell cycle progression and exit 38 
1.2.5 Irreversible exit from the cell cycle: senescence and terminal differentiation 43 
1.3 The development of mouse B and T lymphocytes 46 
1.3.1 From Hematopoietic stem cell to lymphoid progenitors 46 
1.3.2 Early B cell development 47 
1.3.3 Immunoglobulin rearrangement 48 
1.3.4 B cell maturation 49 
1.3.5 Organisation and functions of the spleen 50 
1.3.6 T-dependent B cell activation and development 53 
  6 
1.3.7 T-independent B cell activation and development 55 
1.3.8 T cell development 55 
1.3.9 CD4+ activation and development 59 
1.3.10 Development of CD8+ T cells 63 
1.4 Transcriptional regulation 64 
1.4.1 Regulatory elements 64 
a. Core Promoters 65 
b. Proximal promoters 67 
c. Enhancers 68 
d. Silencers 69 
e. Insulators 70 
f. Locus control regions 70 
1.4.2 The regulation of RNA Pol II at promoters 71 
a. RNA Pol II recruitment 71 
b. Promoter escape and the phosphorylation of RNA Pol II on serine 5 74 
c. Phosphorylation of RNA Pol II on serine 7 75 
d. Transcriptional pausing 75 
e. Transcriptional elongation and phosphorylation of RNA Pol II on serine 2 77 
1.4.3 Chromatin conformation and transcriptional regulation 78 
a. Spatial organization of the DNA in higher eukaryotes 78 
b. Chromatin remodelling 82 
c. Histone variants 83 
i) Histone H3.3 85 
ii) Histone H2A.Z 86 
d. Post-translational modification of histones 87 
i) Histone acetylation 89 
ii) Histone methylation 90 
iii) Histone phosphorylation 92 
iv) Histone ubiquitination 94 
1.5 The Aurora B kinase 96 
1.5.1 Regulation of Aurora B 98 
  7 
1.5.2 Aurora B and chromosome compaction 101 
1.5.3 Aurora B and sister chromatid segregation 102 
1.5.4 Aurora B and cytokinesis 105 
1.5.5 Aurora B and cell cycle regulation 106 
1.5.6 Aurora B and gene regulation 107 
1.5.7 The role of Aurora B in cancer 108 
1.6 Polycomb group proteins 109 
1.6.1 Ezh1/2: the catalytic subunit of PRC2 112 
1.6.2 PRC2 core components and additional interactors 114 
1.6.3 The PRC1 family of polycomb complexes 115 
1.6.4 The role of Ring1A and B in PRC1 activity 116 
1.6.5 PCGF proteins regulate Ring1B activity 118 
1.6.6 Cbx proteins define different PRC1 complexes 120 
1.6.7 Recruitment and role of PRC1 121 
1.6.8 Non-canonical PRC1 complexes 122 
1.6.9 The role of PcG proteins in cancer 123 
1.7 Aim of the study 124 
Chapter 2 - Materials and methods 126 
2.1 Cell culture 126 
2.1.1 B cell isolation 126 
2.1.2 T cell isolation 127 
2.1.3 Conditional knockout mice 127 
2.2 Counterflow Centrifugal Elutriation 128 
2.3 FACS analyses 129 
2.3.1 Propidium iodide staining 129 
2.3.2 Cell surface markers staining 129 
2.4 Chromatin immunoprecipitation (ChIP) 129 
2.4.1 Chromatin preparation 129 
2.4.2 Immunoprecipitation 130 
2.4.3 DNA quantification and quantitative real-time polymerase chain reaction 132 
  8 
2.4.4 Sequential ChIP (ReChIP) 133 
2.5 ChIP-sequencing (ChIP-seq) 134 
2.5.1 Library preparation 134 
2.5.2 Data analysis 135 
2.5.3 Density plot generation 135 
2.5.4 Line plot generation 136 
2.6 Transcriptional analysis 136 
2.6.1 Spike-in RNA preparation 136 
2.6.2 Total RNA extraction and cDNA preparation 137 
2.6.3 RNA quantification 138 
2.7 mRNA-sequencing (mRNA-seq) 138 
2.7.1 Library preparation 138 
2.7.2 Data analysis and quantification 139 
2.8 Proteomics 139 
2.8.1 Protein extraction and western blotting 139 
2.8.2 Protein co-immunoprecipitation 140 
2.8.3 Calcium phosphate transfection 141 
2.8.4 Cell labelling for SILAC 141 
2.8.5 Sample preparation for LC-MS/MS analysis 142 
2.8.6 Mass spectrometry analysis and data processing 143 
Chapter 3 - Identification of new partners of Aurora B outside mitosis 148 
3.1 Introduction 148 
3.2 Isolation of G1 activated B cells by counter-flow centrifugal elutriation 149 
3.3 Indirect SILAC-based determination of Aurora B partners in G1 150 
3.3.1 Introduction to SILAC 150 
3.3.2 Use of an internal standard to perform quantitative mass spec analyses in 
primary cells 151 
3.4 Quantitative analysis of the partners of Aurora B in G1-elutriated, LPS-activated B 
cells 153 
3.5 Validation of the Aurora B-Ring1B interaction 157 
  9 
3.6 Summary 159 
Chapter 4 - Aurora B and Ring1B bind to the regulatory elements of active genes 
in resting lymphocytes 161 
4.1 Introduction 161 
4.2 Aurora B and Ring1B bind to the promoters of active genes in quiescent B cells
 161 
4.3 Genes bound by Aurora B and Ring1B in quiescent B cells are transcribed rather 
than poised 165 
4.4 Aurora B binding is lost upon B cell activation 166 
4.5 Distribution of Ring1B in quiescent and activated B cells 168 
4.6 Cbx7 and Bmi1 both colocalise with Ring1B in quiescent cells but exhibit divergent 
behaviours following activation 169 
4.7 H2A ubiquitination marks silent genes and does not co-localize with PRC1 
components in quiescent and activated B cells 172 
4.8 The histone H2A deubiquitinase USP16 is present at Aurora B target genes and is 
displaced following B cell activation 173 
4.9 Aurora B and Ring1B co-occupy the same promoters 175 
4.10 Aurora B and Ring1B bind to active genes in quiescent resting T cells 177 
4.11 Genome-wide analysis of the distribution of Aurora B and Ring1B in quiescent B 
cells 179 
4.11.1 Quantification of absolute expression levels in resting and activated B cells
 179 
4.11.2 Aurora B and Ring1B bind to the promoters and enhancers of active genes
 181 
4.12 Genome-wide distribution of other key factors in quiescent B cells 186 
4.12.1 Genome-wide analysis of the distribution of the histone variant H2A.Z 186 
4.12.2 Genome-wide analysis of the distribution of Ezh2 and the histone mark 
H3K27me3 187 
4.12.3 Genome-wide analysis of the distribution of Cbx7 188 
4.12.4 Genome-wide analysis of the distribution of USP16 189 
  10 
4.13 Summary 189 
Chapter 5 - Aurora B and Ring1B are involved in regulating transcription in 
quiescent lymphocytes 191 
5.1 Introduction 191 
5.2 Use of conditional knockout models to study of the functions of Aurora B and 
Ring1B in resting lymphocytes 191 
5.2.1 Aurora B cKO system 191 
5.2.2 Ring1B cKO system 192 
5.2.3 Validation of the Aurora B and Ring1B ChIP-seq libraries 193 
5.3 Aurora B promotes transcription of target genes in quiescent lymphocytes 196 
5.4 Ring1B cKO results in reduced transcription of target genes in quiescent B cells
 199 
5.5 Aurora B and Ring1B cKO resting T cells display reduced transcription of target 
genes 201 
5.6 Aurora B and Ring1B cKOʼs affect different steps in the RNA Pol II cycle at the 
promoter of active target genes 203 
5.6.1 Aurora B regulates the levels of S5p Pol II at target genes 203 
5.6.2 Ring1B cKO resting B cells have reduced levels of RNA Pol II at target genes
 205 
5.6.3 Genome-wide effect of Aurora B and Ring1B cKOʼs on binding of 
unphosphorylated and serine 5-phosphorylated RNA Pol II 207 
5.7 The knockouts of Aurora B or Ring1B reduce the viability but not the 
responsiveness of quiescent lymphocytes to activating stimuli 209 
5.8 Summary 213 
Chapter 6 - Aurora B phosphorylates histone H3S28 and modulates Ring1B-
mediated H2A ubiquitination at active promoters 214 
6.1 Introduction 214 
6.2 Aurora B controls phosphorylation of histone H3S28 at active promoters 214 
6.3 Aurora B regulates the levels of H2A ubiquitination at active promoters 217 
  11 
6.3.1 Loss of Aurora B is accompanied by acquisition of the H2Aubq mark at 
promoters 217 
6.3.2 USP16 binding to promoters is lost following knockout of Aurora B 218 
6.3.3 Binding and composition of PRC1 at active promoters is independent of the 
presence of Aurora B or USP16 220 
6.3 MSK1 replaces Aurora B on active promoters after B cell activation 222 
6.3.1 B cell-activation induces a rapid exchange of Aurora B with MSK1 at 
transcriptionally active promoters 222 
6.3.2 MSK1 recruitment following stimulation with LPS is independent of the 
presence of Aurora B 226 
6.4 Summary 227 
Chapter 7 - Discussion 229 
7.1 Aurora B and Ring1B as new players in the quiescence programme 229 
7.2 Two new functions for Aurora B in transcriptional regulation outside mitosis 232 
7.2.1 Aurora B phosphorylates serine 28 on histone H3 in quiescent B cells 232 
7.2.2 Aurora B negatively regulates the levels of monoubiquitination of histone H2A 
in quiescent B cells 233 
7.3 Interaction of Aurora B and Ring1B in quiescent and activated lymphocytes 234 
7.4 Ring1B promotes transcription in quiescent mature lymphocytes 235 
7.5 PRC1 and PRC2 display opposite localizations in quiescent lymphocytes 237 
References 239 
Appendix A 283 
 
  12 
 
List of Figures 
Figure 1.1: Schematic representation of the role of KLF2/LKLF in resting and activated T cells. 35 
Figure 1.2: Schematic representation of the regulation of FoxO transcription factors in resting and 
activated B cell. 37 
Figure 1.3: Schematic representation of the cell cycle-dependent expression of Cyclins and 
Cyclin/CDKs complexes that regulate progression through the cell cycle. 39 
Figure 1.4: The role of RB proteins in G1 regulation. 41 
Figure 1.5: Proposed model for in vitro induced quiescence. 43 
Figure 1.6: Proposed mechanism for p16 and p53 induced senescence. 45 
Figure 1.7: Development of HSCs in the bone marrow and formation of oligopotent progenitors of 
the lymphoid (B, T and NK cells), myeloid (basophils, mast cells, eosinophils, neutrophils, 
dendritic cells and macrophages) and erythroid (erythrocytes and platelets) lineages. 47 
Figure 1.8: Hierarchical representation of B cell development. 49 
Figure 1.9: Schematic representation of the white pulp of the spleen of an adult mouse. 51 
Figure 1.10: Model for splenic maturation of T1 cells into follicular and marginal zone B cells. 52 
Figure 1.11: Schematic representation of different developmental pathways for mature B cells. 54 
Figure 1.12: Hierarchical representation of T cell development from HSCs in the bone marrow 
and blood, where the first T cell specific progenitor (common T cell progenitor, CTP) can be 
identified. 56 
Figure 1.13: Structure of a subcutaneous peripheral lymph node from a mouse. 59 
Figure 1.14: General scheme showing outcomes of CD4+ T cells activation. 60 
Figure 1.15: Proposed mechanisms of action of Treg cells. 62 
Figure 1.16: Basic structure of core promoters. 66 
Figure 1.17: Mechanism of action of regulatory DNA elements on gene expression. 71 
Figure 1.18: The RNA Pol II cycle (clockwise from top-centre). 73 
Figure 1.19: Schematic representation of transcriptional pausing. 76 
Figure 1.20: Schematic representation of nucleosome assembly. 80 
Figure 1.21: Schematic representation of nucleosome remodelling during the activation of a 
regulated gene. 81 
Figure 1.22: Schematic representation of the canonical histones and main histone 84 
variants. 84 
  13 
Figure 1.23: Schematic representation of the position of the major post-translational modifications 
of the tails of canonical histones. 88 
Figure 1.24: Representation of transcriptional activation following activation of the 
Ras/ERK/MAPK pathway. 93 
Figure 1.25: Schematic representation of the ubiquitin-conjugating reaction. 95 
Figure 1.26: Sequence comparison of human Aurora kinases. 97 
Figure 1.27: Localization of Aurora B during mitosis. 103 
Figure 1.28: Different types of microtubule attachments. 104 
Figure 1.29: Hierarchical recruitment of PRCs to PREs in Drosophila. 110 
Figure 1.30: Schematic representation of PRC2 core and ancillary components. 113 
Figure 1.31: Schematic diagram of the different PRC1 complexes. 116 
Figure 1.32: Schematic representation of the Ring1B-Bmi1 heterodimer, which promotes histone 
H2A monoubiquitination in vivo. 119 
Figure 3.1: Differential expression of Aurora B in unsynchronized and G1-elutriated B-cells. 149 
Figure 3.2: Cell cycle distribution in unsynchronized and G1-elutriated (fraction 9ml/min) LPS-
activated B cells. 150 
Figure 3.3: Schematic representation of the SILAC workflow from cell labelling to quantification of 
relative abundance. 151 
Figure 3.4: Experimental scheme of SILAC in primary B cells using a heavy-labelled internal 
standard. 153 
Figure 3.5: Functional annotation of proteins with G1/CTL ratio higher than 1. 154 
Figure 3.6: NIPP1 interacts with Aurora B in G1-elutriated cells despite being detected with a 
G1/CTL ratio of 0.2 in the SILAC-based screening for new potential partners of Aurora B outside 
mitosis. 155 
Figure 3.7: Aurora B interacts with Ring1B but not with Ezh2 in G1-elutriated LPS-activated B 
cells. 158 
Figure 3.8: Co-immunoprecipitation of Aurora B and Ring1B in co-transfected 293T. 159 
Figure 4.1: Characterization of CD43 negative cells isolated from the spleen of adult mice. 162 
Figure 4.2: Distribution of Aurora B, Ring1B and Suz12 on the promoters in quiescent B 164 
cells. 164 
Figure 4.3: Comparison of the transcriptional levels of active genes in resting (quiescent) 166 
and G1-elutriated LPS-activated B cells (G1 LPS-activated). 166 
Figure 4.4: Binding of Aurora B to promoters is lost upon activation. 168 
Figure 4.5: Binding of Ring1B to promoters is maintained following activation. 169 
  14 
Figure 4.6: Cbx7 binds to active promoters in quiescent and LPS-activated B cells, whereas Bmi-
1 binds in quiescent cells but not in G1 activated cells. 171 
Figure 4.7: H2A ubiquitination levels are higher on silent promoters than on active promoters in 
both quiescent and LPS activated cells. 173 
Figure 4.8: USP16 binds to promoters that bind Aurora B and Ring1B in quiescent B cells but not 
in G1 activated B cells. 174 
Figure 4.9: Sequential ChIP demonstrates co-occupancy of Aurora B and Ring1B at active 
promoters in quiescent B cells. 176 
Figure 4.10: Analysis of the composition of the cell population after CD25 negative selection and 
CD4 positive selection. 177 
Figure 4.11: Determination of the transcriptional levels of active genes in resting CD4+ cells. 178 
Figure 4.12: Distribution of Aurora B and Ring1B on the promoters of active and silent genes in 
quiescent resting T cells. 179 
Figure 4.13: Correlation plot of the mRNA-seq samples. 181 
Figure 4.14: Genome-wide analysis in quiescent B cells. 184 
Figure 4.15: Heat maps showing the distribution of Aurora B (red), Ring1B (blue), H2A.Z (purple), 
Ezh2 (black), H3K27me3 (black), Cbx7 (green) and USP16 (orange) within 3kb of the 
transcriptional start site (TSS) in quiescent B cells. 186 
Figure 5.1: Analysis of Aurora B cKO resting B cells. 192 
Figure 5.2: Analysis of Ring1B cKO resting B cells. 193 
Figure 5.3: Genome-wide validation of the signal specificity of the Aurora B and Ring1B binding 
analysed by ChIP. 195 
Figure 5.4: Knockout of Aurora B in resting B cells results in a reduction of transcription 197 
from Aurora B-bound genes. 197 
Figure 5.5: Inhibition of the kinase activity of Aurora B in resting B cells results in a dramatic 
reduction in the level of transcription of Aurora-bound genes. 199 
Figure 5.6: Knockout of Ring1B in resting B cells leads to a substantial reduction in transcription 
of Aurora B-bound genes. 200 
Figure 5.7: The knockouts of Aurora and Ring1B in naïve T cells result in a reduction of total RNA 
produced from Aurora B-bound genes. 202 
Figure 5.8: Aurora B cKO resting B cells exhibit reduced levels of S5p Pol II at promoters but the 
unphosphorylated RNA Pol II is less affected. 204 
Figure 5.9: The kinase activity of Aurora B is required to maintain high levels of S5p Pol II at its 
target promoters. 205 
  15 
Figure 5.10: Knockout of Ring1B reduces the levels of both types of promoter-bound RNA Pol II.
 206 
Figure 5.11: Genome-wide comparison of the distribution and binding intensities of S5p Pol II and 
8WG16 by ChIP-seq in WT, Aurora B and Ring1B cKO cells. 208 
Figure 5.12: Line plots depicting the average reduction in binding of S5p Pol II following the 
knockout Aurora B (left) or Ring1B (right). 209 
Figure 5.13: Resting lymphocytes display reduced viability following knockout of Aurora B or 
Ring1B. 211 
Figure 5.14: Aurora B and Ring1B cKO does not affect activation of resting B cells. 212 
Figure 6.1: Aurora B cKO resting B cells have reduced levels of H3S28ph at the promoters of 
Aurora B target genes. 215 
Figure 6.2: Reduction of the levels of H3S28ph is not accompanied by an increase in the levels of 
PRC2-mediated H3K27me3 in Aurora B cKO resting B cells. 216 
Figure 6.3: The histone mark H2Aubq marks Aurora B target genes in Aurora B cKO resting B 
cells. 218 
Figure 6.4: USP16 no longer associates with active promoters in Aurora B cKO resting B cells.
 219 
Figure 6.5: In the absence of Aurora B, Ring1B binding increases at some active promoters, 
whereas Bmi1 and Cbx7 binding is largely unaltered. 221 
Figure 6.6: MSK1 replaces Aurora B at active target genes following LPS activation. 223 
Figure 6.7: MSK1 and Aurora B rapidly exchange at active promoters following LPS stimulation of 
resting B cells. 225 
Figure 6.8: LPS-induced binding of MSK1 to promoters is not compromised in resting B cells 
where Aurora B as been previously knocked out. 227 
Figure 7.1: Proposed model for the role of Aurora B and Ring1B in resting B cells. 231 
 
  16 
 
List of Tables 
Table 2.1 Antibodies 143 
Table 2.2 Primers for ChIP (promoter region) 144 
Table 2.3 Primers for transcriptional analysis 146 
Table 3.1: Aurora B partners identified by SILAC screening as potential interactors during G1 156 
  17 
 
 Supplementary Tables 
Table 1: SILAC results 
Table 2: mRNA-seq in resting B cells 
  18 
Abbreviations 
 
Acronym Full name 
2A-HUB 2A-histone ubiquitinase 
4-OHT 4-hydroxytamoxifen 
ACF Assembly-complementing factor 
AEBP2 AE binding protein 2 
Akap8l A kinase (PRKA) anchor protein 8-like 
Alkbh7 Alkylation repair homolog 7 
ANRIL CDKN2B antisense RNA 1 
Ap1m1 Adaptor-related protein complex 1, mu 1 subunit 
APC/C Anaphase promoting complex/cyclosome 
APCs Antigen-presenting cells 
ARF ADP-ribosylation facto 
Arhgef2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 
Asx Additional sex combs 
ATM Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
Atp5s ATP synthase, H+ transporting, mitochondrial Fo complex, subunit s 
b-Actin Beta-actin 
B2m Beta-2-microglobulin 
BAF Barrier to autointegration factor 
Bcan Brevican 
BCoR BCL6 corepressor 
BCR B-cell receptor 
  19 
Bmi1 B lymphoma Mo-MLV insertion region 1 homolog 
bp Base pairs 
BRD4 Bromodomain containing 4 
BRE TFIIB-recognition element 
BSA Bovine serum albumine 
Bub1 Budding uninhibited by benzimidazoles 1 
BubR1 Mitotic checkpoint serine/threonine-protein kinase BUB1 beta 
CaCl2 Calcium chloride 
CAK CDK-activating kinase 
CBFb Core-binding factor, beta subunit 
CBX Chromobox proteins 
CCR Carbon catabolite repressor 
Cct3 Chaperonin containing TCP1, subunit 3 (gamma) 
CD Cluster of differentiation 
CDC Cell division cycle 
CDK Cyclin dependent kinase 
cDNA Complementary DNA 
CEE Counterflow centrifugal elutriation 
CHD Chromodomain helicase DNA binding protein 
ChIP Chromatin immunoprecipitation 
ChIP-seq Chromatin immunoprecipitation (chip) with massively parallel DNA sequencing 
CHMP4C Charged multivesicular body protein 4C 
CHRAC Chromatin accessibility complex 
CID Collision-induced dissociation 
CKI CDK kinase inhibitors 
cKO Conditional knockout 
CLP Common lymphoid progenitors 
  20 
Clpp Caseinolytic peptidase 
CMP Common myeloid progenitor 
Co-IP Co-immunoprecipitation 
CPC Chromosomal passenger complex 
CreERT2 Cre-rcombinase fused with Oestrogen receptor T2 
CTD Carboxyl-terminal domain 
CTL Control 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 
CTPs Common T cell progenitor 
Cul3 Cullin 3 
DN Double negative 
DNMT DNA (cytosine-5-)-methyltransferase 
dNTP Deoxyribonucleotide 
DOT1 DOT1-like, histone H3 methyltransferase 
DP Double positive 
DPE Downstream promoter element 
DSIF DRB sensitivity-inducing factor 
Dsn1 MIND kinetochore complex component 
DTT Dithiothreitol 
DUB Deubiquitinase 
E2F Elongation factor 
EDTA Ethylenediaminetetraacetic acid 
Eed Embryonic ectoderm development 
ELP Early lymphoid progenitor 
ERK Extracellular receptor kinase 
ES Embryonic stem 
Esa1 Histone acetyltransferase ESA1 
  21 
ESCRT Endosomal Sorting Complex Required for Transport 
ETPs Early thymic progenitors 
Ezh Enhancer of zeste homolog 
FACS Fluorescent activated cell sorter 
FACT Facilitates chromatin transcription 
Fcrl1 Fc receptor-like 1 
FCS Foetal Calf serum 
Fdx1 Ferredoxin 1 
Foxo Forkhead box 
FPKM Fragments per kilobase of exon per million fragments mapped 
G0 Gap 0 
G1 Gap1 
G2 Gap2 
GATA GATA-binding factor 
Gba Glucosidase, beta, acid 
Gcn5 General control of amino acid synthesis protein 5-like 2 
GMPs Granulocyte-myeloid progenitors 
GSK-3 Glycogen synthase kinase-3 
GTFs General transcription factors 
H2Aubq H2Aubiquitination 
HA Hemagglutinin 
Hapln2 Hyaluronan and proteoglycan link protein 2 
HATs Histone acetyltransferases 
HBP1 HMG-box transcription factor 1 
HBSS Hank's balanced salt solution 
HDAC Histone deacetylases 
Hec1 Deacetylases 
  22 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEVs Kinetochore protein NDC80 homolog 
Hip1r Huntingtin interacting protein 1 related 
HIRA HIR histone cell cycle regulation defective homolog A 
Hox Homeobox 
HP1 Heterochromatin protein 1 
HRP Horseradish peroxidase 
HS Hypersensitivity 
HSA Heat-stable antigen 
HSCs Hematopoietic stem cells 
Icam2 Intercellular adhesion molecule 2 
IDO Indoleamine 2,3-dioxygenase 
IFN-g Interferon-gamma 
Ig Immunoglobulin 
IL Interleukin 
Il2rg Interleukin 2 receptor, gamma 
IM Immature 
INCENP Inner Centromere protein 
INHAT Inhibitor of acetyltransferase 
INK4b Cyclin-dependent kinase 4 inhibitor B 
Inr Initiator 
InsrR Insulin receptor related 
IP Immunoprecipitation 
ISWI Imitation SWI 
Jarid2 Jumonji, AT rich interactive domain 2 
Jmj Jumonji 
Jun Jun proto-oncogene 
  23 
JunD Jun D proto-oncogene 
kb Kilobases 
KCl Potassium chloradi 
KIP Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
KLHL21 Kelch-like 21 
L3MBT2 Lethal(3)malignant brain tumor-like protein 2 
LC Liquid chromatography 
LCRs Locus control regions 
LiCl Lithium chloride 
loxP Locus of X-over P1 
LPS Lipopolysaccharide 
M Mitosis 
M Molarity 
Mad2 Mitotic arrest deficient 
Mapbpip Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 
MAPK Mitogen-activated protein kinase 
MBDs Methyl-binding domain 
MBLR Mel18 and Bmi1-like RING finger protein 
Mef2D Myocyte enhancer factor 2D 
Mel18 Melanoma nuclear protein 18 
MEPs Megakaryocyte erythroid progenitors 
mg Milligrams 
MgCl2 Magnesium chloride 
MgcRacGAP Rac gtpase activating protein 1 
MHC Major histocompatibility complex 
Mical1 Microtubule associated monoxygenase, calponin and LIM domain containing 1 
miR Micro RNA 
  24 
Mis13 MIND kinetochore complex component 
ml Milliliter 
MLL Mixed-lineage leukemia 
mM Millimolar 
Mnt MAX binding protein 
MOF K(lysine) acetyltransferase 8 
MPPs Multipotent progenitors 
mRNA Messanger RNA 
mRNA-seq Mrna sequencing 
MS Mass spectrometry 
MSK1 Mitogen- and stress-activated protein kinase 
mTor Mammalian target of rapamycin 
Mtx1 Metaxin 1 
MYSM-1 Myb-like, SWIRM and MPN domains 1 
MZ Marginal zone 
N-CoR Nuclear receptor co-repressor 
Na2HPO4.2H2O Di- Sodium hydrogen phosphate dihydrate 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
ncRNAs Non coding RNA 
NELF Negative elongation factor 
NF-IL6 Nuclear factor for IL6 
ng Nanograms 
NIPP1 Nuclear inhibitor of protein phosphatase 1 
NIR Novel INHAT repressor 
NK Natural killer 
Nr4a1 Nuclear receptor subfamily 4, group A, member 1 
  25 
NSPC1 Nervous system polycomb 1 
NuA4 Nucleosome acetyltransferase of H4 
NuRD Nucleosome remodelling and histone deacetylase 
NURF Nucleosome remodeling factor 
p-TEFb Positive transcriptional elongation factor-b 
p107 Retinoblastoma-like protein 1 
p130 Retinoblastoma-like protein 2 
p16 Cyclin-dependent kinase inhibitor 2A 
p21 Cyclin-dependent kinase inhibitor 1 
p27 Cyclin-dependent kinase inhibitor 1B 
p53 Tumor protein 53 
PALS Periarteriolar lymphoid sheath 
PBAF Polybromo-associated BAF 
PBS Phosphate buffered saline 
PC Plasma cell 
Pc Polycomb 
PcG Polycomb group protein 
PCGF Polycomb group ring finger 
PCR Polymerase chain reaction 
Ph Polyhomeotic 
PHO Pleiohomeotic 
PhoRC Pho repressive complex 
PI Propidium iodide 
PI3K Phosphoinositide 3-kinase 
PIAS3 Protein inhibitor of activated STAT protein 3 
PIC Pre-initiation complex 
PKC1 Protein kinase C beta 1 
  26 
Plk1 Polo-like kinase 1 
Pmf1 Polyamine-modulated factor 1 
PP Protein phosphatase 
PR-DUB Polycomb repressive-DUB 
PRC Prolycomb repressive complex 
Prcc Papillary renal cell carcinoma 
PREs Polycomb response elements 
PRK1 Protein kinase C-related kinase 1 
PRMTs Protein arginine N-methyltransferases 
Psc Posterior sex combs 
qRT-PCR Quantitative real-time polymerase chain reactions 
RAF Rapidly accelerated fibrosarcoma 
RAS Rat sarcoma 
Rb Retinoblastoma 
RbAp46/48 Retinoblastoma protein associated protein 46/48 
Rbp1 Retinol-binding protein 1 
ReChIP Sequential chip 
RNA Pol II RNA polymerase II 
RNF Ring finger protein 
Robo1 Roundabout, axon guidance receptor, homolog 1 
ROS Reactive oxygen species 
rpm Revolutions per minute 
RPM Reads Per Million of mapped reads 
RPMI Roswell park memorial institute 
Rtr RNA Pol II subunit 
Runx1 Runt-related transcription factor 1 
RYBP RING1 and YY1 binding protein 
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S Synthesis 
S2p Pol II Serine 2-phospho RNA Pol II 
S5p Pol II Serine 5-phospho RNA Pol II 
S7p Pol II Serine 7-phospho RNA Pol II 
SAC Spindle assembly checkpoint 
SAGA Spt-Ada-Gcn5 acetyltransferase 
SANT Swi3, Ada2, N-Cor, and TFIIIB 
SDS Sodium dodecyl sulfate 
SET Su(var), Enhancer of zeste, Trithorax 
Sgo1 Shugoshin 
SIGNR C-type lectin domain family 4, member M 
SILAC Stable isotopic labelling with amino acid in culture 
SKAP Small kinetochore-associated protein 
SKP1 Kinetochore-associated protein 
snRNA Small non coding RNA 
SP1 Specificity protein 1 
Srgn Serglycin 
SUMO Small Ubiquitin-like Modifier 
SUV39H1 Uppressor of variegation 3-9 homolog 1 
Suz12 Suppressor of zeste 12 
SWI/SNF Archetypal remodeller complex with Snf2p (Swi2p) at its core 
SWR1 SWI/SNF related protein 
TAFs TBP associated factors 
TBP TATA-binding protein 
TBS Tris-buffered saline 
TCR T-cell receptor 
TD-60 Telophase disk protein of 60 kda 
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Tfh Follicular T helper 
TF Transcription factor 
TGF-b Transformin growth factor-β 
TH T-helper 
TLE Transducin-like enhance 
TLK-1 Tousled-like kinase-1 
Top3a Topoisomerase (DNA) III alpha 
Tpd52l2 Tumor protein D52-like 2 
Tregs T regulatory 
Tris Trisaminomethane 
TSPs Thymus-settling progenitors 
TSS Transcriptional start site 
Tzfp Testis zinc finger protein 
U Unit 
UbcH5c Ubiquitin carrier protein D3 
USP Ubiquitin-specific proteases 
Vps37b Vacuolar protein sorting 37 homolog B 
w/v Weight on volume 
WAF Cyclin-dependent kinase inhibitor 1A 
Yaf2 YY1-associated factor 2 
YY1 Ying yang 1 
Zbtb24 Zinc finger and BTB domain containing 24 
ZRF1 Zuotin-related factor 1 
μg Microgram 
μl Microliter 
μM Micromolar 
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Chapter 1 - Introduction 
 
1.1 Overview 
The main aim of this study has been to identify new roles of the Aurora B 
kinase outside mitosis. In particular, my PhD project has focused on the 
interaction between Aurora B and the Polycomb group protein Ring1B. I have 
shown that these proteins form a functional complex bound to active promoters in 
resting B and T lymphocytes and regulate transcription of their target genes in 
the quiescent state. 
To introduce the results that I have obtained, I will firstly review the 
published literature on quiescence, the stage of the cell cycle in which this 
functional interaction takes place. Secondly, I will describe the cell system that I 
used to study this interaction: murine lymphocytes. I will then review some key 
aspects of the regulation of gene expression in mammals, as these concepts are 
important for understanding the mechanisms behind the transcriptional 
programme that maintains resting lymphocytes in a quiescent state and ready for 
activation. This will be followed by a description of the known functions of the 
Aurora B kinase in regulating mitosis and cytokinesis. Finally, I will deal with the 
roles of the Polycomb group proteins in regulating gene expression.  
1.2 Quiescence 
1.2.1 Quiescence as an adaptive mechanism 
Quiescence (also termed G0) is defined as a reversible exit from the cell 
cycle, characterised by a reduced size and metabolic activity. Most cells in an 
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adult organism are non-proliferating and some are in a resting state and resume 
proliferation upon encounter with the appropriate stimulus. A classical example is 
resting lymphocytes. In the immune system of higher eukaryotes, each subset of 
quiescent lymphocytes will proliferate only upon encounter with a specific 
antigen. This cell population will expand in order to respond to a specific antigen 
but, otherwise, the demand of energy and nutrients of these cells is modest.   
Quiescence is remarkably conserved from E. coli to humans (O'Farrell, 
2011). In microorganisms such as yeast, quiescence is mostly an adaptive 
response to a lack of nutrients (Laporte et al., 2011). In the absence of essential 
nutrients such as carbon, yeast arrests its cell cycle during the G1-phase and 
enters quiescence (De Virgilio, 2012). Prototrophic yeast strains are able to 
synthesise essential compounds for their metabolism and this ability is utilised in 
quiescence (François and Parrou, 2001). During quiescence, S. cerevisiae 
accumulates glycogen and reinforces its cell wall (De Virgilio, 2012). This series 
of events requires the reorganization of the transcriptional programme and, 
indeed, even in relatively simple organisms such as yeast, a quiescence-specific 
pattern of gene expression exists. 
The quiescence programme causes one fourth of the entire genome of S. 
cerevisiae to become differentially expressed. Most of the genes are silenced 
and the overall transcriptional activity of S. cerevisiae is reduced. Despite the 
global reduction in transcription, RNA Polymerase II is present at most promoters 
and its release from the Mediator complex is likely to be the limiting factor in 
transcription (see section 1.4.2) (Radonjic et al., 2005) Moreover, the overall 
structure of yeast DNA becomes more compacted (Schäfer et al., 2008). The 
global reduction in transcription reduces the translation of new proteins 
(Boucherie, 1985). Proteosomal degradation is high at the onset of quiescence 
but is progressively reduced meaning that protein turnover becomes quite slow 
under these conditions (Bajorek et al., 2003). Mitochondrial respiration is reduced 
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to adjust the metabolism to new conditions and limit the oxidative stress (Cyrne 
et al., 2003). However, quiescent yeast strains exhibit a high resistance against 
oxidants (Costa and Moradas-Ferreira, 2001). 
Similar to yeast, serum starvation causes mammalian cells to adopt a 
quiescent programme characterised by reduced metabolism and protein 
turnover, global reduction of transcription and chromatin compaction. The notion 
that quiescence is also actively regulated in mammalian cells comes from 
pioneering studies where it was observed that 3% of the mRNA in resting 
fibroblasts is not present in proliferating cells and vice versa (Williams and 
Penman, 1975). Interestingly, many of the genes upregulated upon serum 
starvation are repressed in tumours and an antagonizing role for quiescence in 
cancer development has been proposed (Liu et al., 2007). Indeed, tumours often 
arise in adult tissues, where most of the cells are non dividing (Malumbres and 
Barbacid, 2001). The mechanisms that govern the decision between proliferation 
(observed in cancer cells) and quiescence are often disrupted in tumours (Sherr, 
2000).  
In addition to serum starvation, contact inhibition and loss of adhesion are 
also commonly employed to induce quiescence in cultured cells. These 
mechanisms might more closely reflect the type of situations encountered by 
cells in an organism, as serum deprivation is not a physiological phenomenon. 
The size of an organism is limited and the different tissues are 
compartmentalised and can proliferate and expand within certain physical limits. 
Therefore, contact inhibition might reflect a physiological condition that imposes a 
block to cell proliferation and induces the formation of a reservoir of quiescent 
cells ready to replace the dead ones. For example, endothelial cells spend most 
of their life in quiescence at a high density, where competition for nutrients might 
also play a role in the maintenance of this state. However, upon tissue lesion and 
loss of cells they resume proliferation to heal the wound (Lee and Gotlieb, 1999).  
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Many cell types, such as mammary epithelial cells, require the presence of 
a layer of feeder cells and exhibit anchorage-dependence to these cells. Upon 
loss of adhesion, different pathways lead to the arrest of proliferation and the 
engagement of a quiescence programme (Sequeira et al., 2007). Interestingly, in 
cultured fibroblasts, serum starvation, contact inhibition and loss of adhesion lead 
to different patterns of differential gene expression at the onset of quiescence 
but, over time, these three separate programmes converge towards a unique one 
(Coller et al., 2006). 
 
1.2.2 Quiescence as a developmental stage  
Quiescence is not exclusively an adaptive response to unfavourable 
growing conditions that allows a normally proliferating cell to survive in a 
transiently unfavourable environment. Certain cell types are by default resting 
and can remain alive for several months to years (Tough and Sprent, 1994). 
Examples include the endothelial cells present in veins and arteries, satellite cells 
in skeletal muscles, hepatic and pancreatic stellate cells in mammals. 
Mature resting B and T lymphocytes (also termed B and T cells) are also an 
important example of quiescent cells. Resting B cells arise in the spleen where 
transitional B lymphocytes cease proliferation, complete their development and 
becomes mature and quiescent (see section 1.3.4). Resting T lymphocytes are 
released from the thymus to the peripheral lymph nodes as mature cells (see 
section 1.3.8). Both cell types reside in the lymphoid organs in a resting state 
where they are poised to vigorously proliferate and differentiate (as described in 
detail below) only upon encounter with the appropriate antigen.  
Interestingly, the comparison between in vitro induced quiescence in 
fibroblasts (Coller et al., 2006) and naïve T lymphocytes (Diehn et al., 2002) 
shows a 71% overlap in the downregulated genes but only 15% of upregulated 
genes are shared between the datasets. What might explain this difference is the 
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observation that quiescence programmes tend to downregulate genes implicated 
in proliferation, which are often the same among cell types. On the other hand, 
cell-type specific genes that control tissue-specific functions required for survival 
need to be upregulated. Cell type-specific transcriptional factors are often 
implicated in the regulation of the quiescence programmes and cooperate with 
cell cycle inhibitor proteins in the onset of quiescence.  
 
1.2.3 The requirements for resting lymphocytes survival 
An interesting common trait of resting B and T lymphocytes (henceforth 
referred to as B and T cells) is their dependence for survival on a basal level of 
stimulation of the B cell receptor (BCR) and T cell receptor (TCR) respectively. It 
is possible to speculate that, in order to avoid anergy, a condition of irreversible 
unresponsiveness to stimuli, B and T cells must keep their receptors constantly 
stimulated below threshold in order to prevent them from becoming unresponsive 
(Hamilton and Jameson, 2012). Tonic BCR and TCR signalling activates the 
transcriptional factor NF-κB, which promotes the transcription of genes required 
for survival, stimulation and development (Li and Verma, 2002). 
IL-4 is normally produced by T cells during B cell activation but has also 
been shown to be required for the survival of B cells (Zamorano et al., 2001). 
Naïve CD8+ T cells, instead, require stimulation of their IL-7 receptor to remain 
alive and responsive (Schluns et al., 2000). This cytokine is also important for 
naïve CD4+ T cells in culture and in lymphopoenic hosts, although, to date, the 
extent of cytokine-dependence of naïve CD4+ T cells is unknown (Seddon et al., 
2003). 
The Kruppel-like factors (KLFs) and Forkhead box class O transcription 
factors (FoxO) are two groups of transcription factors that play key roles 
specifically in the onset and maintenance of the quiescent programme in resting 
B and T cells (see section 1.4.1). KLF2 is essential for T cell quiescence and 
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survival and its expression peaks in resting T cells and decreases following 
activation (Schober et al., 1999). KLF2 conditional deletion results in a dramatic 
reduction in the number of mature T cells in peripheral lymphoid organs (Kuo et 
al., 1997). It has been proposed that KLF2 induces quiescence by indirectly 
silencing Myc expression. Myc is a proto-oncogene upregulated in several 
tumours and promotes proliferation in normal cells (Johnston et al., 1999). Myc 
promotes cell proliferation by enhancing the expression of cell cycle-regulating 
genes (Kim et al., 1994) (Fig. 1.1).  
 
 
Figure 1.1: Schematic representation of the role of KLF2/LKLF in resting and activated T 
cells.  
KLF2-mediated growth arrest has been attributed mostly to its inhibitory effect on Myc. Myc 
promotes cell growth and proliferation by stimulating the transcription of CDC25 (see section 
1.2.4) and repressing Gadd45 (growth arrest and DNA damage gene-induced gene 45, a cell 
cycle blocker). Other targets of Myc in activated T cells are CD30 and CD71, important for T cell 
activation. CD1a, also relevant for T cell activation is regulated by factors other than Myc and is 
also repressed by KLF2. TCR stimulation (above threshold) inhibits KLF2 and releases Myc from 
its negative regulation, leading to cell proliferation (reproduced with permission from Yusuf and 
Fruman, 2003, Trends in Immunology, copyright (2003) Elsevier). 
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The knockout of Myc in quiescent B cells renders them unresponsive to 
activating stimuli (de Alboran et al., 2001). On the other hand, Myc 
overexpression increases the size of B cells as one of its morphological 
phenotypes (Iritani and Eisenman, 1999). Overexpression of KLF2 in leukaemia 
cell lines results in downregulation of Myc and in a quiescent phenotype (Buckley 
et al., 2001). 
Another member of the KLF family, KLF4, has a prominent role in the 
regulation of quiescence in resting B cells. Klf4 is highly expressed in quiescent 
but not in activated B cells, where its overexpression leads to cell cycle block 
(Yusuf et al., 2008). Interestingly, Klf4 is, together with Pou5f1, Sox2 and Myc, 
one of the genes whose ectopic expression confers pluripotency to differentiated 
fibroblasts (Wernig et al., 2007). This is particularly interesting in light of the 
observation that quiescent cells are resistant to differentiation (Coller et al., 
2006). Serum starved and contact inhibited fibroblasts downregulate the 
expression of myogenic genes when this differentiation programme is stimulated. 
The authors of this study propose that, by inhibiting terminal differentiation, 
quiescence is maintained as a reversible exit from the cell cycle (Coller et al., 
2006). 
FoxO transcription factors (FoxO1, 3a, 4 and 6) are transcriptional 
activators that play roles in apoptosis, cell cycle arrest, cell stress and DNA 
repair (Kops et al., 2002). FoxO transcription factors are negatively regulated 
through phosphorylation by Akt, which is activated in response to growth factors 
(Brunet et al., 1999). Upon phosphorylation, FoxO transcription factors bind to 
14-3-3 proteins and migrate from the nucleus to the cytoplasm, where they 
become inactive (Brunet et al., 2002) (Fig. 1.2). 
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Figure 1.2: Schematic representation of the regulation of FoxO transcription factors in 
resting and activated B cell.  
In quiescent cells, unphosphorylated FoxO resides in the nucleus where it promotes the 
expression of Gadd45, p130 and p27, which together promote exit from the cell cycle before the 
restriction point (see section 1.2.4). Dyrk1 might work as a co-factor but its role is still debated. 
Antigenic stimulation of the BCR (above threshold) activates the PI3K/Akt pathway. Akt 
phosphorylates FoxO transcription factors at three residues. This triggers the displacement of the 
protein from its binding sequence and its relocalization to the cytoplasm, where 14-3-3 proteins 
sequester it. FoxO target genes are no longer activated and this leads to cell cycle entry 
(reproduced with permission from Yusuf and Fruman, 2003 Trends in Immunology, copyright 
(2003) Elsevier). 
 
FoxO1 and 3a are expressed in quiescent B and T cells and their ectopic 
expression in B cells blocks their proliferation (Yusuf et al., 2004). FoxO directly 
promotes the transcription of Klf4 and p130 in quiescent B cells (Yusuf et al., 
2008) and the conditional knockout of FoxO1 in T cells leads to auto-activation 
and reduces the viability of quiescent T cells by directly affecting the IL-7 survival 
pathway (Ouyang et al., 2009). Another target of FoxOʼs is p27 (see below), 
which indicates that they might operate upstream of KLFs in the quiescent 
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programme by directly promoting the exit from the cell cycle of immature B cells 
(Medema et al., 2000). 
Additionally, a different Forkhead transcription factor, FoxP1, promotes the 
maintenance of a quiescent state in resting T cells as opposed to a memory T 
cell state (characterised by slow but detectable proliferation) (Feng et al., 2011). 
The knockout of FoxP1 enhances the responsiveness of resting T cells to IL-7, 
turning them into effector CD8+ cells.  
 
1.2.4 The molecular mechanisms of cell cycle progression and exit 
Cyclins, Cyclin-dependent kinases (CDKs) and CDK kinase inhibitors 
(CKIs) have been identified as key players in the regulation of the different stages 
of the cell cycle and in the mechanisms that trigger quiescence (Fig. 1.3). Cyclins 
and CDKs form stable and active complexes that in turn regulate cell cycle 
decisions through phosphorylation of target proteins. In particular, CyclinD/CDK4-
6 and CyclinE/CDK2 regulate progression through G1 or exit from the cell cycle 
before the transition to S (Blomen and Boonstra, 2007).  
  39 
 
 
 
Figure 1.3: Schematic representation of the cell cycle-dependent expression of Cyclins 
and Cyclin/CDKs complexes that regulate progression through the cell cycle. 
The expression of Cyclin D is triggered by mitogens in early G1 and is preserved until cytokinesis. 
Cyclin E is transiently expressed across the G1/S border. Cyclin A is expressed from early S to 
early mitosis (prometaphase). Cyclin B is expressed in G2 and its degradation at the onset of 
anaphase is required for mitotic progression. The Cyclin D/CDK4-6 complex operates in early G1 
(before the restriction point). The Cyclin E/CDK2 regulates the entry into S. The Cyclin A/CDK2 is 
active at the onset of DNA replication. The Cyclin A/CDK1-2 complex is active in controlling DNA 
replication and repair in mid/late S phase. The Cyclin A/CDK1 complex regulates the start of 
mitosis. CDK1 regulates key steps during mitosis by interacting with Cyclin A and B, which are 
both degraded before metaphase and anaphase respectively. 
 
Cyclin D expression begins early in G1 and reaches the plateau phase 
before the transition into S-phase (Musgrove, 2006). The expression of Cyclin E, 
instead, peaks at the G1/S border and rapidly decreases following the beginning 
of DNA duplication. Importantly, the promoter of Cyclin E is a target of the E2F1 
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transcriptional factor and, therefore, Cyclin D regulates the expression of Cyclin E 
(see below) (Ohtani et al., 1995). The rapid degradation of Cyclin E in early S-
phase is accompanied by an increase in the expression of Cyclin A, whose levels 
are maintained through S, G2 and M (Fung and Poon, 2005). Cyclin B 
expression strongly correlates with mitosis and its degradation is necessary for 
correct chromosomal segregation in anaphase (Zhang et al., 1998). Despite the 
fact that the same E3 ligase (the Anapahse Promoting Complex, see section 
1.5.3) regulates the degradation of both Cyclin A and B, Cyclin A is degraded 
during prometaphase and Cyclin B at the onset of anaphase. The mechanisms 
dictating this differential timing are still poorly understood (den Elzen and Pines, 
2001). 
Cyclin D expression is triggered in response to mitogens in early G1 and is 
the endpoint of the RAS/RAF/MAPK pathway through the binding of ERK 
(extracellular signal-receptor kinase) to the Cyclin D promoter (Albanese et al., 
1995). Ras also stimulates the activation of the PI3K/Akt pathway, which 
promotes the translation and reduces the degradation of Cyclin D1 via two 
mechanisms. Firstly, Akt phosphorylates and activates mTor (mammalian target 
of rapamycin), which, through phosphorylation of downstream targets, promotes 
the translation of the Cyclin D mRNA (Koziczak and Hynes, 2004). Secondly, the 
kinase GSK-3 phosphorylates and promotes the degradation of Cyclin D. The 
phosphorylation of GSK-3 by Akt inhibits this kinase and, indirectly, favours the 
accumulation of Cyclin D in G1 (Diehl et al., 1998). The dependence on external 
mitogens makes Cyclin D a sensor of the environmental conditions by interacting 
with and activating CDK4 or 6 (depending on the tissue) (Matsushime et al., 
1994).  
The binding of Cyclins is necessary to fully activate CDKs, serine-threonine 
kinases whose main targets are retinoblastoma family (RBs) proteins Rb, p130 
and p107 (Ren and Rollins, 2004). This leads to the phosphorylation of Rb, which 
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can bind to E2F transcription factors and sequester them, thus preventing the 
transcription of E2F-mediated transcription of genes required for S-phase entry 
(Stevaux and Dyson, 2002). The interaction between Rb and E2Fs also induces 
expression of Cyclin E in late G1, which associates with and activates CDK2. The 
CyclinE/CDK2 complex further phosphorylates Rb, an event that marks the 
restriction point, the turning point in the G1-phase after which proliferation is 
ensured even in the absence of mitogens (Cooper, 2003). In its 
hyperphosphorylated form, Rb no longer binds to E2Fs, which transcribe genes 
required for S-phase entry (Stevaux and Dyson, 2002) (Fig. 1.4). 
 
 
Figure 1.4: The role of RB proteins in G1 regulation.  
Unphosphorylated Rb is unable to bind E2F TFs. p130 binds and represses E2F TFs in 
quiescence (here termed G0). Phosphorylation of Rb by Cyclin D/CDK4-6 allows it to bind to E2F 
and promotes the transcription of Cyclin E. At the same time, this binding prevents E2Fs from 
activating the transcription of genes that promote entry into S. The Cyclin E/CDK2 complex 
hyperphosphorylates Rb, releasing E2Fs, which can now activate the transcription of genes that 
lead to entry into S.  p21 and p27 CKIs (also known as WAF1 and KIP1) repress the 
CyclinE/CDK2 complex but can be sequestered by the CyclinD/CDK4-6 complex. INK4 CKIs 
(p16, p15, p18 and p19) negatively regulate the CyclinD/CDK4-6 complex (reproduced with 
permission from Malumbres and Barbacid, 2001, Nature Reviews Cancer, copyright (2001) 
Nature Publishing Group). 
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CKIs inhibit the activity of CDKs by disrupting their association with Cyclins 
(Sherr and Roberts, 1999). The WAF/KIP CKIs (p21 and p27) antagonize the 
Cyclin E/CDK2 complex and bind to Cyclin D/CDK4-6 preventing them from 
binding to CDK2. The INK4 CKIs (p16, p15, p18 and p19) target CDK4-6. INK4 
CKIs displace WAF/KIP CKIs from the Cyclin D/CDK4-6 complex, thus making 
them available for Cyclin E/CDK2 inhibition (Sherr and Roberts, 1999). 
Quiescent cells exhibit reduced levels of Cyclin D as a result of reduced 
mitogenic stimulation (Ladha et al., 1998). As a consequence, one of the 
hallmarks of quiescence is the presence of high levels of unphosphorylated Rb 
(Ezhevsky et al., 2001). Another RB family protein, p130, plays a pivotal role in 
quiescent cells. p130 forms a complex with the E2F transcription factor E2F4, 
which actively prevents the transcription of genes required for S-phase entry 
(Smith et al., 1996) (Fig. 1.5). 
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Figure 1.5: Proposed model for in vitro induced quiescence.  
Under normal mitogenic stimulation, the MEK/MAPK pathway stimulates Cyclin D production and 
prevents p21 and p27 inhibition of Cyclin D/CDK4-6. This complex hyposphorylates Rb, which 
can bind to E2F. Lack of mitogens leads to accumulation of unphosphorylated Rb and allows 
p130 and p107 to bind to E2F and completely repress them. Contact inhibition inhibits the 
formation and the activity of the Cyclin D/CDK4-6 complex. Loss of adhesion (for adherent cells) 
might prevent proliferation by allowing p21 and p27 to exert their inhibitory function on the Cyclin 
E/CDK2 before the restriction point (reproduced with permission from Blomen and Boonstra, 
2007, Cellular and Molecular Life Sciences, copyright (2007) Springer). 
 
1.2.5 Irreversible exit from the cell cycle: senescence and terminal 
differentiation 
Senescence is an irreversible process and disruptions in the senescence-
programme are linked to cancer (Campisi, 2001). As the term implies, 
senescence is linked to the age of the cell. Unlike immortalized cells, primary 
cells have a finite number of doublings (Hayflick, 1965). Once a cell has 
exhausted its reproductive capability it exits the cell cycle but, unlike apoptosis, 
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which is a programmed cell death, senescence does not lead to cell death. 
Senescent cells are larger and have higher metabolic activities than quiescent 
cells, which is likely to result from the fact that senescent cells exit the cell cycle 
close the G1/S border (Demidenko and Blagosklonny, 2008).  
Mechanistically, high expression of the CKIs p21 and p16 constitutes the 
hallmark of the senescent state. p21 expression increases towards the last cell 
cycles in the lifespan of a cell, whereas p16 expression peaks in senescent cells 
(Mirzayans et al., 2010). This suggests that p21 triggers entry into senescence 
before the cell can progress through the restriction point and p16 reinforces this 
state. Ectopic expression of p16 can trigger cell cycle exit and senescence in 
proliferating cancer cells (Dai and Enders, 2000).  
p16 inhibits CDK4/6-mediated phosphorylation of Rb (Takahashi et al., 
2006). p21 is upregulated following p53 activation, which is triggered by DNA 
damage and telomere depletion, a hallmark of cellular aging (Beliveau et al., 
2007). p53 is a tumour suppressor that regulates growth arrest, apoptosis and 
DNA repair (Reinhardt and Schumacher, 2012). p53 is activated by DNA 
damage, hypoxia, oncogenes and other stressful conditions. Although Cyclin D 
expression is dependent on mitogens, expression of CKIs is also enhanced by 
MAPK kinases (Sewing et al., 1997).  
Above a certain threshold,, stimulation can cause senescence by promoting 
the expression of p21, a concept known as mitogen hyperstimulation 
(Blagosklonny, 2003). Moreover, mitogen hyperstimulation leads to the 
accumulation of reactive oxygen species (ROS), which causes DNA damage and 
is observed in senescent cells (Macip et al., 2002). Interestingly, accumulation of 
ROS is observed even in cultured cells over time (Hagen et al., 1997). DNA 
damage triggers p53 activation, which in turn leads to the expression of p21 (Fig. 
1.6). 
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Figure 1.6: Proposed mechanism for p16 and p53 induced senescence.  
Hypermitogenic stimulation is a form of stress that can lead to the activation of p53 with or without 
the intermediate step of the generation of ROS and ROS-induced DNA damage. p53 activation 
leads to the upregulation of p21 and p21-mediated senescence entry. Sustained MEK/MAPK 
stimulation by mitogens can also lead to the upregulation of p16, which, as a CKI, is involved in 
the maintenance of senescence (reproduced with permission from Blomen and Boonstra, 2007, 
Cellular and Molecular Life Sciences, copyright (2007) Springer). 
 
Differentiated cells represent another type of viable and metabolically active 
non-proliferating cell. Although initially thought to be irreversibly post-mitotic in 
vivo, dedifferentiation and cell cycle re-entry has been documented, for example 
in Schwann cells (Mirsky et al., 2008). However, for the majority of fully 
differentiated cells, cell cycle exit is a one-way process and cells do not normally 
re-enter the cell cycle. Examples of terminally differentiated cells include plasma 
cells, which constitute the last stage in the differentiation of B cells and whose 
function is to secrete very large amounts of soluble immunoglobulin (Ig) 
molecules (Lisowska-Bernstein et al., 1970). 
The CKIs p27 and p21 seem to play key roles in the establishment of 
differentiation programmes. Both proteins are generally upregulated in 
differentiated cells and this has led to the formulation of a general model in which 
p27 increases over the CDK4-6 saturation point and progressively inhibits CDK2 
(Hsieh et al., 2000). In addition, p21 has been proposed to induce the 
transcriptional programme required for differentiation of neuroblastoma cells 
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(Poluha et al., 1996). According to this model, p21 would exert its function after 
p27-mediated cell cycle arrest (Zezula et al., 2001). Rb is also implicated in 
differentiation in some cell types. For example, in muscle cells it binds to the 
differentiation repressor HBP1 and represses it (Shih et al., 1998). Rb also binds, 
in its phosphorylated form, to the transcription factor MyoD activating its 
myogenic activity (Gu et al., 1993). Another example is the interaction of 
phosphorylated Rb with NF-IL6, which enhances the capacity of NF-IL6 to 
promote monocyte and macrophage differentiation (Chen et al., 1996). 
 
1.3 The development of mouse B and T lymphocytes 
1.3.1 From Hematopoietic stem cell to lymphoid progenitors 
In a developing mouse embryo, the first step in the formation of the 
hematopoietic system is the differentiation of pluripotent stem cells into 
haematopoietic stem cells (HSCs). HSCs are multipotent stem cells that are 
characterised by the ability to self-renew and differentiate into more than one 
lineage (Cumano et al., 1993). HSCs progressively lose part of their 
differentiation and self-renewal capacity as they develop into multipotent 
progenitors, which can then further differentiate into an early lymphoid progenitor 
(ELP) or a common myeloid progenitor (CMP) (Fig. 1.7). 
ELPs constitute the first progenitors with strong lymphoid and weak myeloid 
potential and are therefore more likely to develop into natural killer (NK) cells, B 
or T lymphocytes (Igarashi et al., 2002). Conversely, CMPs differentiate 
preferentially into erythrocytes, platelets, basophils, mast cells, eosinophils, 
neutrophils, dendritic cells or macrophages (Fig. 1.7) (Akashi et al., 2000). These 
terminal products of HSC differentiation are relatively short-lived and therefore 
haematopoiesis is required throughout the lifespan of an adult organism.  
HSCs are present in the bone marrow of adult mice and humans (Kiel et al., 
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2005). Adult HSCs are normally quiescent and fewer than 10% of them resume 
proliferation and differentiation every day (Weissman, 2000). This balanced 
equilibrium ensures that fresh leukocytes and erythrocytes are generated on a 
daily basis, without consuming all of the resources available to an adult 
organism. 
 
 
Figure 1.7: Development of HSCs in the bone marrow and formation of oligopotent 
progenitors of the lymphoid (B, T and NK cells), myeloid (basophils, mast cells, 
eosinophils, neutrophils, dendritic cells and macrophages) and erythroid (erythrocytes 
and platelets) lineages. 
HSCs generate different types of multipotent progenitors (MPPs), which further develop into early 
lymphoid progenitors (ELPs) or common myeloid progenitors (CMPs). ELPs loose part of their 
multipotency and differentiate into either common lymphoid progenitors (CLP) or granulocyte-
myeloid progenitors (GMPs) but not megakaryocyte erythroid progenitors (MEPs). CMPs can 
preferentially differentiate into GMPs or MEPs. CLPs further specialize into CLP-2, which mostly 
give rise to B lymphocytes. GMPs are oligopotent myeloid progenitors. MEPs are mostly erythroid 
progenitors (reproduced with permission from Bhandoola et al., 2007, Immunity, copyright (2007) 
Elsevier).  
 
1.3.2 Early B cell development 
In the bone marrow, ELPs further differentiate into common lymphoid 
progenitors (CLPs), which can give rise to the first B cell progenitor the pre-pro-B 
cell (also known as Fraction A), although they also retain the ability to 
differentiate into T cells (Welner et al., 2008). CLPs begin to synthesise the 
receptor for IL-7, a cytokine fundamental for B and T cells development and 
survival in adult mice (Vosshenrich et al., 2003). Pre-pro-B cells are 
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characterised by the presence of the surface marker B220, which is specific of 
the B cell lineage (Hardy et al., 1991). 
Another key surface marker in the B (and T) cell lineage is CD43 (also 
known as leukosialin) (Gulley et al., 1988). This marker is present on early B cells 
but has an expression pattern that is the opposite to B220, decreasing as pre-
pro-B cells differentiate into early pro-B (Fraction B) and late pro-B (Fraction C) 
(Hardy et al., 1991). Globally, pro-B cells exhibit a decreasing dependence on 
layers of feeder stromal cells and increased response to IL-7 for their proliferation 
(Hardy et al., 1991). 
 
1.3.3 Immunoglobulin rearrangement  
Immunoglobulin (Ig) rearrangement is a crucial process for the formation of 
an effective immune system (Jung et al., 2006). This process involves the 
random recombination of the different parts (V,D and J) of the Ig heavy, kappa 
and lambda loci and generates potentially infinite combinations (Li et al., 2004). 
This creates a degree of diversity in the population of lymphocytes that 
guarantees the recognition of virtually any antigen (Jung et al., 2006). 
Ig rearrangement begins in early and late pro-B cells, with D-J 
rearrangement of the heavy chain detected in both, whereas pre-pro-B cells 
express germ line Ig (Hardy et al., 1991). Large pre-B cells are characterised by 
the complete rearrangement (VDJ) of the heavy chain genes but still have germ 
line light chain genes (Sakaguchi and Melchers, 1986). This leads to the 
formation of a pre-B cell complex (pre-BCR) on the surface, where a heterodimer 
of λ5 and VpreB (called surrogate light chain or SL chain) substitutes for the light 
chain  (Pillai and Baltimore, 1987).  
The formation of the pre-BCR complex is a fundamental checkpoint and 
failure to form this complex blocks B cell development (Melchers et al., 1993). 
The pre-BCR complex triggers the burst in proliferation observed for large pre-B 
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cells, thus ensuring enrichment of a population of cells capable of correctly 
presenting a rearranged and properly folded heavy chain (Hardy et al., 1991). 
Signalling through the pre-BCR allows the transition from large to small pre-B 
cells, where V-D rearrangement of the light chain takes place (Shapiro et al., 
1993). 
 
1.3.4 B cell maturation 
Once small pre-B cells have completed V-D rearrangement, they become 
immature B cells and migrate from the bone marrow to the white pulp of the 
spleen (Allman et al., 1993) The spleen belongs to the group of secondary 
lymphoid organs together with Peyerʼs patches, subcutaneous and mesenteric 
lymph nodes, and is the site of immature B cell maturation (Picker and Butcher, 
1992) (Fig. 1.8). 
 
 
Figure 1.8: Hierarchical representation of B cell development.  
In the bone marrow, CLPs differentiate into pre-pro-B cells (here termed Committed progenitors). 
Pro-B cells begin to rearrange their heavy-chain and become pre-B cells once their pre-BCR is 
complete. Light chain rearrangement marks the end of the development of the BCR in the bone 
marrow, as immature B cells express a mature BCR and migrate towards the spleen. Here they 
develop into T1 and T2 B cells and mature into resting follicular and marginal zone B cells. 
Follicular zone B cells are not confined solely to the spleen and populate the other secondary 
lymphoid organs. B cell activation leads to the formation of terminally differentiated plasma cells 
and resting memory B cells (reproduced with permission from Bottero et al., 2006, Cell Death and 
Differentiation, copyright (2006) Nature Publishing Group). 
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Immature B cells have an estimated half-life of 3-4 days, are characterised 
by low level of B220 on their surface and constitute only 5-10% of the total B cells 
present in the spleen (Sprent, 1993). In this organ, immature B cells undergo full 
maturation by passing through up to 3 intermediate stages (termed T1, T2 and 
T3)  (Allman et al., 2001). 
 
1.3.5 Organisation and functions of the spleen 
The spleen is composed of a red and a white pulp. The red pulp is the site 
of filtering of the blood and is highly enriched in macrophages, which engulf old 
erythrocytes and actively participate in the recycling of the iron present in 
haemoglobin (Kristiansen et al., 2001). This area also contains antibody-
secreting B cells, which are thus conveniently positioned to release antibodies 
into the circulatory system (Sze et al., 2000). 
The white pulp constitutes the largest lymph node in the body of both 
humans and mice (Cesta, 2006). From the inside to the outside, the white pulp is 
composed of a central arteriole, a T cell zone (also known as periarteriolar 
lymphoid sheath, PALS), follicles (also known as B cell zones) and an outer 
marginal zone (Mebius and Kraal, 2005) (Fig. 1.9). As implied by their name, the 
T and B cell zones are enriched for T and dendritic cells and B cells respectively, 
and are the sites of the T-cell-dependent activation and germinal centre formation 
(Jacob and Kelsoe, 1992).  
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Figure 1.9: Schematic representation of the white pulp of the spleen of an adult mouse. 
The central arterioles originate from the afferent main splenic artery. The follicle contains 
quiescent follicular B cells and follicular dendritic cells and is the site of formation of germinal 
centres. The T-cell zone contains dendritic and T cells. The marginal zone is composed by 
endothelial cells macrophages, marginal zone B cells, dendritic cells and memory B cell  
(reproduced with permission from Mebius and Kraal, 2005, Nature Reviews Immunology, 
copyright (2005) Nature Publishing Group). 
 
The marginal zone is histologically more complex. Endothelial cells 
compose the area surrounding follicles and PALS (Balázs et al., 2001). 
Sialoadhesin-expressing macrophages form a layer close to the white pulp 
(Munday et al., 1999).  
Marginal zone macrophages delimit the outermost border of the white pulp. 
These cells express SIGNR-1, which captures antigens present in the blood, and 
are therefore important for the T-independent activation of marginal zone B cells 
(see below) (Geijtenbeek et al., 2002). The area in between these two types of 
macrophages contains dendritic cells, MZ and memory B cells (Liu et al., 1991). 
B cell maturation in the spleen gives rise to different subsets of mature B 
cells that are located in physically distinct areas of this organ. T2 cells mature 
into follicular type I and II B cells (Cariappa et al., 2007). Follicular B cells are 
mature B cells characterised by their ability to recirculate from the spleen and 
migrate to other lymph nodes (Allman and Pillai, 2008) (Fig. 1.10).  
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Figure 1.10: Model for splenic maturation of T1 cells into follicular and marginal zone B 
cells.  
Rather than proceed through a hierarchical developmental model, T2 cells are likely to bypass the 
T3 stage and directly develop into type II (FOLII) cells, which have the potential of developing into 
marginal zone precursors (MZP) and marginal zone mature cells (MZ). Alternatively, T2 (and T3) 
cells can differentiate into type I follicular B cells (FOLI) (reproduced with permission from Allman 
and Pillai, 2008, Current Opinion in Immunology, copyright (2008) Elsevier). 
 
T2 cells also develop into marginal zone precursor B-cells, which become 
marginal zone (MZ) B cells and lose the surface marker CD23 (Srivastava et al., 
2005). MZ B cells remain largely in the marginal, outer layer of the spleen 
(Mebius and Kraal, 2005). The decision between follicular or MZ B cell 
development largely depends on the extent of the stimulation of the B cell 
receptor (BCR) on the surface of IM B cells (Cariappa et al., 2001). High BCR 
stimulation promotes the development of mature follicular B cells, whereas a 
weak BCR signalling leads to the formation of a MZ B cell. However, the BCR is 
required for the survival of all B cells in the periphery (Kraus et al., 2004). 
Follicular and MZ B cells differ in the markers that are expressed on the cell 
surface: CD23 and high IgD on the former and high HSA and CD1d on the latter 
(Allman and Pillai, 2008). 
Both types of mature B cells normally survive in a quiescent state and wait 
for encounter with the antigenic stimulus that will active their proliferation and 
  53 
activate the immune response (Paul et al., 1987). Follicular B cells play a key role 
in T-dependent activation, which is mediated by antigen-presenting cells (APCs) 
and T-helper (TH) cells (see section 1.3.6) and represent, by far, the largest 
population of mature resting B cells in the spleen (Singer and Hodes, 1983). 
Activation of follicular B cells leads to formation of terminally differentiated long-
lived plasma cells (PC) and memory B cells Only 5% of the total pool of splenic 
resting B cells is composed of MZ B cells, which play an important role in T-
independent activation following bacterial infection, leading to the formation of 
short-lived PCs (Andersson et al., 1972). 
 
1.3.6 T-dependent B cell activation and development 
Mature follicular B cells are located in the follicles of the spleen and 
peripheral lymph nodes. Physically, these regions are adjacent to T cell 
reservoirs known as T-cell zones (Pillai and Cariappa, 2009). The activation of T 
cells by APCs (see section 1.3.9) triggers the relocalization of T cells towards the 
edge of the follicles (Ansel et al., 1999). At the same time, antigens initiate a 
cascade of events that leads to a migration of B cells towards the T-cell zone 
(Garside et al., 1998). This generates a germinal centre (GC), which is 
characterised by B cell proliferation, rearrangement of the immunoglobulin 
variable (V) genes and clonal selection to ensure the proliferation of cells capable 
of recognizing the specific antigenic peptide (Berek et al., 1991). A proportion of 
clonally selected B cells exit the GC and become memory B cells (McHeyzer-
Williams and Ahmed, 1999). 
Memory B cells constitute a heterogeneous population of quiescent, 
selected, mature B cells that, upon re-encounter with the specific antigen that 
generated them, can rapidly mount an immune response by quickly resuming 
proliferation (Good-Jacobson and Shlomchik, 2010). Alternatively, GC B cells can 
further develop into plasmablasts that migrate to regions of the lymph nodes 
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adjacent to blood capillaries (Sze et al., 2000). In these regions, termed junction 
zones, plasmablasts actively proliferate and terminally differentiate into long-lived 
PCs (García De Vinuesa et al., 1999) (Fig. 1.11). 
 
 
Figure 1.11: Schematic representation of different developmental pathways for mature B 
cells.  
Upon encounter with blood-borne antigens, MZ B cells proliferate and develop into short-lived 
plasma cells, which rapidly become apoptotic. This pathway is also observed in splenic follicular 
B cells. Alternatively, follicular B cells can develop into memory B cells or plasmablasts. Upon 
second exposure to the antigen that generated them, memory B cells rapidly proliferate and 
directly form plasmablasts. These short-lived cells complete the developmental programme by 
becoming terminally differentiated long-lived plasma cells, which secrete immunoglobulins and 
are localized primarily in the bone marrow. Plasma cells are also present in secondary lymphoid 
organs and at sites of inflammation, where they eventually become apoptotic and die (reproduced 
with permission from Radbruch et al., 2006, Nature Reviews Immunology, copyright (2006) 
Nature Publishing Group). 
 
Long-lived PCs develop in secondary lymphoid tissues and home mostly to 
the bone marrow (Manz et al., 1997). Terminal differentiation of a proliferating 
plasmablast into a terminally differentiated long-lived PC is marked by exit from 
the cell cycle in G1 (Vernino et al., 1992). PC will then go on exerting their sole 
function as Ig-secreting cells and will no longer resume proliferation (Tourigny et 
al., 2002). 
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1.3.7 T-independent B cell activation and development 
MZ B cells are able to respond to blood-borne antigens and mount an 
effective immune response in the absence of TH cells (Balázs et al., 2002). 
Examples of T-independent antigens include lipopolysaccharide (LPS), present 
on the surface of bacteria (Martin and Kearney, 2002). The response of MZ B 
cells to antigens is a proliferative burst followed by formation of short-lived PCs 
(Martin and Kearney, 2002). MZ B cells develop into intermediate plasmablasts, 
which move from the marginal zone to the red pulp, in a region adjacent to blood 
vessels (O'Connor et al., 2002). These short-lived PC undergo apoptosis 
following a period of intensive production of Igʼs  (Auner et al., 2010). Follicular 
and memory B cells are also capable of generating short-lived PC in response to 
sustained antigen exposure (Radbruch et al., 2006). 
 
1.3.8 T cell development 
The development of B and T cells overlaps in the earliest stages, until 
progenitors rapidly migrate from the bone marrow to the blood vessels before 
reaching the thymus (Wright et al., 2001). Indeed, all T cells precursors are 
detectable in the blood of adult mice (Umland et al., 2007) (Fig. 1.12). 
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Figure 1.12: Hierarchical representation of T cell development from HSCs in the bone 
marrow and blood, where the first T cell specific progenitor (common T cell progenitor, 
CTP) can be identified.  
The thymus is the site of T cell maturation and TCR selection. Here blood-borne precursors enter 
in response to the cytokine CCR9 and become thymus-settling progenitors (TSPs). In the thymus 
they develop into double negative 1(DN1) or early thymic progenitors (ETPs). ETPs develop into 
double negative 2 and then 3 (DN2 and 3) cells, whereas DN1 can directly lead to the formation 
of DN3. DN3 become double positive (DP) T cells, which express both CD4 and CD8 on their 
surface. Single positive (SP) mature, naïve T cells are the result of different stimulation of either 
receptor and migrate from the thymus to the secondary lymphoid organs (reproduced with 
permission from Bhandoola et al., 2007, Immunity, copyright (2007) Elsevier). 
 
The first T cell-specific progenitor population is found in the blood and are 
called circulating T cell progenitors (CTPs) (Rodewald et al., 1994). These cells 
exhibit diminished B cell, myeloid and erythroid differentiation potential both in 
vivo and in vitro (Krueger and von Boehmer, 2007). ELPs, CLP1s, CLP2s and 
CTPs express the surface marker CCR9, which is important for their entry into 
the thymus (Schwarz et al., 2007). In the thymus, T cell progenitors are globally 
termed thymus-settling progenitors (TSPs) (Izon, 2008). TSPs receive strong 
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differentiation stimulation by thymic stromal cells through the Notch pathway 
(Radtke et al., 1999). TSPs develop into early thymic progenitors (ETPs) and 
double-negative 1 (DN1) cells, which are defined by their common lack of CD3, 
CD8 and CD25, the presence of CD44 and CD117 (also known as Kit) (Shortman 
and Wu, 1996).  
ETPs are characterised by low levels of CD4 on their surface, whereas DN1 
cells are completely devoid of this marker (Michie et al., 1998). DN1 cells can be 
further divided into subsets, based on the markers on their surface. DN1a and b 
are characterised by the absence (DN1a) or presence (DN1b) of CD24 on their 
surface (Porritt et al., 2004). DN1c cells have particularly high levels of CD24 but 
lower levels of Kit than DN1a and b. DN1d and e are defined by the presence of 
IL-7 receptor and lack of Kit. They differ for the presence (DN1d) or absence 
(DN1e) of CD24.  
ETPs acquire CD25 and become double negative 2 (DN2) cells (Lind et al., 
2001). These cells possess some multi-lineage potential as they can differentiate 
into NK and DC as well as DN3 T cells (Shen et al., 2003). Both DN1s and DN2 
cells differentiate into DN3 cells, which are characterised by the reduction in the 
expression of CD44 and Kit as well as reduced DC and NK differentiation 
potential (Benz and Bleul, 2005). DN3s downregulate CD25 and CD44 
expression and become DN4 T cells (Godfrey et al., 1993). Similar to the BCR 
receptor, T cells progressively rearrange the V, D and J regions to generate 
heterogeneous combinations of T cell receptors (TCRs) during their development 
in the thymus (Capone et al., 1998). There are 4 TCR loci (α, β, γ and δ) that are 
subject to rearrangement in T cells (von Boehmer, 1990).  
The  α and γ TCR loci contain V and J segments, the β locus V, D and J, 
the δ locus J and D. Most mature T cells have a rearranged TCR composed of a 
heterodimer of α and β (TCRαβ) but a distinct population of TCRγδ also exists 
(Pardoll et al., 1987). The choice is dictated by the intensity of signalling through 
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the Notch ligand in the thymus: high in the case of TCRαβ and low in that of 
TCRγδ (Ciofani et al., 2006). The rearrangement of the genes in the β locus 
begins in DN2 cells and this promotes the subsequent rearrangement of the α 
locus (Petrie et al., 1995). DN4s can either generate a TCR-bearing T cell or 
proliferate and express CD4 and CD8 surface markers and become double 
positive (DP) T cells (Ciofani et al., 2006). DP cells complete the maturation of 
their TCR receptors by rearranging the α locus (Guo et al., 2002).  
DPs are immature T cells that present the receptors for major 
histocompatibility complex (MHC) class-I (CD8) and class-II (CD4) antigens 
(Germain, 1994). MHC antigens are peptides expressed on the surface of most 
cells as a response to the presence of cytosolic and extracellular antigens 
respectively. Class-I antigens are expressed on most cells, whereas class-II are 
synthesized by B cells, macrophages, dendritic cells, monocytes and endothelial 
cells.  
The resolution of the double positive state to single positive (SP) CD4+ or 
CD8+ cells marks the maturation of T cells  (Germain, 2002). The length of 
stimulation of CD4 or CD8 drives the developmental choice between CD4 versus 
CD8 differentiation (Yasutomo et al., 2000). SP CD4+ and CD8+ cells 
(henceforth referred to as CD4+ and CD8+ respectively) leave the thymus as 
quiescent mature cells (Feng et al., 2011) and populate secondary, peripheral, 
lymphoid organs: mostly subcutaneous lymph nodes but also the mesenteric 
lymph node, Peyerʼs patches and, to a lesser extent, the spleen  (Williams and 
Butcher, 1997). 
Peripheral lymph nodes have a structure similar to the white pulp of the 
spleen (Fig. 1.13). The inner paracortex contains naïve T cells and DCs, while 
resting B and follicular DCs are located in the adjacent cortex (Drayton et al., 
2006). Mature lymphocytes enter the lymph nodes via the high endothelial 
venules (HEVs), while DCs are transported by the afferent lymphatic vessels 
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(Randolph et al., 2005). 
 
 
Figure 1.13: Structure of a subcutaneous peripheral lymph node from a mouse.  
Similar to the white pulp in the spleen, subcutaneous lymph nodes are divided into a T cell zone 
(paracortex) and follicular zone (cortex). Lymphocytes are introduced via the high endothelial 
venules (HEVs), while dendritic cells enter via the afferent lymphatic vessels. Cells in the cortex 
secrete CXCL13, which promotes the migration of B cells towards the paracortex. CCL19 and 21, 
instead, position DCs and T cells towards the B cell zone, thus promoting the formation of 
germinal centres in the cortex. The cortex is protected by an external capsule (reproduced with 
permission from Drayton et al., 2006, Nature Immunology, copyright (2006) Nature Publishing 
Group). 
 
DCs activate T cells by means of their MHC antigens, which stimulate the 
TCR, and by co-stimulation of CD28 on the surface of T cells (King et al., 1996). 
As in the spleen, stromal and endothelial cells secrete different cytokines that 
help to position B and T cells in close proximity, in order to stimulate the 
formation of GCs in the cortex (Cyster, 2003). SP naïve (CD25-) T cells compose 
more than 80% of the pool of total T cells in peripheral lymph nodes, whereas the 
spleen contains naïve as well as memory T cells (Williams and Butcher, 1997).  
 
1.3.9 CD4+ activation and development 
The TCRs on the surface of CD4+ T cells recognize MHC class-II on the 
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surface of APCs, leading to activation of T cells (Abbas et al., 1996). Several 
types of activated, effector T-helper cells (TH) have been identified: TH1, 2, 9, 17 
and follicular (Tfh) (Mosmann and Coffman, 1989). 
 
 
Figure 1.14: General scheme showing outcomes of CD4+ T cells activation.  
Exposure to pathogens triggers the activation of naïve CD4+ T cells and leads to formation of 
effector T helper (TH1 and 2 only shown here) and regulatory T cells. Dendritic cells operate as 
antigen presenting cells and stimulate the TCR and CD28 receptor on naïve T cells through their 
MHC antigen and CD80/86 respectively. TH1 cells secrete IFN-γ, which promotes cytotoxic 
activity of effector CD8+ T cells and macrophage activity. TH2 cells secrete cytokines (IL-4, 5 and 
6) that stimulate B cell activation and eosinophil recruitment. Regulatory T cells control the 
immune response by negatively regulating the activities of effector T cells and neutrophils 
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(reproduced with permission from Mills, 2004, Nature Reviews Immunology, copyright (2004) 
Nature Publishing Group). 
 
TH1 cells respond to the stimulation of their TCRs by secreting cytotoxic 
granule proteins and interferon-γ (IFN-γ), which activate macrophages and 
stimulate CD8+ T cells (Smeltz et al., 2002). They are implicated in mounting an 
immune response against intracellular bacteria, viruses, fungi and protozoa 
(Sadick et al., 1987). TH2 cells respond to extracellular pathogens and promote B 
cell activation by stimulating them through the BCR and CD40 receptor and by 
secreting IL-4 (Singer and Hodes, 1983) (Fig. 1.14).  
TH9 cells are closely related to TH2 but secrete high levels of IL-9 
(Veldhoen et al., 2008). TH17 cells share a spectrum of targets similar to TH1 
and are characterised by the secretion of IL-17A, E and F (Weaver et al., 
2006). Tfh cells stimulate follicular B cells and are distinct from TH2 by the 
secretion of stimulating IL-21 rather than IL-4 and by a different transcriptional 
programme (Chtanova et al., 2004).  
Activated CD4+ T cells can also become induced or adaptive regulatory T 
cells (Tregs), as opposed to the subset of naturally occurring, thymic Tregs 
generated in the thymus by clonally selecting the TCR via the interaction with a 
peripheral self-peptide (Sakaguchi et al., 1995). Natural Tregs play a pivotal role 
in the control of immunological responses and in the prevention of autoimmune 
diseases as they negatively regulate effector T cells and APS  (Vignali et al., 
2008) (Fig. 1.16). Natural and induced Tregs can inhibit effector T cells through 
secretion of immunosuppressive cytokines transforming growth factor-β (TGF-β) 
and IL-10 (Annacker et al., 2003).  
Alternatively, natural Tregs secrete cytolytic cytokines such as granzyme A 
and B or perforin (Grossman et al., 2004). Treg cells are distinguishable from 
naïve SP T cells as they express high levels of the surface marker CD25 (a 
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marker acquired also by activated SP T cells) (Zelenay et al., 2005). CD25 is a 
component of the IL-2 receptor, a cytokine that promotes proliferation in activated 
T cells (De La Rosa et al., 2004). Therefore, it has been postulated that Tregs 
deprive activated SP T cells of IL-2, thus blocking their proliferation (Pandiyan et 
al., 2007). Lastly, Tregs can act upstream and inhibit DC activation of SP T cells. 
Tregs present the cytotoxic T-lymphocyte antigen 4 (CTLA4) on their surface and 
trigger the release by DCs of the immunosuppressive molecule indoleamine 2,3-
dioxygenase (IDO) (Fallarino et al., 2003). 
 
 
Figure 1.15: Proposed mechanisms of action of Treg cells.  
(A) Tregs secrete immunosuppressive cytokines such as TGF-β, IL-10 and 35, which repress T 
cell proliferation. (B) Tregs release cytotoxic molecules (granzyme A and B and perforin) that 
trigger the apoptosis of effector T cells. (C) The CD25 on the surface of Tregs and activated T 
cells is a receptor for the stimulatory cytokine IL-2. Tregs can capture IL-2 and starve effector T 
cells. (D) Tregs express CTLA4 on their surface, which stimulates the CD80/86 receptor on 
  63 
dendritic cells. This stimulates the release of immunosuppressive IDO from dendritic cells 
(reproduced with permission from Vignali et al., 2008, Nature Reviews Immunology, copyright 
(2008) Nature Publishing Group). 
 
Following acute stimulation of the TCR, CD4+ cells exit quiescence and 
resume proliferation (Varga and Welsh, 1998). Most of these activated cells are 
short-lived, but a subset of them differentiate into long-lived CD4+ memory T 
cells (Harrington et al., 2008). Memory T cells provide a mechanism to trigger a 
stronger and faster immunological response upon re-encounter with the antigen 
that generated them (Zinkernagel et al., 1996). 
Memory T cells proliferate rapidly following stimulation (Sallusto et al., 
2004). They can either be central memory cells (characterised by the expression 
of CCR7, a surface marker required for homing in secondary lymphoid organs) or 
effector memory cells (which are negative for CCR7 and reside at peripheral 
sites) (Henao-Tamayo et al., 2010). Both types of memory cells are capable of 
producing IFN-γ upon restimulation but central memory T cells have a stronger 
proliferative tendency and are the only memory T cells capable of secreting IL-2 
(Unsoeld et al., 2002). 
 
1.3.10 Development of CD8+ T cells  
Quiescent CD8+ cells can differentiate into short-lived effectors, long-lived 
memory T cells or Treg cells (Kim et al., 2010). A notable difference between 
CD4+ and CD8+ resting cells is the dramatic proliferative burst observed in the 
latter following stimulation (Murali-Krishna et al., 1998). Activated CD8+ cells 
produce and secrete high quantities of cytotoxic granule proteins and antiviral 
cytokines (Podack and Kupfer, 1991). The vast majority of these highly 
proliferating cytolytic effectors become apoptotic within 2-3 weeks of activation 
but a small fraction develop into memory T cells (Kaech and Ahmed, 2001). 
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Stimulation of resting CD8+ cells can also lead to the production of regulatory T 
cells (Kim et al., 2010). CD4+ and CD8+ Tregs inhibit different cell types, with the 
latter uniquely controlling Tfh cells (Kim et al., 2010). 
 
1.4 Transcriptional regulation 
One of the central aims of this thesis is to investigate the mechanisms that 
regulate the transcriptional programme of quiescent lymphocytes. In this section, 
I will cover some general concepts of eukaryotic transcription and review the 
recent literature on the role of chromatin and histone modifications in 
transcriptional control. 
 
1.4.1 Regulatory elements 
The mouse genome (mm9) encompasses 28,661 protein-encoding genes. 
With a few exceptions, these genes are present in their germline configuration in 
every mouse cell, from the pluripotent embryonic to the terminally differentiated 
ones. Therefore, what defines each cell type from the others is the regulation of 
gene expression. A transcriptional programme can be defined as a mechanism to 
regulate the differential expression of sets of genes. The regulation of gene 
expression can occur at different stages: transcription of the DNA sequence of a 
gene into an immature RNA, maturation (or processing) of immature RNA into a 
messenger RNA (mRNA), transport of RNA from the nucleous (site of the 
transcription) to the cytoplasm (site of translation of into peptide sequences), 
stability of the RNA, translation and stability of the protein encoded by the mRNA. 
The regulation of RNA transcription is believed to be a major determinant of the 
expression of a gene, but regulation of RNA processing and stability can also 
have important roles (Maston et al., 2006). 
Many genes have regulatory elements upstream or within their DNA 
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sequence. These regulatory elements can promote or repress transcription and 
are often regulated in a tissue-specific manner. Regulatory elements are often 
hypersensitive to the action of the enzyme DNase I (Wu, 1980) and DNase 
hypersensitivity is a widely exploited method for mapping regulatory regions 
across genomes (Crawford et al., 2006). Briefly, DNases cleave DNA regions not 
based on their sequence but on their accessibility, which is affected by the 
organisation of DNA into nucleosomes (Wu et al., 1979). Binding of transcription 
factors and the transcriptional machinery partially displaces nucleosomes leading 
to hypersensitivity relative to surrounding regions (Gross and Garrard, 1988). 
DNase hypersensitive regions (DNase HS) can be either constitutive or 
inducible. Constitutive DNase HS regions are found both at transcriptionally 
positive elements (promoters and enhancers and locus control regions) and 
negative elements (silencers, insulators) (Gross and Garrard, 1988). DNase 
sensitivity can also be acquired as a previously silent gene becomes active 
(Elgin, 1988).  
 
a. Core Promoters 
Core promoters are generally located around the transcriptional start site 
(TSS) of eukaryotic genes and constitute the minimal regulatory element required 
for transcription (McKnight and Kingsbury, 1982). These regions define the TSS 
of a transcript as they recruit the components of the pre-initiation complex (PIC), 
which serves as a positioning mechanism for RNA Pol II (Safer et al., 1985). The 
PIC is composed of the general transcription factors (GTFs) TFIIA, B, D, E, F and 
H, RNA Pol II and the Mediator complex (Hahn, 2004). 
Transcription factors bind to specific DNA sequences and promote or 
repress transcription (in which case they are termed silencers or repressors) 
(Ptashne and Gann, 1997). Transcription factors can directly interact with the PIC 
but often operate by recruiting other proteins that lack DNA binding domains (co-
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activators or co-repressors), which interact with the PIC (Kadonaga, 2004). 
Moreover, transcription factors regulate transcription by recruiting chromatin-
remodelling factors and histone-modifiers (discussed below). 
According to the canonical model of transcriptional activation, the assembly 
of the PIC begins with the binding of TFIID to a DNA sequence within the core 
promoter known as the TATA box (Starr and Hawley, 1991) (Fig. 1.16). TFIID is a 
multi-protein complex composed by a TATA-binding protein (TBP) and several 
TBP associated factors (TAFs) (Reinberg et al., 1987). TBP is a universal 
eukaryotic transcription factor that binds to the TATA box at core promoters (Wu, 
1985). 
 
Figure 1.16: Basic structure of core promoters.  
Consensus sequences are displayed below the names (reproduced with permission from Smale 
and Kadonaga, 2003, Annual Review of Biochemistry, copyright (2003) ANNUAL REVIEWS). 
 
TAFs work as co-activators and govern the specificity of TBP binding 
(Dynlacht et al., 1991). TAFs also bind to other components of core promoters: 
TAF1 and 2 bind to the Initiator (Inr), TAF6 and 9 to the Downstream Promoter 
Element (DPE) (Smale and Kadonaga, 2003) (Fig. 1.16). TFIIA stabilizes the 
interaction between the TATA box and TFIID (Liu et al., 1999). TFIIB binds to 
another element of core promoters called the TFIIB-recognition element (BRE) 
and bridges between TFIID and RNA Pol II, thus establishing the direction of 
transcription (Lagrange et al., 1998). 
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There is evidence that RNA Pol II binds to the core promoter as a 
preformed holoenzyme, which contains the Mediator complex together with 
TFIIE, TFIIF and TFIIH (Myer and Young, 1998). The Mediator complex is a large 
multi-protein complex, which is required for optimal activation of transcription in 
eukaryotes in vivo (Jiang et al., 1998). TFIIE and H are important for 
transcriptional initiation through the phosphorylation of the carboxyl-terminal 
domain (CTD) of RNA Pol II and will be discussed later. 
 
b. Proximal promoters 
Proximal promoters are located within 100 bp upstream of core promoters 
(La Volpe et al., 1983). Proximal promoters often coincide with unmethylated 
CpG-rich regions called CpG islands (Bird, 1980). Current evidence suggests 
that CpG islands promote transcription of housekeeping, tissue-specific and 
developmental genes (Deaton and Bird, 2011). The distribution of CpG islands 
across the genome frequently overlaps with sites of transcriptional initiation and 
has helped with the identification of new TSSs (Carninci et al., 2006). CpG 
islands are often associated with an open DNA configuration but not necessarily 
with active transcription as RNA Pol II binding at CpG islands is observed even at 
silent genes (Guenther et al., 2007). Similarly, there is evidence that activating 
transcription factors might bind to CpG islands constitutively and independently of 
the transcriptional status of the gene (Cuadrado et al., 2001).  
CpG islands are enriched for binding sites for the transcription factor Sp1 
(G/T-GGGCGG-G/A-G/A-C/T) called the GC box element. Sp1 binds to these 
regions and recruits TBP even in the absence of a TATA box, thus allowing the 
formation of the PIC (Butler and Kadonaga, 2002). TATA-less promoters are 
quite frequent, particularly at CpG-rich promoters (Carninci et al., 2006). CpG 
islands also contain binding sites for other transcription factors such as E2F and 
ETS (Jaeger et al., 2010). However, not all CpG islands contain binding motifs for 
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activators and there is also evidence that they mediate the recruitment of 
repressors such as Polycomb group proteins (see section 1.6) (Mendenhall et al., 
2010).  
Cytosines in CpG islands can also become C5-methylated, a covalent 
modification that is thought to reinforce silencing (Stein et al., 1982). Historically, 
DNA methyltransferases (DNMT) 3A and B were termed de novo 
methyltransferases as they methylate unmodified cytosines, whereas DNMT1 
preferentially methylates hemimethylated DNA and is therefore implicated in the 
copy of this mark to newly synthesised DNA strands during S phase (Jones and 
Liang, 2009). However, DNMT3A and B are also required for the maintenance of 
the mark and all three enzymes are required for the correct development of 
mammals (Okano et al., 1999). It is important to point out that DNA methylation 
does not always impair the binding of transcription factors (Hsieh, 2000).  
At silent promoters, DNA methylation, however, frequently co-localizes with 
the repressive histone mark H3K9me3 (see section 1.4.3) and reinforces 
transcriptional repression through the binding of methyl-binding domain proteins 
(MBDs), which recruit repressive histone-modifiers  (Bogdanović and Veenstra, 
2009). Methylated cytosines are also bound by Tet1, which converts the methyl 
group into a hydroxymethyl group (Tahiliani et al., 2009). This phenomenon leads 
to different effects on promoters depending on the context. In ES cells conversion 
to hydroxy-methyl cytosine positively affects transcription at certain promoters, 
possibly by removing MBDs. However, it can also allow the recruitment of 
repressive complexes such as PRC2 (see section 1.6) (Wu et al., 2011a). 
Additionally, Tet1 promotes gene repression by directly recruiting co-repressors 
such as SIN3A (Williams et al., 2011). 
 
c. Enhancers 
Enhancers stimulate transcription of their target genes by promoting 
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formation of the PIC (Banerji et al., 1983). Unlike promoters, enhancers work 
independently of their orientation and show positional flexibility relative to the 
TSS (Banerji et al., 1981). Enhancers are often found upstream of proximal 
promoters but can also be located within or downstream from the gene they 
control (Gillies et al., 1983).  
Similar to proximal promoters, enhancers feature binding sites for 
transcriptional activators (termed enhancer binding factors) (Atchison, 1988). 
Despite their distance from the TSS, factors that bind to enhancers can directly 
interact with the Mediator complex and TFIID through the recruitment of the 
Cohesin complex, which causes the DNA structure to loop out (Hadjur et al., 
2009). The recruitment of histone modifiers and chromatin remodelling 
complexes by enhancer-bound factors is also crucial and, indeed, enhancers are 
characterised by the presence of particular histone variants (H3.3 and H2A.Z) 
and modifications (H3K27ac and H3K4me1/2) (see below) (Ong and Corces, 
2012).  
Furthermore, non-coding RNAs are transcribed directly at enhancers and 
have been shown to promote the interactions of enhancer-bound complexes to 
the promoter-bound PIC (Wang et al., 2011b). For some genes, enhancers could 
also be the site of initial recruitment of the PIC, as in the case of the E enhancer 
of the pD1 promoter in the TCRβ locus (Spicuglia et al., 2002).  
 
d. Silencers 
Silencers and enhancers share similar properties: both operate in a 
position- and orientation-independent fashion and both work through the binding 
of DNA binding proteins (Laimins et al., 1986). Silencers contain binding sites for 
repressors, which can directly impair the binding of the PIC or of activators 
(Harris et al., 2005). Alternatively, repressors can recruit histone-modifiers that 
cause chromatin to adopt an inaccessible conformation (heterochromatin), which 
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I will discuss later (Srinivasan and Atchison, 2004). 
 
e. Insulators 
Insulators define boundaries between DNA domains and block the effects of 
activators and silencers that regulate neighbouring genes (Chung et al., 1993). 
Insulators can restrain the effect of enhancers and proximal promoters by 
sequestering activators (Defossez et al., 2005). Insulators might block 
heterochromatic-spread by recruiting histone-modifiers that promote the 
formation of an open chromatin structure (euchromatin) (Litt et al., 2001). 
 
f. Locus control regions 
Locus control regions (LCRs) are regions capable of conferring position-
insensitive and copy-dependent expression on a linked gene in a transgenic 
assay (Grosveld et al., 1987, Dillon et al., 1997). LCRs contain multiple clusters 
of transcription factor binding sites. These regions are bound by transcription 
factors and histone-modifiers, which generate an overall open conformation that 
promotes transcription (Tolhuis et al., 2002). LCRs operate independently of the 
position and orientation of the genes they control (Spilianakis et al., 2005).
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Figure 1.17: Mechanism of action of regulatory DNA elements on gene expression.  
(A) Enhancers are distal elements and promote transcription through the binding of activators that 
stimulate the recruitment of the PIC. (B) Silencers promote transcriptional repression through the 
binding of repressors, which in turn recruits chromatin-remodelers that lead to the formation of a 
compact structure. (C) Insulators confine the effects of enhancers to their target genes by 
sequestering activators (here depicted). At the same time, they restrict the activity of silencers by 
recruiting histone-modifiers that promote the formation of an open chromatin structure and 
antagonize silencer-induced chromatin compaction. (D) Locus control regions (LCRs) globally, 
promote the transcription of loci or groups of genes. This is achieved through the formation of an 
overall open chromatin structure and through direct contact between LCR sequences and their 
target promoters (reproduced with permission from Maston et al., 2006, Annual review of 
genomics and human genetics, copyright (2006) ANNUAL REVIEWS). 
 
1.4.2 The regulation of RNA Pol II at promoters 
a. RNA Pol II recruitment 
Eukaryotic RNA Pol II is composed of 12 evolutionary conserved subunits 
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called Rbp1-12 (Allison et al., 1985). Rbp1 is the largest subunit of this complex 
and the one that mediates binding to the DNA (Kimura et al., 1997). The 
carboxyl-terminal domain (CTD) of Rpb1 contains multiple repeats of the peptide 
N-Tyr-Ser-Pro-Thr-Ser-Pro-Ser-C (Corden et al., 1985). There are 52 repeats of 
this sequence in the mammalian CTD, although the heptapeptide shows 
increased sequence variations towards the N-terminus (Egloff and Murphy, 
2008). This long repeated region of the protein is subject to a dynamic cycle of 
post-translational modifications that play an essential role in regulating 
transcription and are involved in the recruitment of proteins implicated in the 
processing of immature RNAs (also known as pre-mRNAs) (Bentley, 2005) (Fig. 
1.18). 
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Figure 1.18: The RNA Pol II cycle (clockwise from top-centre).  
Unphosphorylated RNA Pol II is recruited to promoters by the PIC. The phosphorylation of the 
CTD by TFIIH on serine 5 disrupts the interaction between RNA Pol II and the Mediator complex 
(promoter clearance) and marks the beginning of transcription (initiation). RNA Pol II reaches the 
pausing site where a decision is made between transcriptional arrest and elongation. p-TEFb is 
implicated in RNA Pol II commitment to elongation at this stage through serine 2 phosphorylation 
and removal of negative elongation factors. The activity of p-TEFb is enhanced by the 
phosphorylation of serine 7 on the CTD, also mediated by TFIIH, which might occur after 
promoter clearance and during transcriptional pausing. Elongating RNA Pol II is therefore 
phosphorylated on serine 2, 5 and 7, although serine 5 is progressively lost toward the 3ʼ end of 
the gene. Possibly reflecting a role in transcriptional termination and 3ʼ end maturation of 
transcripts, both serine 2 and 7 marks persists after the transcriptional end site. Finally, the 
mRNA is released from the enzyme, which is dephosphorylated and removed from the DNA. 
Soluble RNA Pol II is recruited by the Mediator complex and can start another round of 
transcription (reproduced with permission from Brookes and Pombo, 2009, EMBO reports, 
copyright (2009) Nature Publishing Group). 
 
Between recruitment of RNA Pol II and completion of a transcription cycle, 
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the CTD of RNA Pol II undergoes specific phosphorylations on different residues 
at specific stages of the transcriptional process (Komarnitsky et al., 2000). 
 
b. Promoter escape and the phosphorylation of RNA Pol II on serine 5 
As previously described, current evidence indicates that RNA Pol II is 
recruited to the DNA as part of a holoenzyme that features the Mediator complex 
and the GTFs TFIIE, F and H (see section 1.4.1). Mediator recruits the 
unphosphorylated form of RNA Pol II and any phosphorylation of the CTD 
disrupts this interaction and the recruitment of RNA Pol II to promoters (Chesnut 
et al., 1992). 
Following recruitment of RNA Pol II, phosphorylation of serine 5 on the CTD 
(S5p Pol II) disrupts the interaction between Mediator and RNA Pol II, which can 
leave the promoter region and begin to move towards the 3ʼ-end of the gene 
while transcribing a complementary RNA (Komarnitsky et al., 2000) (Fig. 1.18). 
Serine-5 phosphorylation is mediated by TFIIH, which is recruited to the PIC by 
TFIIE (Søgaard and Svejstrup, 2007). TFIIH is composed of 10 subunits that 
form a core and a kinase domain, with the former implicated in the denaturation 
of DNA during the beginning of transcription (Saunders et al., 2006). The kinase 
domain of TFIIH (also known as CAK: CDK-activating kinase) contains a Cyclin 
H/CDK7 complex (which phosphorylates the CTD) and a regulatory subunit 
(Madt1) (Shiekhattar et al., 1995).  
S5p Pol II is also a mark recognized by enzymes responsible for the 5ʼ-end 
methylguanosine capping of pre-mRNAs and by histone-modifiers that generate 
typical patterns of histone marks at active promoters (described below)  (Fabrega 
et al., 2003). The loss of S5p Pol II has a stronger impact on nascent and 
precursor mRNAs than on fully spliced, polyadenylated mRNAs (Helenius et al., 
2011). Indeed, the levels of S5p Pol II do not necessarily correlate with 
transcriptional levels in ES cells, as S5p Pol II is present at both active and 
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Polycomb-repressed genes, where little or no elongation and productive 
transcription is observed. 
 
c. Phosphorylation of RNA Pol II on serine 7 
TFIIH also phosphorylates the CTD on serine 7 (S7p Pol II) at core 
promoters (Akhtar et al., 2009). S5p and S7p Pol II are marks observed at core 
promoters and their localization decreases dramatically in the gene bodies 
(Brookes et al., 2012). S7p Pol II is always observed in conjunction with S5p Pol 
II at the promoter of actively transcribed genes, whereas S5p Pol II alone can be 
detected at some repressed genes (Brookes et al., 2012).  
S7p Pol II is required for the expression of non-coding small nuclear RNAs 
(snRNAs) (Egloff et al., 2007). This activity is mediated through recruitment of the 
Integrator, a 12-subunit complex that regulates the 3ʼ end formation of snRNAs 
(Baillat et al., 2005). Moreover, S7p Pol II recruits p-TEFb (positive transcriptional 
elongation factor-b), which phosphorylates RNA Pol II on serine 2 (S2p Pol II) 
thus triggering transcriptional elongation (see section 1.4.2d)  (Czudnochowski et 
al., 2012). 
 
d. Transcriptional pausing 
Following initiation and release from the PIC, S5p Pol II frequently stops its 
5ʼ to 3ʼ progression approximately 25-50 bp downstream of the TSS, a region 
termed the pausing site (Gariglio et al., 1981) (Fig. 1.19). Transcriptional pausing 
is observed at many housekeeping and inducible genes, regardless of their 
transcriptional status (Guenther et al., 2007). Between transcription of the first 
25-50 nucleotides and full transcription of the gene, structural changes are likely 
to be required (Core and Lis, 2008).  
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Figure 1.19: Schematic representation of transcriptional pausing.  
(A) The negative elongation factors DSIF and NELF stop the progression of S5p Pol II 20-50 bp 
downstream of the TSS. S5p Pol II helps to recruit factors implicated in RNA capping, which 
takes place at pausing sites. In some instances, a stalled RNA Pol II backtracks a variable 
distance from the actual pausing site and a now-unaligned 3ʼ end transcript extrudes from the 
enzyme. To resume transcription this transcript has to be degraded. (B) TFIIS potentiates the 
RNA Pol II intrinsic RNase activity toward the extruding, unaligned transcript and limits 
transcriptional arrest. p-TEFb (and probably CDK12) phosphorylates the CTD on serine 2, which 
recruits elongation factors, histone-modifiers, splicing and 3ʼ-end maturation factors. p-TEFb 
binding also coincides with displacement of NELF from the pausing site (reproduced with 
permission from Saunders et al., 2006, Nature Reviews Molecular Cell Biology, copyright (2006) 
Nature Publishing Group). 
 
mRNA capping occurs during this phase and it has been postulated that this 
pause serves as a checkpoint before further phosphorylation of the CTD recruits 
other enzymes to the CTD involved in splicing and 3ʼ processing (Palangat et al., 
2005). Pausing sites coincide with the localization of negative elongation factors: 
DSIF and NELF  (Yamaguchi et al., 1999). DSIF is composed of the subunits 
Spt4 and Spt5 (Hartzog et al., 1998). Interestingly, Spt5 promotes RNA capping 
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in vitro, thus corroborating the hypothesis that transcriptional pausing is a key 
moment to ensure correct processing of pre-mRNAs (Wen and Shatkin, 1999). 
NELF is composed of four subunits (A, B, C/D and E) and might bind directly to 
the nascent transcript via its RNA-binding subunit NELF-E (Yamaguchi et al., 
1999). The release of RNA Pol II from pausing sites is a rate-limiting step in 
transcription and is regulated by the general transcription factor TFIIS and by p-
TEFb.  
The stalled RNA Pol II often backtracks from pausing sites and the now 
unaligned 3ʼ end of the pre-mRNA extrudes from the enzyme (Pal and Luse, 
2003). For transcription to resume, these unaligned 3ʼ end ribonucleotides need 
to be cleaved. Backtracking constitutes a rate-limiting step and, depending on the 
length of the sequence covered, pausing can become a transcriptional arrest, 
which leads to the formation of abortive short and unprocessed transcripts 
(Voliotis et al., 2008). RNA Pol II has a weak RNase activity and can therefore 
degrade short unaligned 3ʼ end portions generated during pausing (Shirai and 
Go, 1991). The GTF TFIIS enhances this RNase activity and reduces 
transcriptional arrest after backtracking (Fig. 1.19B) (Adelman et al., 2005). 
 
e. Transcriptional elongation and phosphorylation of RNA Pol II on serine 2 
At the pausing site, RNA Pol II can either be S5p Pol II or S5p/S7p Pol II. 
Phosphorylation of Serine 7 enhances the kinase activity of the p-TEFb complex 
towards serine 2 of the CTD (S2p Pol II) (Czudnochowski et al., 2012) (Fig. 1.19). 
p-TEFb is composed by Cyclin T and CDK9 and has been shown to promote 
elongation in vivo (Ni et al., 2008). Other kinases, such as CDK12 in complex 
with Cyclin K, have been shown to phosphorylate the CTD on serine 2 as well 
(Bartkowiak et al., 2010). p-TEFb binding has also been shown to displace NELF 
and, therefore, p-TEFb and CDK12 might cooperate to remove negative 
regulators of elongation and switch the CTD to its elongating configuration  
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(Levine, 2011). S2p Pol II promotes the recruitment of enzymes implicated in 
mRNA splicing and 3ʼ end maturation as well as histone-modifiers, which are 
responsible for the deposition of particular histone marks found on the bodies of 
transcribed genes (see below) (Buratowski, 2009).  
S2p Pol II is also recognized by Spt6, which further promotes elongation 
(Yoh et al., 2007). Distribution of S2p Pol II across the body of a gene increases 
from the pausing site towards the transcriptional end site and peaks 
approximately 1kb downstream of the termination site, in antithesis to what is 
observed for S5p Pol II (Brookes et al., 2012) (Fig. 1.18). Serine-5 
phosphorylation is progressively lost as the polymerase progresses towards the 
3ʼ end of the gene through the action of the phosphatase Rtr1 (Mosley et al., 
2009) and Ssu72 (Reyes-Reyes and Hampsey, 2007). 
 
1.4.3 Chromatin conformation and transcriptional regulation 
a. Spatial organization of the DNA in higher eukaryotes 
In most eukaryotes, the DNA is organised in a beads-on-a-string structure 
called chromatin. The nucleosomes form the repetitive structural units of 
chromatin (Fig. 1.20). A nucleosome is composed of an octamer of highly basic 
histones around which the DNA is wound (Luger et al., 1997). The histone 
octamer is organised as dimers: histones H3 and H4 form two dimers that 
associate with two dimers of histone H2A and H2B. The DNA is wrapped around 
this structure (147 bp, in 1.65 superhelical turns) from which unstructured histone 
tails extrude (Andrews and Luger, 2011) (Fig. 1.20). A fifth histone (H1) can 
interact with the DNA between nucleosomes (linker DNA) and generate a tighter, 
higher-order chromatin structure. 
The positioning and the density of nucleosomes have been shown to 
influence transcription. In vitro studies have demonstrated that nucleosomes 
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reduce transcription by 75% compared to naked DNA templates, which are 
similar to linker DNA. Nucleosomes affect the recruitment of RNA Pol II and the 
PIC, but elongation is not blocked by the presence of nucleosomes thanks to 
proteins that travel with S2p Pol II and remove nucleosomes ahead of the 
enzyme (Lorch et al., 1987). This observation is in agreement with the sensitivity 
to DNase that characterises regulatory elements (Crawford et al., 2004). Since 
nucleosomes protect DNA from the activity of DNases the DNase I sensitivity 
data provide evidence that regulatory elements are located in nucleosome-
depleted or -poor regions.  
Constitutive DNase sensitive regions possess distinguishing features that 
make them constitutively nucleosome-poor (Yuan et al., 2005). These 
constitutively open regions are normally localised at genes that are constitutively 
active in an organism (Schones et al., 2008). These regions usually lack a TATA 
box and present a high percentage of poly dA:dT in their sequence, which are 
harder to bend in order to position histones (Struhl, 1985). CpG islands are also 
common at these genes and these DNA sequences tend to generate unstable 
nucleosomes (Ramirez-Carrozzi et al., 2009). 
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Figure 1.20: Schematic representation of nucleosome assembly.  
The DNA (black) is wrapped around an initial tetramer composed by two histone H3 (blue) and 
H4 (green) dimers. Subsequently, two dimers of histone H2A (yellow) and H2B (red) are 
incorporated (reproduced with permission from Cockerill, 2011, FEBS Journal, copyright (2011) 
John Wiley and Sons). 
 
Pioneer factors are a class of transcriptional factors that initiate chromatin 
remodelling and allow other co-factors to be recruited to nucleosome-rich 
chromatin regions (Zaret and Carroll, 2011). Pioneer factors such as FoxA, FoxE, 
FoxO, TLE and GATA factors can bind to nucleosome rich regions through direct 
interactions with the nucleosome (Cirillo et al., 2002). Pioneer factors share 
domains with the linker histone H1, which avidly binds to nucleosomes (Sekiya et 
al., 2009).  
Furthermore, FoxA factors have been shown to displace H1, possibly by 
competing with it for binding sites on nucleosomes (Taube et al., 2010). Like 
histone H1, the pioneer factor FoxL1 maintains its association with chromatin 
even during mitosis and might therefore flag promoters for activation or silencing 
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in the daughter cell (Yan et al., 2006). 
Two mechanisms for how pioneer transcription factors operate have been 
described. FoxO factors, for example, cause a direct perturbation of the 
interaction between the core nucleosome and the DNA, facilitating the opening of 
chromatin (Hatta and Cirillo, 2007). Alternatively, pioneer factors can bind to 
tissue-specific promoters and, if the correct stimulus is received, can serve as 
pre-formed scaffolding units for other factors (Levine, 2010). Following the initial 
binding of activators and repressors, these factors recruit chromatin-remodelers 
and histone-modifiers, which alter the local structure of chromatin and promote or 
repress the binding of the PIC (Fig. 1.21).  
 
 
Figure 1.21: Schematic representation of nucleosome remodelling during the activation of 
a regulated gene.  
Upon binding to its target sequence, a transcription factor can recruit chromatin-remodelers 
and/or histone-modifiers that alter the structure of neighbouring regions. This exposes additional 
binding sites and leads to recruitment of more activators and to the acquisition of an open 
chromatin structure that allows the binding of the PIC (reproduced with permission from Cairns, 
2009, Nature, copyright (2009) Nature Publishing Group). 
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b. Chromatin remodelling 
Chromatin-remodelers are co-factors that use the energy obtained from 
hydrolysis of ATP to assemble, eject and move nucleosomes (Cosma et al., 
1999). Chromatin-remodelers interact with histone modifications, DNA-binding 
proteins and other co-factors. Based on their structural domains, they are 
classified into four families: SWI/SNF, ISWI, CHD and INO80 (Clapier and 
Cairns, 2009). 
SWI/SNF family members (BAF and PBAF) contain a bromodomain and an 
HSA-domain (which functions as a DNA helicase) (Mohrmann and Verrijzer, 
2005). Bromodomains recognize acetylated residues on histone tails, which are 
associated with active promoters (see section 1.4.3). SWI/SNF remodelers move 
and eject nucleosomes to open promoters and activate transcription (Lorch et al., 
1999). 
ISWI members (NURF, CHRAC and ACF) contain a SANT and a SLIDE 
domain that together bind to unmodified histone tails and DNA (Corona and 
Tamkun, 2004). CHRAC and ACF regulate nucleosomal spacing, creating a 
regular phasing and promoting repression, possibly by hiding activator binding 
sites inside nucleosomes (Längst et al., 1999). However, because NURF tends to 
randomize nucleosome phasing, this ISWI remodeler promotes activation of 
several essential genes (Deuring et al., 2000). 
CHD members (CHD1, 2, 3, 4, 5, 9 and NuRD) feature two chromodomains, 
which recognize and promote direct binding to DNA, RNA and methylated 
histone tails (see section 1.4.3) (Marfella and Imbalzano, 2007). CHD members 
can both promote or repress transcription. In the first instance, they do so by 
sliding or ejecting nucleosomes, following recognition with transcriptionally 
positive histone methylation marks (see section 1.4.3). Alternatively, CHD 
members interact with histone deacetylases and methyl-CpG binders and 
therefore couple histone remodelling (sliding and spacing) with histone 
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deacetylaton and DNA methylation. The INO80 family members (INO80 and 
SWR1) are structurally related but regulate chromatin remodelling via different 
pathways, as part of different multi-protein complexes (INO80.com and 
SWR1.com) (Bao and Shen, 2007). INO80.com can bind to DNA (like SWI/SNF 
members) and enhance transcription in vitro (Shen et al., 2000). 
INO80 regulates nucleosome positioning by mobilizing octamers along the 
DNA (Udugama et al., 2011) This mechanism is similar to the one used by ISWI 
members and, like them, INO80 might both promote and repress gene 
expression, as its ablation in vivo leads to an equal number of genes up- and 
downregulated (Jónsson et al., 2004). SWR1 is the catalytic subunit of the SWR1 
complex and replaces H2A-H2B with H2A.Z-H2B dimers (see below) (Kobor et 
al., 2004). 
 
c. Histone variants 
With the sole exception of histone H4, variants exist for all other canonical 
histones (H1, H3, H2A and H2B). Some of these variants differ by only one 
residue (i.e., histone H3 and its variant H3.2) (Marzluff et al., 2002). However, 
some are associated preferentially with specific histone modifications and, 
therefore, they might contribute to the differential recruitment of histone-modifiers 
(Hake and Allis, 2006). Other groups of non-canonical histone variants play 
specific roles in different processes such as gene regulation, X-chromosome 
inactivation and DNA damage repair (Talbert and Henikoff, 2010)(Fig. 1.22). 
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Figure 1.22: Schematic representation of the canonical histones and main histone 
variants.  
For each sequence, the N-terminal tail and the globular core containing the conserved histone 
fold domain and the C-terminal tail are highlighted. Different shades of colour indicate highly 
divergent sequences, whereas single amino acids are shown. Circles, triangles, trapezoid and 
squares represents post-translational modification specific for each histone variant (circles stand 
for phosphorylation, triangles for acetylation, trapezoid for ubiquitination and squares for 
methylation). The macro-domains of the different types of macroH2A histone are not drawn to 
scale. which is responsible for intra-histone interactions, constitutes the conserved portion among 
variants. MacroH2A1.1 and 1.2 are splice variants and these differences are highlighted by using 
white and black triangles in the macro domains (reproduced with permission from Bernstein and 
Hake, 2006, Biochemistry and Cell Biology, copyright (2006) NRC Research Press). 
 
Non-canonical variants usually replace canonical histones in a DNA 
replication independent manner and are transcribed throughout the cell cycle. 
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Some of these histones have a specific genomic location, such as the histone H3 
variant CENP-A, which is found exclusively at centromeres and regulates 
kinetochore assembly during mitosis (Régnier et al., 2005). The histone H2A 
variant macroH2A is particularly enriched on the inactive X-chromosome 
(Costanzi and Pehrson, 1998). 
Other variants are expressed in particular tissues, such as the testis-
specific H2B variants H2B1A and H2AFWT (Churikov et al., 2004). Histone H1 
variants exhibit both tissue-specific and cell cycle-specific patterns of expression 
within the same cell type (Izzo et al., 2008). The H2A variant H2A.Bbd (H2A.Lap 
in mouse) is expressed in the spermiogenic fraction of mammalian testis and 
specifically associates with acetylated H4-containing nucleosomes (Ishibashi et 
al., 2010). 
Some non-canonical histones are ubiquitously expressed and play key 
functions. H2A.X, for example, is covalently modified (phosphorylated, acetylated 
and ubiquitinated) following double-stranded DNA breaks and, in this form, 
recruits the enzymes required for DNA repair (Ikura et al., 2007). Other variants 
are involved in gene regulation and will be discussed in greater depth. 
 
i) Histone H3.3  
The histone variant H3.3 differs from the canonical histone H3 by only four 
residues (Loyola and Almouzni, 2007). While canonical H3 (also known as H3.1) 
is deposited into nucleosomes only during S-phase, H3.3 is also deposited 
outside S (Ahmad and Henikoff, 2002). H3.3-containing nucleosomes are usually 
located in DNA hypersensitive regulatory elements, which display high turnover 
(Teves and Henikoff, 2011).  
It has been shown that H3.3-containing nucleosomes are less stable than 
those containing H3.1 (Jin and Felsenfeld, 2007). This characteristic has the 
potential to allow H3.3-containing nucleosomes to alter the chromatin structure of 
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active promoters, where H3.3 is particularly enriched and presents histone 
modifications normally associated with transcription (Chow et al., 2005). 
Moreover, the deposition of H3.3 by the histone regulator A (HIRA) complex has 
been shown to antagonize the recruitment of histone-modifiers responsible for 
repressive histone marks  (Sutcliffe et al., 2009). 
 
ii) Histone H2A.Z 
H3.3 is often found together with the H2A variant H2A.Z around the TSS of 
active genes in mammals or at enhancers (Henikoff, 2008). H2A.Z forms a less 
stable interaction with H2B than canonical H2A (Placek et al., 2005). H3.3-
H2A.Z-containing nucleosomes assembled in vitro are particularly unstable and 
their presence at the TSS is likely to facilitate the recruitment of the PIC following 
their removal (Jin and Felsenfeld, 2007).  
H2A.Z is conserved among species and is required for viability in 
Tetrahymena, Drosophila and mouse (Guillemette and Gaudreau, 2006). 
Positioning of H2A.Z by the SWR1 remodeler has been proved and genome-wide 
studies in human CD4+ T cells have shown that its localization is restricted to the 
first 3 nucleosomes upstream and downstream of the TSS (Schones et al., 
2008). Interestingly, H2A.Z is found at both active and silent genes in budding 
yeast, although the latter group encompasses genes that are poised for 
activation (Raisner et al., 2005).  
H2A.Z ablation in quiescent yeast strains results in a failure to activate 
inducible genes following growth restimulation (Li et al., 2005). One of the 
functions of H2A.Z is to oppose heterochromatin spreading and, at least in 
plants, H2A.Z deposition antagonizes DNA methylation (Zilberman et al., 2008). 
Similar to canonical H2A, H2A.Z is subject to post-translational modifications at 
its N- and C-terminal domain and these histone marks might regulate the stability 
of H2A.Z in the context of nucleosomes and determine the transcriptional activity 
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of genes that have this variant incorporated at their promoters (Draker et al., 
2011).  
Interestingly, the proximity of H2A.Z to the TSS is directly proportional to the 
transcriptional activity of active promoters in mice (Bargaje et al., 2012). In 
addition to its positive role in transcriptional initiation, the presence of H2A.Z 
downstream of the TSS at pausing sites positively regulates elongation in yeast 
(Santisteban et al., 2011). H2A.Z is also found at pericentric heterochromatin in 
mammalian cells, where it interacts with the components of the Chromosomal 
Passenger Complex (see section 1.5) (Rangasamy et al., 2003). 
Deposition of H2A.Z is required for centromere silencing and chromosome 
segregation during mitosis in yeast (Hou et al., 2010). Interestingly, centromeric 
histones can be divided into those that contain H2A.Z and those that contain 
CENP-A as these two variants are mutually exclusive (Greaves et al., 2007). 
During mouse spermatogenesis, H2A.Lap1 is specifically inserted at the -1 
nucleosome (relative to the TSS) of active genes instead of H2A.Z and its 
deposition partly unfolds chromatin (Soboleva et al., 2012). 
 
d. Post-translational modification of histones 
One of the ways in which co-factors can regulate transcription is to alter the 
stability of core nucleosomes by introducing post-translational modifications of 
histone residues.  The histone tails are regions of the proteins, generally at the N-
termini, that protrude from the nucleosome and are the principal, albeit not 
exclusive, sites of post-translational modification associated with transcriptional 
regulation (Luger et al., 1997). Histone tails can be acetylated, methylated, 
phosphorylated and monoubiquitinated (Fig. 1.23). 
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Figure 1.23: Schematic representation of the position of the major post-translational 
modifications of the tails of canonical histones.  
The following modification are shown: acetylation (ac), methylation (me), phosphorylation 
(ph) and monoubiquitination (ub1) (reproduced with permission from Bhaumik et al., 2007, Nature 
Structural and Molecular Biology, copyright (2007) Nature Publishing Group). 
 
Multiple modifications occur on different histone tails and on different residues 
within the same nucleosome. This generates a layer of transcriptional regulation 
referred to as the histone code (Strahl and Allis, 2000). Histone modifications are 
implicated in several mechanisms such as DNA repair, mitosis and 
transcriptional regulation. For the purpose of this thesis, I will now focus on the 
role of histone modifications in transcriptional regulation. The role of histone 
modifications in mitosis will be covered in section 1.5.  
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i) Histone acetylation 
Nucleosomes are assembled by enzymes called chaperones, which 
recognize acetylated histones and load them onto the DNA (Verreault, 2000). 
After being translated in the cytoplasm, histone acetyltransferases (HATs) 
acetylate the lysine residues of cytoplasmic histones by using acetyl coenzyme A 
as a source of acetyl moieties. After chaperones have recognized and deposited 
the acetylated histone on the nucleosome, this mark is rapidly erased by histone 
deacetylases (HDACs) (Shahbazian and Grunstein, 2007).  
Once they form part of nucleosomal DNA, several residues on all histones 
can be re-acetylated by HATs. Globally speaking, histone acetylation loosens the 
nucleosomal structure, favours DNA accessibility and therefore promotes 
transcription (Mutskov et al., 1998). The acetylation of lysine 16 on histone H4 
(H4K16ac) is particularly important, as it is required to maintain an open 
chromatin conformation (euchromatin) and is found on the promoters and gene 
body of active genes (Wang et al., 2008).  
Acetylation of other residues is also required for proper gene activation (Kuo 
et al., 1998). Two major HAT complexes have been identified: SAGA and NuA4. 
Gcn5, the catalytic subunit of SAGA, acetylates preferentially histones H3 and 
H2B, whereas Esa1, which belongs to NuA4, targets H4 and H2A (Suka et al., 
2001). These complexes are recruited by activators and other histone 
modifications that are often found on active genes, such as trimethylation of 
lysine 4 and 36 on histone H3 (H3K4me3 and H3K36me3) (Ng et al., 2003). 
H3K4me3 is present on the promoters, whereas H3K36me3 is present on the 
coding region (Krogan et al., 2003). Histone trimethylation constitutes a mark, 
which is recognized by the chromodomain present in different classes of proteins 
mostly implicated in silencing (discussed later) as well as members of SAGA and 
NuA4. 
The chromatin loosening initiated (and maintained) by H4K16ac is 
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enhanced by further histone acetylation, which in turn promotes recruitment of 
activators at promoters (Lee et al., 1993). However, H4K16ac has a paramount 
role in antagonizing the formation of higher-order chromatin compaction and 
nucleosome remodelling that would impede access to chromatin (Shogren-Knaak 
et al., 2006). The acetylated histone marks generated by HATs are read by co-
factors such as the SWI/SNF remodelling complex, which bind to them through 
their bromodomains (Barbaric et al., 2001).  
The Elongator complex, which interacts with the hyperphosphorylated RNA 
Pol II during elongation, contains a HAT domain and might directly mediate 
histone acetylation on gene bodies, loosening nucleosomal DNA and facilitating 
the passage of RNA Pol II (Close et al., 2006). Conversely, HDACs repress 
transcription by removing the acetyl mark (Robert et al., 2004). HDACs also 
promote the binding of repressors, such as SANT domain-containing proteins, 
which recognize unmodified histone tails and promote silencing through 
chromatin remodelling (Hartman et al., 2005). 
 
ii) Histone methylation 
Unlike histone acetylation, which is a general mark for active or poised 
genes, histone methylation can serve as a mark for active as well as silent genes 
depending on the residue (Saunders et al., 2006). Lysines can be mono-, di- or 
trimethylated. Arginines are monomethylated, or they can be symmetrically or 
asymmetrically dimethylated. Histidines are monomethylated (Greer and Shi, 
2012). Lysine-methyltransferases include SET-domain-containing and DOT1-like 
protein families, arginines are methylated by protein arginine N-
methyltransferases (PRMTs) (Greer and Shi, 2012).  
Lysine-demethylases belong to the jumonji C (JmjC)-domain-containing 
dioxygenases and amine oxidases families (Greer and Shi, 2012). Some 
methyltransferases and demethylases are directly recruited to specific DNA 
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sequences (Woo et al., 2010). Additionally, non-coding RNAs (ncRNAs) have 
been shown to participate in the recruitment of these histone-modifiers (Tsai et 
al., 2010). 
Interestingly, although they are mediated by different families of enzymes, 
DNA and histone methylation are linked. Some histone methyltransferases 
contain methyl-CpG-binding domains and their recruitment and activity is 
augmented by DNA methylation (Rajakumara et al., 2011). At the same time, 
DNMTs are recruited by histone marks such as H3K9me3 and thus participate in 
reinforcing silencing (Hsieh, 2000). 
As previously mentioned, H3K4me3 is generated by several 
methyltransferases (such as SETD1A/B and MLLs) and usually marks active 
promoters. H3K4me3 also promotes recruitment of HATs (Santos-Rosa et al., 
2002). In addition, methyltransferases responsible for generating H3K4me3 can 
form complexes with demethylases specific for the trimethylation of lysine 27 on 
histone H3 (H3K27me3), a well-characterised repressive mark established by the 
Polycomb repressive complex 2 (PRC2) (see section 1.6) (Miller et al., 2008). 
However, H3K4me3 and H3K27me3 can be present on the same promoter in a 
group of genes in ES cells (termed bivalent). These genes are repressed but 
poised for activation following differentiation (Stock et al., 2007).  
H3K36me3 marks the body of active genes, where it recruits HATs and 
might regulate alternative splicing, as its level is higher in constitutively rather 
than in alternatively spliced exons and introns (Kolasinska-Zwierz et al., 2009). 
H3K36me2 peaks at the promoters of active genes and, together with 
H3K36me3, antagonises the repressive functions of PRC2-mediated H3K27me3 
(Schmitges et al., 2011). While H3K4me3 marks promoters, H3K4me1 is usually 
detected at enhancers of active genes (Heintzman et al., 2007). H3K9me3 is 
found at inactive promoters, where its chromodomain is bound by 
heterochromatin protein 1 (HP1) (Fischle et al., 2005).  
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The site-specificity of each histone methylation means that it is difficult to 
make global assumptions about the effects of the methyl-motif on the stability of 
nucleosomes. This heterogeneity is likely to stem from the wide spectrum of 
proteins that recognize the different methyl marks on histone tails. 
 
iii) Histone phosphorylation 
All histones are subject to phosphorylation by a large number of kinases 
and dephosphorylation by phosphatases (Nowak and Corces, 2000). Histone 
phosphorylation is generally associated with transcriptional activation 
(Kouzarides, 2007). This comes primarily from observations in cells where the 
RAS/ERK/MAPK signalling as been activated (Barratt et al., 1994). The ultimate 
effectors of this signalling cascade are the mitogen and stress-activated kinases 
1 and 2 (MSK1 and 2), which phosphorylate serine 10 and 28 on histone H3 
(H3S10ph and H3S28ph) at the promoters of immediate-early genes, such as c-
fos and c-jun, in response to mitogenic stimulation (Drobic et al., 2010). This is 
thought to facilitate transient activation of these genes, before the phospho-mark 
is removed by protein phosphatase 2A (PP2A) (Simboeck et al., 2010).  
The H3S10ph mark is read by 14-3-3 proteins, a large family of co-factors 
that are involved in several signalling pathways (Macdonald et al., 2005). 14-3-3 
proteins recruit the SAGA complex, leading to the acetylation of lysine 14 on 
histone H3 (H3K14ac) (Drobic et al., 2010). This phospho-acetyl motif 
(H3S10ph/K14ac) constitutes an even better docking site for 14-3-3 proteins, 
whose binding shields H3S10ph from the phosphatase activity of PP2A 
(Simboeck et al., 2010). 14-3-3 proteins can also recruit the SWI/SNF 
remodelling complex, which allows recruitment of the PIC and transcriptional 
initiation (Drobic et al., 2010) (Fig. 1.24). 
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Figure 1.24: Representation of transcriptional activation following activation of the 
Ras/ERK/MAPK pathway.  
(A) Silent promoters are marked by the repressive H3K9me3 modification, which serves as a 
binding site for HP1 proteins (such as HP1γ). Following stimulation, MSK1 phosphorylates serine 
10 on histone H3, which triggers the displacement of HP1γ and the binding of 14-3-3 proteins. 14-
3-3 proteins loosely bind to H3S10ph but recruit HATs that acetylate lysine 14 on histone H3. In 
this phospho-acetyl configuration, 14-3-3 proteins can bind more stably to promoters and facilitate 
recruitment of other co-activators. (B) Repressors such as Polycomb group proteins bind to lysine 
27 on histone H3 and deposit the repressive H3K27me3 mark on the promoter of silent genes. 
MSK1 phosphorylation of nearby serine 28 triggers the displacement of Polycomb repressors (but 
not the removal of H3K27me3) and constitutes on its own an excellent binding motif for 14-3-3 
proteins. 
 
H3S10ph and 14-3-3 proteins stimulate transcriptional elongation at 
pausing sites by recruiting HATs. The resulting acetyl-mark is read by the 
bromodomain protein BRD4, which then recruits p-TEFb (Zippo et al., 2009). 14-
3-3 proteins display the same binding affinity for H3S10ph/K14ac and H3S28ph 
alone in vitro (Macdonald et al., 2005). H3S28ph antagonizes PRC2 recruitment 
and the subsequent trimethylation of lysine 27 (Lau and Cheung, 2011). 
Interestingly, H3S28ph but not H3S10ph has been shown to physically interact 
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with S5p Pol II in vivo, suggesting a non-redundant role for these marks in 
transcriptional activation (Lau and Cheung, 2011).  
Histone H3 is also phosphorylated on threonine 11 (H3T11ph) by the 
protein kinase C-related kinase 1 (PRK1) (Metzger et al., 2008). This mark is 
read by the H3K9 demethylase JMJD2C, which contributes to the removal of the 
repressive marks H3K9me2/me3 from the promoters of androgen receptor-
responsive genes in response to stimulation. However, phosphorylation and 
methylation on the same histone tail are not always mutually exclusive, and 
histone phosphorylation can even be a mechanism to reinforce histone 
methylation when it constitutes a positive mark. The protein kinase C beta 1 
(PKC1) phosphorylates threonine 6 on histone H3 (H3T6ph) following androgen 
stimulation (Metzger et al., 2010). This mark blocks the activity of the H3K4me3 
demethylase LDS1 and promotes transcription.   
Finally, histone H1 can be phosphorylated at multiple residues. It has been 
postulated that the number rather than the position of the phosphorylated 
residues is important for the role of this post-translational modification on gene 
regulation.  Indeed, in its hyperphosphorylated form, histone H1 is displaced from 
chromatin, in turn revealing transcriptional factors binding sites and promoting 
transcription (Zheng et al., 2010). 
 
iv) Histone ubiquitination 
Polyubiquitination is a general mechanism for targeting proteins for 
proteasomal degradation. On the other hand, monoubiquitination of histones is a 
reversible post-translational modification acquired by histones H2A, H2A.Z and 
H2B, which is associated with transcriptional silencing (H2A and H2A.Z) or 
activation (H2B) (Komander and Rape, 2012). Ubiquitination is a multi-step 
process that involves a ubiquitin-activating enzyme (E1), which activates ubiquitin 
and transfers it to a ubiquitin-conjugating enzyme (E2) (Fig. 1.25).  
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Figure 1.25: Schematic representation of the ubiquitin-conjugating reaction.  
Ubiquitin binds in an ATP-dependent reaction to a ubiquitin-activating enzyme (E1). Ubiquitin is 
then transferred to a ubiquitin-conjugating enzyme (E2) that lacks substrate recognition capacity. 
The ubiquitin-protein-isopeptide ligase (E3) mediates the recognition and binding of ubiquitin to 
the lysine of a specific substrate. Monoubiquitination is a reversible process implicated in signal 
transmission. Polyubiquitination, in contrast, marks substrate proteins for proteosomal 
degradation (reproduced with permission from Osley, 2006, Briefings in Functional Genomics, 
copyright (2006) Oxford University Press). 
 
Ubiquitin is transferred from E2 to the substrate by a ubiquitin-protein-
isopeptide ligase (E3). In mammals, H2A is monoubiquitinated on lysine 119 
(H2Aubq), H2A.Z on lysine 120 or 121 (H2A.Zubq) and H2B on lysine 120 
(H2Bubq). H2Aubq is associated with transcriptional silencing through inhibition 
of elongation (Zhou et al., 2008). The H2Aubq mark can be generated by two 
enzymes: Ring1B (which will be discussed in session 1.6) and 2A-HUB, which is 
part of the N-CoR/HDAC complex. Ubiquitination of H2A by 2A-HUB has been 
shown to repress the transcription of a subset of chemokine genes in 
macrophages (Zhou et al., 2008). H2Aubq blocks recruitment of the Spt16 
subunit of the FACT complex. This complex is responsible for displacing H2A-
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H2B dimers from nucleosomes allowing RNA Pol II to transit (Zhou et al., 2008).  
In addition, there is evidence that H2Aubq promotes chromatin compaction 
through recruitment of H1 (Jason et al., 2005). H2A.Z is ubiquitinated by Ring1B 
and removal of this mark by the deubiquitinase USP10 results in activation of 
androgen receptor-dependent genes (Draker et al., 2011). H2Aubq 
deubiquitination is also associated with transcriptional derepression (Higashi et 
al., 2010). USP16 regulates expression of Hox genes by removing the repressive 
Ring1B-mediated H2Aubq mark (Joo et al., 2007). MYSM-1 preferentially 
deubiquitinates acetylated H2A and leads to increased binding of transcription 
factors (Jiang et al., 2011). Deubiquitination by USP21 counterbalances H2Aubq-
mediated inhibition of H3K4 trimethylation and promotes transcriptional initiation 
(Nakagawa et al., 2008).  
Unlike H2Aubq, ubiquitination of H2B is required for trimethylation of H3K4 
at promoters and plays a positive role in transcriptional initiation (Lee et al., 
2007). H2Bubq facilitates elongation probably by cooperating in FACT-mediated 
H2A-H2B removal (Pavri et al., 2006). Bre1, the mammalian E3 ligase for H2B, is 
recruited by activators to promoters before transcriptional initiation but H2Bubq 
can only be formed following S5p Pol II formation and promoter escape in vivo, 
as ablation of TFIIH eliminates this mark (Xiao et al., 2005). 
In yeast, the DUB Ubp8 removes H2Bubq and, surprisingly, is required for 
transcription (Wyce et al., 2007). Ubp8 is required for S2p Pol II formation and for 
elongation at pausing sites. The other yeast H2Bubq DUB, Ubp10, is, on the 
other hand, implicated in promoting silencing at telomeres (Osley, 2006). 
1.5 The Aurora B kinase 
The Aurora kinases are serine/threonine kinases, originally identified in 
Drosophila in a screen to identify regulators of the mitotic spindle function (Glover 
et al., 1995). Subsequent work identified Aurora kinase homologues in S. 
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cerevisiae (named Ipl1) and S. pombe (Ark1) (Brown et al., 2004). In mammals, 
three Aurora kinases have evolved: Aurora A, B and C.  
The mammalian Aurora kinases share a conserved catalytic domain in the 
central portion of the proteins and differ mostly at the N-terminal domain. The 
latter is implicated in protein-protein interactions (Fig. 1.26) (Brown et al., 2004). 
Similar to their Drosophila counterpart, the Aurora kinases orchestrate mitosis in 
mammalian cells. However, as a result of their different N-termini, Aurora A and 
B interact with different sets of proteins and exhibit different localizations during 
mitosis, which also translates into different functions (Carmena and Earnshaw, 
2003).  
 
 
Figure 1.26: Sequence comparison of human Aurora kinases.  
The A- and D-Boxes (at the amino and carboxy-termini respectively) are implicated in recognition 
of these kinases by the enzymes that regulate their degradation. The catalytic domain resides 
within the highly conserved kinase domain and is termed the T-Box. Percentages represent the 
sequence homology between human Aurora kinases (reproduced with permission from Keen and 
Taylor, 2004, Nature Reviews Cancer, copyright (2004) Nature Publishing Group). 
 
Aurora C is closely related to Aurora B and the two kinases share INCENP 
as a partner (Sasai et al., 2004). Moreover, a switch in roles between Aurora B 
and C is observed early during embryogenesis (Fernández-Miranda et al., 2011). 
Aurora C expression is tissue-specific and, after late blastocyst formation, is 
restricted to the testis. In meiotic cells, the gene that encodes Aurora C (Aurkc) is 
under the control of the transcription factor Testis Zinc Finger Protein (Tzfp) 
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(Tang et al., 2001).  
Aurora A and B are both ubiquitously expressed and are subject to 
regulation during the cell cycle with expression peaking in G2. Expression of the 
two kinases is controlled by transcription factors such as E2F1, E2F4 and FoxM1 
(Kimura et al., 2004). For the purposes of this work, I will first describe the 
regulation and functions of Aurora B during mitosis and I will then discuss the 
documented roles for the kinase outside mitosis.  
 
1.5.1 Regulation of Aurora B 
Activation of the kinase activity of Aurora B is a multistep process that 
begins with the autophosphorylation of its T-loop (Sessa et al., 2005). Although 
this is sufficient for substrate-specific phosphorylation in vitro, activation of 
Aurora B in vivo requires binding to the Inner Centromere Protein (INCENP) 
(Yang et al., 2009). INCENP is a microtubule binding protein that contains a 
sequence (the IN-box) at its C-terminal domain, which interacts with the N-
terminus of Aurora B and induces a conformational change in the active site of 
Aurora B (Sessa et al., 2005). An additional conformational change is required for 
full activation of Aurora B in vivo and is triggered by the phosphorylation of a 
region on INCENP (called the TSS motif). Aurora B itself is responsible for this 
phosphorylation and current evidence suggests that this is accomplished via an 
in trans-activation mechanism, mediated by a nearby, fully active Aurora B (Kelly 
et al., 2007). Support for this idea comes from the observation that Aurora B-
INCENP complexes tend to form small clusters. 
 Additionally, INCENP mediates the interaction of Aurora B with Survivin, a 
protein originally identified as a mediator of apoptosis (Ambrosini et al., 1997). 
Survivin interacts both with the N-terminus of INCENP and with the active site of 
Aurora B and stimulates its kinase activity (Chen et al., 2003). Survivin is also 
required for efficient localization of Aurora B at centromeres late in prophase 
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(Wang et al., 2010a) together with another protein, Borealin, which interacts with 
the N-terminal domain of INCENP but not directly with Aurora B (Klein et al., 
2006). Survivin and Borealin are required for the proper localization of Aurora B 
and INCENP at centromeres from late prophase until metaphase (Jeyaprakash et 
al., 2007). The recruitment of both Survivin and Borealin is regulated by histone 
modifications. Survivin binds to the phosphorylated threonine 3 on histone H3, 
which is generated by the kinase Haspin (Kelly et al., 2010). Aurora B 
accumulation at these regions is favoured by Aurora B phosphorylation of 
Haspin, thus generating a positive loop for the recruitment of both kinases to 
centromeres (Wang et al., 2011a).  
Borealin interacts with the Shugoshin proteins (Sgo1 and 2), which bind to 
the phosphorylated threonine 120 on histone H2A (H2AT120) (Yamagishi et al., 
2010). This mark is generated by the kinase Bub1, which plays also a role in the 
spindle assembly checkpoint together with Aurora B (see below) (Kawashima et 
al., 2010). Borealin is also subject to phosphorylation by CDK1, which favours 
the binding to Shugoshin proteins (Tsukahara et al., 2010). Similar to its role in 
recruiting Haspin, Aurora B promotes recruitment of Bub1 at centromeres, 
therefore positively regulating the binding of Borealin and, in turn, its own 
localization to centromeres (Ricke and van Deursen, 2011).  
Aurora B, INCENP, Survivin and Borealin together form a complex called 
the Chromosomal Passenger Complex (CPC) whose components travel together 
throughout mitosis (Carmena and Earnshaw, 2003). Interestingly, Aurora C can 
substitute for Aurora B as the catalytic subunit of this complex when exogenously 
overexpressed and is therefore also considered to be a member of the CPC 
(Slattery et al., 2009). Other proteins interact with Aurora B during mitosis but are 
not part of the CPC.  
In C. elegans, the Tousled-like kinase-1 (TLK-1) activates Aurora B in an 
INCENP-dependent manner, but this mechanism, to date, has not been reported 
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in mammals (Han et al., 2005). The Polo-like kinase 1 (Plk1) also promotes 
Aurora B activation by phosphorylating Survivin (Chu et al., 2011). Moreover, 
Plk1 cooperates with Aurora B in regulating the bipolar orientation of sister 
chromatids (see below) (Salimian et al., 2011). The DNA-damage kinase Chk1 
phosphorylates Aurora B and promotes Aurora B in trans-activation of INCENP 
(Petsalaki et al., 2011). Mps1 phosphorylates Borealin and is implicated in the 
regulation of kinetochore attachments with Aurora B (see section 1.5.3) (Jelluma 
et al., 2008). TD-60 plays a role in localizing Aurora B at centromeres and might 
operate in a similar manner to Chk1 by creating a cluster of Aurora B-INCENP 
complexes at centromeres (Rosasco-Nitcher et al., 2008).  Aurora B and Survivin 
have also been reported to interact with centromeric minor satellite RNAs, which 
would help to recruit the CPC and stimulate Aurora B kinase activity towards 
CENP-A (Ferri et al., 2009).  
Towards the end of cytokinesis Aurora B is polyubiquitinated by the 
Anaphase Promoting Complex/Cyclosome (APC/C), which recognizes the D-box 
of Aurora B and targets the kinase for proteosomal degradation (Stewart and 
Fang, 2005). Additionally, monoubiquitination by the Cul3-KLHL21 E3 ligase 
triggers the displacement of Aurora B from centromeres at the onset of anaphase 
(Maerki et al., 2009). Aurora B is also targeted by the SUMO (small ubiquitin-
related modifier) E3 ligase PIAS3 during mitosis (Ban et al., 2011). This post-
translational modification, which is also found on Borealin, regulates the 
localization of Aurora B on centromeres but not its activity (Fernández-Miranda et 
al., 2010).  
Aurora B is subject to negative regulation by the protein phosphatases 1 
and 2A (PP1 and 2A) (Murnion et al., 2001). These phosphatases operate in 
conjunction with other proteins that regulate their target specificity. The 
Sds22/PP1 and EB1/PP2A complexes directly dephosphorylate Aurora B at its 
catalytic site (Barr et al., 2011). RepoMan/PP1 targets histone H3 and negatively 
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affects Survivin-mediated Aurora B recruitment to centromeres by removing the 
H3T3ph mark (Vagnarelli et al., 2011). Moreover, RepoMan/PP1 
counterbalances Aurora B activity by dephosphorylating H3S10ph/S28ph. The 
KNL1/PP1 complex dephosphorylates Aurora B targets at kinetochores (Liu et 
al., 2010) (see section 1.5.3). 
 
1.5.2 Aurora B and chromosome compaction 
At the onset of mitosis the replicated DNA begins to condense into the 
compact structure of the mitotic chromosomes. During late G2 and early 
prophase, Aurora B localizes with the other members of the CPC on the 
chromosome arms (Hayashi-Takanaka et al., 2009). This correlates with 
increasing phosphorylation of serine 10 and 28 on histone H3 along the 
chromosomes (Hendzel et al., 1997). 
Unlike the promoter-localized H3S10ph or H3S28ph that is involved 
promoter opening and transcriptional activation (see section 1.4.3), Aurora B-
mediated mitotic H3S10ph/S28ph spreads along the chromosome arms and is 
accompanied by a global compaction of the DNA (Hayashi-Takanaka et al., 
2009). These events are also associated with displacement of binding of the HP1 
proteins from the H3K9me3 mark (Hirota et al., 2005). It has been suggested that 
HP1 proteins could be involved in recruiting the CPC to the chromosome arms 
through interaction with INCENP, which has been shown to directly interact with 
HP1α in vitro (Ainsztein et al., 1998). However, in vivo the recruitment of the CPC 
is likely to be mediated by an additional partner of INCENP, POGZ, which is 
required for displacement of the HP1α and activation and localization on 
chromosome arms of Aurora B (Nozawa et al., 2010). The deposition of the 
H3S10ph mark requires prior deubiquitination of histone H2A by the histone 
deubiquitinase USP16 (Joo et al., 2007). This deubiquitinase requires 
phosphorylation to become active and move from the cytoplasm to the nucleus at 
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the onset of mitosis, where it resides until cytokinesis (Cai et al., 1999).  
Compaction of the mitotic chromosome requires the presence of ring-like 
protein complexes called Condensin I and II (Samoshkin et al., 2009). 
Recruitment and maintenance of Condensin I on chromosomes requires Aurora 
B activity throughout mitosis (Nakazawa et al., 2011). Aurora B also regulates the 
concentration of the Cohesin complex on centromeres during late prophase, 
where the CPC relocalizes, driven by Survivin and Borealin (Klein et al., 2006). 
The maintenance of Cohesin at centromeres by Aurora B might be due to its 
ability to keep Sgo1 at centromeres (Dai et al., 2006). Sgo1 keeps sister 
chromatids together until the onset of anaphase when, following degradation of 
Cohesin by Separase, sister chromatids migrate to opposite sides of the mitotic 
spindle (Kitajima et al., 2006).  
 
1.5.3 Aurora B and sister chromatid segregation 
From late prophase until the end of metaphase, the CPC localizes at 
centromeres where it promotes correct attachment of kinetochores to the 
microtubules of the mitotic spindle (Fig. 1.27) (Cimini et al., 2006). To ensure that 
the sister chromatids segregate their DNA equally between the two daughter 
cells, each chromatid pair must bind to two microtubules originating from 
opposite sites of the mitotic spindle (Cleveland et al., 2003). This type of 
attachment is called bipolar or amphitelic. 
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Figure 1.27: Localization of Aurora B during mitosis.  
The levels of Aurora B (red) peak at the G2/M border, before prophase. At this stage the protein 
is diffused on the DNA (stained with the DAPI dye, blue), where it promotes its compaction. Later 
in prophase and prometaphase, Aurora B is concentrated at the centromeres. In metaphase, all 
chromosomes are lined up at the centre of the cell and Aurora B regulates the correct attachment 
of microtubules to kinetochores. After sister chromatid separation, Aurora B is retained in the 
central part of the spindle, where it helps the formation of the contractile actinomyosin ring 
required for daughter cells separation and assesses correct chromatid segregation before 
cytokinesis (reproduced with permission from Hake et al., 2005, Proceedings of the National 
Academy of Sciences of the United States of America, copyright (2005) National Academy of 
Sciences, U.S.A.).  
 
Incorrect attachments (e.g. syntelic and merotelic attachments) lead to 
unequal distribution of chromatids between the two daughter cells (Fig. 1.28) 
(Lampson et al., 2004). Syntelic attachments are characterised by two 
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kinetochores bound to a microtubule. Merotelic attachments are generated upon 
binding of one kinetochore to two microtubules. 
 
 
Figure 1.28: Different types of microtubule attachments.  
Bipolar attachments (here termed bi-oriented and amphitelic) lead to correct segregation of sister 
chromatids towards opposite poles of the mitotic spindle (represented here by centrosomes). 
Incorrect attachments can be syntelic (two kinetochores bound to the same microtubule), 
monotelic (only one kinetochore bound to one microtubule) or merotelic (one kinetochore bound 
to two microtubules) (reproduced with permission from Keen and Taylor, 2004, Nature Reviews 
Cancer, copyright (2004) Nature Publishing Group). 
 
 Aurora B ensures that the correct chromosome attachment is in place by 
destabilizing the kinetochore-microtubule interaction in the event of syntelic and 
merotelic attachments (Cimini et al., 2006). Bipolar attachments generate a 
physical tension that dissociates Aurora B (which resides at the centromeres) 
from the KMN network (Dsn1/Mis13, KNL1/Blinkin and Ndc80/Hec1) located at 
the outer kinetochores (Liu et al., 2009). This allows dephosphorylation of the 
components of the KMN network by the KNL1/PP1 complex, which further 
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stabilizes the attachment by recruiting other complexes such as Astrin, the small 
kinetochore-associated protein (SKAP) and the Ska complex members Sk1, 2 
and 3 (Welburn et al., 2010). 
Incorrect attachments, on the other hand, fail to generate such physical 
tension and Aurora B can continue to phosphorylate Ncd80/Hec1 and other 
substrates such as the microtubule-depolymerising kinesin MCAK (Knowlton et 
al., 2006). Phosphorylation of these proteins releases the microtubules from the 
kinetochore and triggers activation of the spindle assembly checkpoint (SAC) 
(Lampson and Cheeseman, 2011). A multi-protein complex (composed of Mad2, 
Mad3/BubR1, Bub3 and CDC20) blocks progression of mitosis, preventing 
incorrect chromatid segregation (Schmidt et al., 2010).  
This is achieved by preventing activation of the APC/CCDC20 E3 ligase and 
subsequent degradation of Cyclin B and Securin (Musacchio and Salmon, 2007). 
The latter protein inhibits Separase, the protease that removes Cohesin rings 
from the centromeres and permits separation of sister chromatids.  Aurora B also 
activates the SAC via phosphorylation of the Ataxia telangiectasia mutated 
kinase (ATM) (Yang et al., 2011). This kinase, which is normally activated 
following DNA damage, is phosphorylated in mitosis by Aurora B in the absence 
of DNA damage. The phosphorylated ATM in turn phosphorylates Bub1, which is 
also required for SAC activation in addition to its role in Sgo1 and 2 recruitment at 
centromeres (Yang et al., 2011). 
 
1.5.4 Aurora B and cytokinesis 
During anaphase, the CPC relocates to the midzone microtubules of the 
mitotic spindle and regulates the formation of the central spindle while the sister 
chromatids are pulled towards the opposite poles of the mitotic spindle (Carmena 
and Earnshaw, 2003). Aurora B promotes the formation of a cluster of 
centralspindlin complexes by phosphorylating the homodimer of kinesin-6 motor 
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protein MKLP1 (Douglas et al., 2010). These centralspindlin complexes (formed 
by a homodimer of MKLP1 and a dimer of the GTPase MgcRacGAP) create a 
bundle of microtubules, which promotes recruitment of factors implicated in the 
formation of the actinomyosin contractile ring responsible for cytokinesis (Glotzer, 
2009).  
In the event of defects in either nuclear pore formation or sister chromatid 
separation, Aurora B can also block cytokinesis, possibly by phosphorylating 
CHMP4C (Carlton et al., 2012). CHMP4C is a subunit of the ESCRT-III complex, 
which provides constrictive force during the cell separation (Wollert et al., 2009). 
CHMP4C interacts with Borealin and its phosphorylation by Aurora B has been 
shown to block cytokinesis (Carlton et al., 2012). This checkpoint is known as the 
abscission checkpoint and constitutes a last safeguard that protects a cell from 
tetraploidization (Steigemann et al., 2009). Finally, Aurora B promotes the actual 
contraction of the actinomyosin ring that leads to the separation of the daughter 
cells by phosphorylating the Myosin Regulatory Light Chain-2 (Murata-Hori et al., 
2000). 
 
1.5.5 Aurora B and cell cycle regulation 
The expression of Aurora B reaches its lowest level in cycling cells following 
re-entry of the daughter cells into G1, when the protein is polyubiquitinated and 
targeted for proteosomal degradation. Aurora B is however expressed at a basal 
level throughout the cell cycle. In CD28-deficent T cells, Aurora B interacts with 
Survivin and mammalian target of Rapamycin (mTor) (Song et al., 2007). These 
cells exhibit a block in the cell cycle progression at the G1/S border, which can 
be relieved by Aurora B ectopic expression. This leads to the phosphorylation of 
mTor and its downstream effectors Rb, Cyclin A and CDK1 and 2. Although 
these aforementioned proteins are known targets of mTor, it is also possible that 
Aurora B directly phosphorylates them.  
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Aurora B has also been shown to phosphorylate and negatively regulate the 
activity of the tumour suppressor p53 (Gully et al., 2012). Phosphorylation of p53 
by Aurora B suppresses the inhibitory effect of p53 on cell proliferation by 
promoting its degradation and impairing its activity as a transcription factor. 
Interestingly, Aurora B interacts with p53 both in interphase (in the nucleus) and 
during mitosis (in the cytoplasm). This result was however obtained in 
transformed cell lines, where Aurora B is highly expressed throughout the cell 
cycle and localizes in the nucleus in interphase (Abdullah et al., 2005). The direct 
negative regulation of the tumour suppressor p53 is observed upon Aurora B 
ectopic overexpression and might relate to the role of Aurora B in cancer, where 
it is often overexpressed (see below). Aurora B and p53 have also been shown to 
share a common partner, NIR (novel INHAT repressor), which negatively 
regulates p53 functions (Wu et al., 2011b). 
 
1.5.6 Aurora B and gene regulation 
Aurora B expression persists outside mitosis in terminally differentiated 
plasma cells, where it displaces HP1β from H3K9me3 by phosphorylating the 
nearby serine 10 (Sabbattini et al., 2007). In this context, Aurora B might 
reinforce silencing by promoting the formation of a constitutively heterochromatic 
domain. Interestingly, Aurora B-mediated H3S10ph leads to opposite effects in 
pituitary cells, where it displaces HP1β and activates thyroid hormone receptor-
regulated genes (Tardáguila et al., 2011). These genes normally have the thyroid 
receptor bound to their promoters, where it recruits co-repressors such as 
HDACs. Upon stimulation with thyroid hormone, a conformational change in the 
receptor converts it into an activator. The resulting transcriptional activation is 
accompanied by an increase in the levels of H3S10ph and a release of HP1β 
from chromatin. Aurora B acts as a co-activator at these promoters by 
phosphorylating histone H3 and in turn promotes transcription. This effect of 
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Aurora B on transcription is not related to mitosis as the cells are mostly in G1-
phase (80-90%) (Tardáguila et al., 2011). 
 
1.5.7 The role of Aurora B in cancer 
Disruptions in the regulation of Aurora B functions can lead to uncontrolled 
proliferation, chromosomal abnormalities (aneuploidy and polyploidy), 
tumorigenesis and metastasis (Norton and Massagué, 2006). Aurora B 
overexpression is observed in several tumours, which has led to the hypothesis 
that Aurkb (the gene that encodes for Aurora B in mammals) can act as an 
oncogene (Fu et al., 2007). In tumour cells Aurora B overexpression is often 
associated with tetraploidy, which leads to genomic instability and tumorigenesis 
(Nguyen et al., 2009). However, polyploidy is observed even upon ectopic 
overexpression of a constitutively inactive mutant or ablation of the kinase, 
possibly as a consequence of inactivation of the spindle assembly and ablation 
checkpoint (Fu et al., 2007). This suggests that a certain amount of Aurora B 
activity is fundamental to guarantee the correct mitosis of non-tumoral cells.  
In prostate cancer, Aurora B is subject to dynamic acetylation/deacetylation 
regulation during mitosis (Fadri-Moskwik et al., 2012). Acetylation of Aurora B 
leads to reduced activity and increased mitotic abnormalities. Aurora B 
overexpression is observed in metastatic melanoma and results from hyper-
stimulation of FoxM1 by the ERK pathway (Bonet et al., 2012).  
Specific chemical inhibitors of Aurora B such as AZD1152 are showing 
promising results in the treatment of several malignancies such as acute 
myelogenous leukaemia, multiple myeloma, colorectal and breast cancer. New 
inhibitors are currently being designed for use in other tumours (Oke et al., 2009). 
AZD1152 reduces cell proliferation by stimulating senescence and apoptosis in 
melanoma cells (Bonet et al., 2012). This compound has also proved successful 
in blocking the proliferation of cells isolated from patients with acute myeloid 
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leukaemia (Walsby et al., 2008). 
1.6 Polycomb group proteins 
Polycomb group (PcG) proteins were originally discovered in Drosophila, 
where the first member of the group (Polycomb or Pc, the gene for which was 
identified by P. Lewis in 1947), regulates body segmentation (Lewis, 1978). The 
mutations of other genes cause a similar phenotype to that observed in Pc 
mutants (Margueron and Reinberg, 2011). The proteins encoded by these genes 
were therefore named PcG proteins and for some of them mammalian 
homologues have been identified (Levine et al., 2002). 
In Drosophila, PcG proteins are organized into two repressive complexes 
(PRC1 and 2), the PHO-repressive complex (PhoRC) and the Polycomb 
repressive deubiquitinase (PR-DUB) (Simon and Kingston, 2009). PhoRC 
regulates the recruitment of PRC2 in Drosophila and is composed by the DNA 
binding protein (PHO) and a methyl-lysine binder (dSfmbt), which binds to the 
H3K9me1/2 and H4K20me1/2 marks (Klymenko et al., 2006). PR-DUB is 
composed by the H2A deubiquitinase Calypso and the chromodomain containing 
protein Asx and this complex antagonizes PRC1-mediated gene silencing 
(Scheuermann et al., 2010). The core components of PRC1 and 2 are conserved 
from Drosophila to mammals as well as some of the components of PhoRC and 
PR-DUB. For the purpose of this work, I will focus on the role of mammalian 
PRC1 and 2 components. 
By operating as co-factors in the regulation of a large number of genes, 
PRC1 and 2 regulate stem cell pluripotency, self-renewal, cell cycle progression, 
senescence, genomic imprinting and differentiation (Prezioso and Orlando, 
2011). Moreover, many PcG proteins are overexpressed and are involved in 
tumourigenesis and tumour progression (Richly et al., 2010). The best-
characterised mode of action of PRC1 and 2 is the post-translational modification 
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of histone H2A and H3 respectively. Nevertheless, both complexes might 
regulate the structure of chromatin by other as yet unidentified mechanisms.  
PcG proteins have been mostly described as co-repressors that operate at 
promoters. Recently, it has become increasingly clear that the mechanisms for 
recruiting these complexes in mammals are more complicated and variable than 
was originally thought from comparisons with the mechanisms observed in 
Drosophila. 
 
 
Figure 1.29: Hierarchical recruitment of PRCs to PREs in Drosophila.  
PhoRC recognises the PHO/YY1 binding motif present in PREs. This leads to the recruitment of 
PRC2 and the deposition of the H3K27me3 mark. This post-translationational modification is read 
by Pc in PRC1, which monoubiquitinates H2A (not shown) and blocks transcriptional initiation 
(reproduced with permission from Wang et al., 2004, Molecular Cell, copyright (2004) Elsevier). 
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Both PRC1 and PRC2 lack a subunit with a DNA binding domain. In 
Drosophila, Polycomb Response Elements (PREs) contain the binding motif for 
PHO (Chan et al., 1994). This in turn recruits PRC2 and leads to the 
trimethylation of lysine 27 on histone H3. Drosophila Pc and its mammalian 
homologues Cbx proteins read this mark and mediate the recruitment of the 
PRC1 component that reinforces silencing by means of the H2Aubq mark (Fig. 
1.29) (Sing et al., 2009).  
Binding motifs for YY1 (the mammalian homologue of PHO) do not, 
however, correlate well with PRC1 and 2 binding in vivo in mammals, which 
implies that other recruiting mechanisms might also be in place in mammals 
(Wilkinson et al., 2006). In this respect, genome-wide studies have uncovered the 
propensity of PcG proteins to colocalise with CpG islands devoid of binding sites 
for transcriptional factors (Ku et al., 2008). Indeed, GC-rich regions that do not 
contain such activating domains are sufficient to recruit PRC2 and initiate 
silencing in ES cells (Mendenhall et al., 2010). 
PRC2 contains, among its ancillary subunits, Jarid2, a catalytically inactive 
histone demethylase that binds with PRC2 at GC-rich regions (Li et al., 2010). 
DNA methylation of GC-rich regions is associated with the reinforcement of a 
repressive state following the deposition of the H3K9me3 mark (Branco et al., 
2012). The binding of PRC2 to DNA methylated GC-rich promoters is dependent 
on the prior binding of Tet1, which convert methyl-cytosines into hydroxymethyl-
cytosines (Wu et al., 2011a).  
ncRNAs generated by paused RNA Polymerases have also been shown to 
recruit and enhance the activity of PRC2 (Kanhere et al., 2010). PRC2 is itself 
recruited in trans by the H3K27me3 mark deposited by PRC2-mediated H3 
methylation and this mechanism is implicated in the maintenance of repression 
(Margueron et al., 2009). It is important to stress that although the hierarchical 
model derived from Drosophila seems to be correct in some instances, many 
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examples of PRC2-independent recruitment of PRC1 have been described 
(Tavares et al., 2012).  
 
1.6.1 Ezh1/2: the catalytic subunit of PRC2  
The core of mammalian PRC2 is composed of Ezh1 or Ezh2, Suz12, Eed 
and RbAp46/48 (Fig. 1.30) (Margueron and Reinberg, 2011). Ezh1 and 2 are 
mutually exclusive in PRC2 complexes and contain a HMT domain called SET 
(named after the Drosophila proteins that contain it: Su(var), Enhancer of zeste, 
Trithorax) (Margueron et al., 2008). Ezh2 methylates both mono- and di-
methylated lysine 27 on histone H3 thus generating two distinct repressive 
marks: H3K27me2 and H3K27me3 (Cao and Zhang, 2004). H3K27me2 is 
implicated in the maintenance of a repressed state at promoters by preventing 
acetylation of H3K27 (Simon and Kingston, 2009). The H3K27me3 histone mark 
is read by chromodomain-containing proteins (such as Cbx proteins, see below), 
which recruit PRC1 and in turn reinforce silencing (Fischle et al., 2003).  
Ezh1 has a weaker HMT activity than Ezh2 and is more abundant in non-
dividing cells than Ezh2, which is highly expressed in proliferating ES cells (Su et 
al., 2003). Binding of Ezh1 has also been observed at a small subset of active 
genes in ES cells, where it can deposit the H3K27me3 mark and compensate for 
Ezh2 in knockout cells (Shen et al., 2008). Ezh1 might also repress transcription 
via mechanisms other than histone methylation, such as the induction of higher-
order chromatin compaction via an unknown mechanism (Margueron et al., 
2008). 
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Figure 1.30: Schematic representation of PRC2 core and ancillary components.  
Ezh1 or Ezh2 act as the catalytic subunit of the complex through their SET domains, which 
possess HMT activity. Ezh1 and Ezh2 also have an RNA-binding motif that has been proposed to 
be involved in their recruitment. Eed is important for recruitment of the complex to previously 
trimethylated lysine 27 on histone H3. Suz12 also has an RNA-binding region and interacts with 
ncRNAs in vivo (not shown here). Suz12 allows the interaction between Ezh1/2 and RbAp46/48, 
which binds to the H3/H4 dimers. Ancillary subunits include Jarid2, AEBP2 and PCL1/2/3. There 
is evidence that Jarid2 might be involved in mediating the recruitment of PRC2 to CpG islands. 
There is also evidence for involvement of AEBP2 in mediating the interaction of PRC2 with DNA 
sequences important for its recruitment, PLC1/2/3 recruit PRC2 by reading histone modifications 
and potentiate the HMT activity of the complex (reproduced with permission from Margueron and 
Reinberg, 2011, Nature, copyright (2011) Nature Publishing Group). 
 
Ezh2 contains an RNA binding domain and its association with long 
ncRNAs is enhanced by its phosphorylation on threonine 350 (Kaneko et al., 
2010). The phosphorylation of serine 21 by Akt, on the other hand, blocks the 
binding of Ezh2 to nucleosomes and results in reduced levels of H3K27me3 and 
derepression of Hox genes (Cha et al., 2005). Ezh2 is required for lineage 
commitment in ES cells and for heavy chain rearrangement, which marks the 
development of pro B into pre B cells (Su et al., 2003). During muscle 
development, Ezh2 represses genes necessary for the development of 
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myoblasts into myotubes (Caretti et al., 2004). In the same cell type, however, 
Ezh1-containing PRC2 complexes bind to active promoters, which are devoid of 
the repressive H3K27me3 mark (Mousavi et al., 2011). In myoblasts, Ezh1-PRC2 
interacts with RNA Pol II and promotes elongation. Knockdown of Ezh1 in 
myoblasts leads to impaired myogenic differentiation.  It is possible that Ezh1- 
and Ezh2-containing complexes are differentially regulated at active and 
repressed promoters through interaction with different partners. 
 
1.6.2 PRC2 core components and additional interactors 
Eed plays a fundamental role in the recruitment of PRC2 to target genes by 
reading the H3K27me3 mark (Margueron et al., 2009). In Drosophila, mutations 
that disrupt this recognition impair the binding of PRC2 to PREs, reduce the 
global levels of H3K27me2/3 and disrupt embryonic development. In ES cells, 
knockout of Eed blocks their proliferation and differentiation (Shen et al., 2008).  
Suz12 is required for ES cell differentiation but its function is still not fully 
understood (Pasini et al., 2007). Interaction of Suz12 with short ncRNAs 
generated by paused RNA Pol II has been described and this might provide an 
additional way to recruit PRC2 and to arrest RNA Pol II at the pausing stage 
(Kanhere et al., 2010). Suz12 knockout in ES cells is accompanied by a sharp 
reduction in H3K27me2/3 and an increase in H3K27ac and H3K36me3 (Jung et 
al., 2010). Interestingly, Suz12 seems to be required for the deposition of another 
repressive histone mark, H3K9me3, by another HMT: SUV39H1 (de la Cruz et 
al., 2007). Indeed, these proteins can directly interact and the presence of 
H3K9me3 together with H3K27me3 is probably a mechanism of reinforcement of 
gene silencing during development (Alder et al., 2010). Suz12 binds directly to 
Ezh1/2 and RbAp46 (or 48), a histone chaperone that binds to the H3-H4 dimer 
in the nucleosome and mediates Ezh1/2 binding to chromatin (Song et al., 2008).  
Additional proteins associate with PRC2 but are not required for optimal 
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activity of the complex in vivo. Jarid2 belongs to the Jumonji family of histone 
demethylases but lacks enzymatic activity (Margueron and Reinberg, 2011). The 
role of Jarid2 in regulating Ezh2 activity is still unclear, as its knockdown does not 
significantly affect the levels of H3K27me3 in vivo (Shen et al., 2009). However 
Jarid2 enhances PRC2 activity in vitro. The presence of a GC-binding domain 
suggests that Jarid2 is responsible for the preferential binding of PRC2 to these 
regions in mammals (Li et al., 2010). Another candidate for involvement in PRC2 
recruitment is the zinc finger protein AEBP2, which enhances the activity of 
PRC2 and contains a DNA binding domain (Kim et al., 2009). 
PCL1, 2 and 3 are Ezh2 and Suz12 partners that are differentially 
expressed in a tissue-specific manner (Walker et al., 2010). Similar to the four 
core PRC2 members, depletion of PCL2/3 in ES cells enhances self-renewal and 
impairs differentiation. This is due to the loss of H3K27me3 observed at PLC2/3-
PRC2 targets, which implies a positive role for these proteins in PRC2 activity 
(Hunkapiller et al., 2012). 
 
1.6.3 The PRC1 family of polycomb complexes 
In Drosophila, the core components of PRC1 are dRing (the catalytic 
subunit), Pc (Polycomb), Ph (Polyhomeotic) and Psc (Posterior sex combs) 
(Saurin et al., 2001). Mammalian homologues for these components have been 
identified and, both in Drosophila and humans, PRC1 can be co-purified with 
substoichiometric amounts of other PcG proteins and GTFs (Levine et al., 2002). 
PRC1 was found to block the activity of the SWI/SNF remodelling complex in 
vitro (Shao et al., 1999).  
A large body of evidence is now accumulating that, instead of being a single 
core complex with ancillary subunits like PRC2, PRC1 represents a family of 
complexes whose only common denominators are the catalytic module subunits, 
Ring1A and Ring1B, which always associate with one of the six Psc homologues 
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(PCGF proteins) identified in mammals (NSPC1, Mel18, PCGF3, Bmi1, PCGF5 
and MBLR) (fig.1.31) (Gao et al., 2012).  
 
 
Figure 1.31: Schematic diagram of the different PRC1 complexes.  
PRC1 complexes always feature Ring1A, Ring1B and one PCGF as the core catalytic subunit. All 
these complexes share histone H2A ubiquitination activity. Cbx proteins and RYBP/YAF2 
generate mutually exclusive complexes and might influence differential requirements for Ring1B 
recruitment to chromatin (reproduced with permission from Gao et al., 2012, Molecular Cell, 
copyright (2012) Elsevier). 
 
1.6.4 The role of Ring1A and B in PRC1 activity 
Ring1A and B were identified as interactors with the mammalian homologue 
of Pc (M33) and represent the mammalian homologues of dRing (Schoorlemmer 
et al., 1997). Both Ring1A and B are E3 ligases that monoubiquitinate histone 
H2A in vitro, albeit with different efficiencies (Wang et al., 2004). It is likely that 
Ring1A enhances Ring1B activity in vivo and its knockout in mice results in 
anterior transformations and abnormalities in the axial skeleton (del Mar Lorente 
et al., 2000). Knockout of Ring1B is embryonically lethal (Voncken et al., 2003). 
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Therefore, unlike Ezh1 and 2, Ring1A and B are always co-purified as part of the 
same complex  (Vidal, 2009).  
Ring1B-mediated H2Aubq facilitates the binding of histone H1 to 
nucleosomes and might therefore provide a mechanism for enhancing gene 
silencing by promoting chromatin compaction (Jason et al., 2005). Knockdown of 
Ring1B is followed by a loss of H2Aubq and de-repression of target genes (Wang 
et al., 2004). Interestingly, a Ring1B mutant that is inactive as an E3 ligase can 
still repress transcription of Hox genes (Eskeland et al., 2010). However, it is 
possible that other repressive mechanisms could compensate for Ring1B-
mediated silencing. For example, PRC2 could recruit SUV39H1 and promote the 
deposition of the H3K9me3 mark (de la Cruz et al., 2007). Indeed, SUV39H1 and 
Ring1B have been shown to be mutually exclusive in the regulation of silent 
genes, with the former implicated in a stronger repression of developmental 
genes (Alder et al., 2010). H2Aubq covers the inactive X-chromosome, where the 
binding and activity of Ring1B are independent from PRC2-mediated H3K27me3 
(Schoeftner et al., 2006). Ring1B has been shown to ubiquitinate the histone 
variant H2A.Z (Sarcinella et al., 2007). This post-translational modification is also 
associated with the silencing of target promoters (Draker et al., 2011). 
Ring1B and H2Aubq are believed to poise silent genes in ES cells for later 
activation (Stock et al., 2007). These genes, originally termed bivalent, are 
distinguished from fully silenced genes by the simultaneous presence of an 
activating (H3K4me3) and repressive (H3K27me3) mark on their promoters 
(Azuara et al., 2006, Bernstein et al., 2006a). In some cell types, particularly in 
the haematopoietic system, knockout or knockdown experiments of Ring1B (Yu 
et al., 2012), Bmi1 (Majewski et al., 2010) or Mel-18 (Jacob et al., 2011) result in 
the downregulation of some of genes bound by them. Rather surprisingly, PRC1 
and PRC2 components associate with the promoters of active cytokines genes in 
activated CD4+ cells and the knockdown of members of both complexes leads to 
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transcriptional repression of these active Polycomb target genes (Jacob et al., 
2011). 
Additionally, the transcription factor ZRF1 is recruited to poised genes by 
Ring1B by means of the H2Aubq mark (Richly et al., 2010). Upon retinoic acid-
induced differentiation, ZRF1 binds to H2Aubq and displaces Ring1B, resulting in 
partial loss of the H2Aubq, probably through recruitment of the histone 
deubiquitinase USP21 (Nakagawa et al., 2008). Therefore, H2Aubq can be a 
mark for recruitment of a transcriptional activator, which then displaces the 
ubiquitinating enzyme upon induction of gene expression. 
At least five H2A deubiquitinases are known and, apart from USP21, two 
more are involved in transcriptional activation in vivo (Vidal, 2009). USP16 
regulates chromosome compaction and the expression of Hox genes (Joo et al., 
2007). In doing the latter, USP16 counteracts PRC1 by removing the H2Aubq 
mark from promoters but, interestingly, not displacing the complex (Joo et al., 
2007). MYSM-1 plays a fundamental role in B cell development through 
derepression of the promoters of genes encoding key transcriptional factors 
(Jiang et al., 2011). 
 
1.6.5 PCGF proteins regulate Ring1B activity 
Ring1B can ubiquitinate nucleosomal H2A in vitro without any co-factors 
other than ubiquitin, the ubiquitin-activating enzyme E1 and the Ring1B-specific 
E2 ligase, UbcH5c (Buchwald et al., 2006). However, the efficiency of the 
reaction is greatly enhanced by the presence of Ring1A and Bmi1 (Cao et al., 
2005). Upon interaction with Bmi1 (also known as PCGF4), UbcH5c can bind 
more efficiently to Ring1B (Buchwald et al., 2006). Moreover, Bmi1 facilitates the 
substrate recognition of Ring1B by stabilizing the interaction with the nucleosome 
(Fig. 1.32) (Li et al., 2006). The Ring1B-Bmi1 dimer benefits from conformational 
changes that the proteins induce in one another, which in turn stabilize the 
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interaction. To summarise, Bmi1 enhances Ring1B activity by promoting 
substrate recognition and by stabilizing the association between the E2 (UbcH5c) 
and the E3 ligase (Ring1B) (Li et al., 2006). 
 
 
Figure 1.32: Schematic representation of the Ring1B-Bmi1 heterodimer, which promotes 
histone H2A monoubiquitination in vivo.  
Ring1B interacts with Bmi1 through their RING domains. Furthermore, the N-terminus of Ring1B 
interacts with Bmi1, which in turn mediates the interaction between Ring1B and the nucleosomal 
substrate. The E2 ligase (UbcH5c) can therefore more stably interact with the E3 (Ring1B) 
(reproduced with permission from Li et al., 2006, Journal of Biological Chemistry, copyright (2006) 
American Society for Biochemistry and Molecular Biology). 
 
Another PCGF protein, Mel18, interacts with and stimulates Ring1B E3 
ligase activity towards histone H2A (Elderkin et al., 2007). Mel18 must be 
phosphorylated in order to confer Ring1B specificity towards nucleosomal 
substrates. In contrast, phosphorylation of Bmi1 by the MAPKAP kinase 3 (3pK) 
leads to its displacement from chromatin (Voncken et al., 2005). This event is cell 
cycle-regulated and seems to peak during G2 and mitosis (Voncken et al., 1999). 
Phosphorylation of Bmi1 by Akt, however, protects it from proteosomal 
degradation and favours its nuclear localization (Kim et al., 2011). 
Ectopic expression of Mel18 in Bmi-deficient ES cells restores silencing of 
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some PRC1 target genes, which implies a certain degree of redundancy between 
the two proteins (Elderkin et al., 2007). Given the fundamental role of PCGFs in 
Ring1B activity in vivo, it is not surprising that active Ring1B has always been 
copurified with one of them (Gao et al., 2012). Indeed, PCGF1 (also known as 
NSPC1) associates with Ring1A/B in the PRC1-related complex BCoR-Fbxl10 
(see below) and promotes, at least in vitro, the ubiquitination of histone H2A  
(Gearhart et al., 2006).  
 
1.6.6 Cbx proteins define different PRC1 complexes 
Five Chromobox proteins (Cbx2, 4, 6, 7 and 8) represent the mammalian 
homologues of Drosophila Pc (Tajul-Arifin et al., 2003). This definition is based 
on the affinity of their chromodomain for H3K27me3 (Pearce et al., 1992). Other 
Cbx proteins, such as HP1 proteins, contain a different chromodomain that 
allows them to bind with higher affinity to the H3K9me3 mark (Fischle et al., 
2003). Because Cbx proteins are mutually exclusive and each one of them 
defines a different Ring1B-containing complex, their functions might be non-
redundant in vivo (Vandamme et al., 2011). Indeed, these proteins exhibit 
different patterns of nuclear localization, possibly due to different protein-protein 
interactions (Vincenz and Kerppola, 2008). The expression of Cbx2, 4 and 8 
increases during differentiation of ES cells where they regulate different sets of 
genes as part of PRC1 complexes (Morey et al., 2012). 
Cbx4 has been shown to interact with 14-3-3 proteins although this 
interaction has no effect on its binding to Ring1B (Vandamme et al., 2011). Cbx6 
is expressed in ES cells but it does not associate with Ring1B on chromatin in 
vivo, although its knockdown leads to gene derepression (Morey et al., 2012).  
Cbx6 and 7 are the only Pc homologues expressed in pluripotent ES cells and 
Cbx7 represses the expression of Cbx2, 4 and 8 as part of a PRC1 complex 
(O'loghlen et al., 2012).  
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During differentiation, the expression of Cbx7 decreases, which has led to 
the hypothesis that its expression is directly proportional to the degree of 
pluripotency of ES cells (O'loghlen et al., 2012). Interestingly, however, Cbx7 is 
highly expressed in some differentiated cell types such as GC lymphocytes (Scott 
et al., 2007). Notably, Cbx7 exerts an important role in the regulation of cellular 
senescence and proliferation (see section 1.2.5) by repressing the 
INK4b/ARF/INK4a locus (Gil et al., 2004). In this instance, Cbx7 is recruited not 
only by the H3K27me3 mark but also via a direct interaction with the long ncRNA 
ANRIL (Yap et al., 2010).  
Cbx7 exhibits strong binding to both H3K9me3 and H3K27me3 in vitro 
(Bernstein et al., 2006b). In differentiated cells Cbx8 binds at several Cbx7 target 
genes, including the INK4b/ARF/INK4a locus (Dietrich et al., 2007). Cbx7 
expression diminishes in in vitro differentiated ES cells as Cbx8 expression 
increases (O'loghlen et al., 2012). Two microRNAs (miR-125 and 181) have been 
shown to promote the repression of Cbx7 expression during ES cell 
differentiation (O'loghlen et al., 2012).  
 
1.6.7 Recruitment and role of PRC1 
The ability of Cbx proteins to recognize H3K27me3 provided evidence for 
the canonical model of PRC1 recruitment, discussed above. According to the 
hierarchical model, PRC1 binding requires the H3K27me3 to be read by the Cbx 
subunit. Nevertheless, PRC1 recruitment and the deposition of H2Aubq can 
occur in the absence of the H3K27me3 mark (Schoeftner et al., 2006). Cbx 
proteins exhibit different binding affinities to other methylated residues in addition 
to H3K27me3 and, thus, it is possible that different histone marks are used as a 
recruitment signal for PRC1 complexes in the absence of H3K27me3 (Bernstein 
et al., 2006b). Moreover, ncRNAs might play a bigger role under these 
circumstances (Yap et al., 2010). Lastly, it is possible to envisage a role for 
  122 
transcription factors such as YY1, the mammalian homologue of the Drosophila 
DNA-binding PHO (Atchison et al., 2003). 
RYBP and its homologue YAF2 bridge the interaction between YY1 and 
Ring1B (García et al., 1999). Indeed, RYBP has been shown to be present in 
active PRC1 complexes that bind to chromatin and ubiquitinate H2A in the 
absence of H3K27me3 (Tavares et al., 2012). Interestingly, RYBP-containing 
PRC1 exhibits a stronger E3 ligase activity in vitro than Cbx-containing PRC1 
(Gao et al., 2012). RYBP and Cbx proteins are mutually exclusive in PRC1 
complexes as they compete for the same binding site on Ring1B (Wang et al., 
2010b). However, in vivo RYBP- and Cbx2-containing complexes are very often 
found in the vicinity of the same genes (Gao et al., 2012). The role of YY1 in the 
H3K27me3-independent recruitment of Ring1B has been questioned, as the 
protein is not co-immunoprecipitated with either Ring1B or RYBP in vivo (Gao et 
al., 2012).  
Other transcriptional factors (Runx1 and CBFβ) have been shown to recruit 
Ring1B and Bmi1 to active genes in megakaryocytes and thymocytes (Yu et al., 
2012). In these cells, PRC1 is recruited to active genes where it might fine-tune 
the expression of its target genes. Quite surprisingly, the knockdown of Ring1B 
leads to the upregulation of nearly a third of its target genes (Yu et al., 2012). 
Despite its known role as a silencer, therefore, the biological role of Ring1B might 
be affected by the factors that interact with it. It is important to bear in mind that 
Drosophila Pc blocks transcriptional initiation but does not impair the recruitment 
of the PIC to Polycomb-repressed genes (Dellino et al., 2004).  
 
1.6.8 Non-canonical PRC1 complexes 
Ring1A/B are also components of other non-canonical PRC1 complexes, 
which regulate transcription. The E2F6.com complex represses target genes in 
quiescent, serum-starved fibroblasts and is removed following cell cycle re-entry 
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(Ogawa et al., 2002).  This complex contains the transcription factor E2F6, the 
Cbx protein HP1γ, YAF2, the PCGF homologue MBLR and L3MBT2, which binds 
to methylated histones (Ogawa et al., 2002). 
Another stable complex with a role in transcriptional regulation is 
BCoR/Fbxl10 (Sánchez et al., 2007). This complex contains the co-repressor 
BCoR, the PCGF protein NSPC1, RYBP, the E3 ligase SKP1 and the H3K36 
demethylase Fbxl10 (Gearhart et al., 2006). By coupling the monoubiquitination 
of H2A with the removal of the H3K36me3 mark, BCoR/Fbxl10 silences its target 
genes in B cells (Gearhart et al., 2006). 
Finally, proteomics analysis of the Ring1A/B-interactome has revealed 
several proteins associated with transcriptional activation and elongation. In 
leukaemias, Ring1A/B have been shown to interact with the elongation factor p-
TEFb and with DOT1L, which is responsible for the H3K79me3 mark on the body 
of transcribed genes (Mueller et al., 2007). Moreover, the methyltransferase 
responsible for H3K4me3 (MLL1) and the HAT responsible for H4K16ac (MOF) 
have also been co-purified together with Ring1A/B in human cells (Dou et al., 
2005). 
 
1.6.9 The role of PcG proteins in cancer 
PcG proteins are overexpressed in several tumours and this usually 
correlates with the metastatic potential of the tumour (Suvà et al., 2009). It is 
possible that the tumourigenic activity of PcG proteins resides in their silencing of 
genes involved in differentiation which in turn leads to self-renewal and 
proliferation of cancer stem cells (Richly et al., 2011). This is likely to be the case 
for Ezh2, which is overexpressed in numerous tumours, such as bladder tumour, 
breast cancer, colorectal cancer, glioblastoma, oral squamous carcinoma and 
prostate cancer. However, PRC1 members, such as Bmi1, seem to operate 
differently. Bmi1 is overexpressed in bladder tumour, breast cancer, squamous 
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cell carcinoma, glioblastoma, leukaemias and neuroblastoma (Richly et al., 
2011). In breast cancer, its overexpression correlates with good prognosis as 
opposed to the overexpression of Ezh2 (Pietersen et al., 2008). 
In glioblastoma cancer cells, Bmi1 and Ezh2 seem to cooperate via two 
different mechanisms: Ezh2 promotes self-renewal and tumourigenisis of cancer 
stem cells, whereas Bmi1 positively regulates the proliferation of more 
differentiated glioma stem cells (Richly et al., 2011). Bmi1 is likely to favour 
proliferation through its inhibition of the INK4a locus (Jacobs et al., 1999). 
Overexpression of Ring1B is detected in lymphomas, gastric and colon tumours 
(Sánchez-Beato et al., 2006). However, Ring1B can also reduce proliferation 
through its inhibition of the Cyclin D gene (Calés et al., 2008).  This regulation 
occurs in normal HSC and other early lymphoid progenitors in adults, conferring 
a regulatory role for Ring1B in the homeostasis of the hematopoietic system. In 
lymphomas and leukaemias, the misregulation of Ring1B expression disrupts this 
equilibrium and leads to uncontrolled proliferation of early, immature progenitors 
(Calés et al., 2008). 
Interestingly, Cbx7 expression is lost in lung cancer, which has led to its 
classification as an oncosuppressor in this type of tumour (Forzati et al., 2012). A 
reason for this might be its negative role in the regulation of HDAC2, which 
promotes tumourigenesis in a number of cases through its downregulation of the 
E-cadherin gene (Federico et al., 2009). However, Cbx7 is overexpressed in GC-
derived follicular carcinomas and plays a role in the generation of this malignancy 
through its repression of the INK4a locus (Scott et al., 2007). 
1.7 Aim of the study 
The core question of this paper is whether Aurora B plays a role in 
regulating gene expression aside from its mitotic functions. In particular, I 
focused my attention on the haematopoietic system, due to the prior results on 
  125 
Aurora B in plasma cells published by our group. I have searched for new 
partners of Aurora B in non-mitotic mature lymphocytes and functionally 
characterised the functional interaction with Ring1B. 
I have focused my study on resting lymphocytes as both proteins co-occupy 
the promoters of active genes and discovered that they cooperate to maintain the 
expression of these genes. These results identify a new role for both proteins 
during a critical stage in the development of the immune system.  
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Chapter 2 - Materials and methods 
 
2.1 Cell culture 
Primary murine lymphocytes and I.29+ cells were cultured in RPMI medium 
(Lonza) supplemented with 15% foetal calf serum (FCS, Sigma), 0.1 U/mL 
penicillin (Lonza), 0.1 μg/mL streptomycin (Lonza), 2 mM L-Glutamine (Lonza) 
and 50 μM beta-mercaptoethanol (Gibco). B cells were cultured in the presence 
of 6 ng/ml IL-4 (R&D). T cells were cultured in the presence of 10 ng/ml IL-7 
(R&D).  293T cells were cultured in DMEM (Lonza) supplemented with 10% 
foetal calf serum (FCS, Sigma), 0.1 U/mL penicillin (Lonza), 0.1 μg /mL 
streptomycin (Lonza) and 2 mM L-Glutamine (Lonza). 
 
2.1.1 B cell isolation 
Resting B cells were isolated from the spleens of 6 to 8-week-old mice. The 
spleens were dissected and minced on sieves and the single-cell suspensions 
were centrifuged on a Ficoll-Paque (GE Healthcare) cushion to remove 
erythrocytes and dead cells. The resulting splenocytes were resuspended at a 
concentration of 107 cells/ml in 0.1% BSA/HBSS (both from Sigma) 
supplemented with 5% goat serum (Lonza) and anti-CD16 antibody (BD). The 
cells were firstly incubated with biotinylated anti-CD43 antibody (BD) and then 
with Dynabeads Biotin Binder beads (Invitrogen) to capture CD43+ cells. Bound 
CD43+ cells were removed by 4 sequential magnetic separations. The remaining 
population of CD43- cells was cultured at a concentration of 2-5x106 cells/ml.   
For B cell activation experiments, lipopolysaccharide (LPS) (Sigma) was 
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resuspended at 10mg/ml in HBSS and used at a final concentration of 12.5 
µg/ml. Anti-CD40 antibody (BD) was used at a final concentration of 5 µg/ml, 
together with anti-Igκ antibody (BD) at 0.5 µg/ml. After activation, B cells were 
kept in culture for a maximum of 3-4 days.  
 
2.1.2 T cell isolation 
Naïve CD4+ T cells were isolated from peripheral subcutaneous and 
mesenteric lymph nodes of 6 to 8-week-old mice. The lymph nodes were 
dissected and minced on sieves the single-cell suspensions were centrifuged on 
a Ficoll-Paque (GE Healthcare) cushion to remove dead cells. The purified cells 
were resuspended at a concentration of 108 cells/ml in 2% FCS/PBS (Invitrogen). 
Firstly, CD25+ positive cells were removed by negative selection using the CD25 
Microbead kit mouse and LS columns (Miltenyi Biotec). In the resulting 
population of CD25- cells, CD4+ cells were positively selected using CD4 (L3T4) 
Microbeads mouse and LS columns (Miltenyi Biotec). These purified 
CD4+/CD25- T cells were cultured at a concentration of 2-5x106 cells/ml. 
 
2.1.3 Conditional knockout mice  
Aurora B conditional knockout (cKO) mice were generated by Dr. Monica 
Roman Trufero by crossing homozygous Rosa26-CreERT2 mice with a strain of 
mice containing exons 2 and 6 of the Aurora B gene flanked by loxP sites for 
homologous recombination (a kind gift from Dr. Marcos Malumbres, CNIO, 
Madrid). The offspring generated from this cross will stably express CreERT2, as 
its gene is stably integrated in the ubiquitously expressed Rosa26 cassette. 
Following stimulation with 4-hydroxytamoxifen (4-OHT), CreERT2 migrates inside 
the nucleus and the Cre recombinase targets the Aurora B gene for Cre-
mediated recombination, effectively shutting down the expression of the Aurora B 
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gene. The Ring1B cKO/Rosa26-CreERT2 mice were a kind gift of Dr. Miguel Vidal 
(CNIO, Madrid). 
 
2.2 Counterflow Centrifugal Elutriation 
G1-fractions of activated B cells were isolated from unsynchronised 
populations by means of counterflow centrifugal elutriation in a Beckman Coulter 
Avanti J-26 XP Series centrifuge (Beckman Coulter), using a JE-5.0 Rotor 
(Beckman Coulter). After 3 days of in vitro culture with LPS or anti-CD40, 4-8x108 
activated B-cells were thoroughly resuspended in 50 ml of ice cold elutriation 
medium (RPMI supplemented with 1% FCS, 0.1 U/mL penicillin and 0.1μg/ml 
streptomycin), passed twice through an 18 gauge needle and loaded into a 
Sanderson chamber at constant flow of 6 ml/minute. The centrifuge was set at a 
constant speed of 2,300 rpm and 4°C temperature. Throughout the procedure, 
the elutriation medium was constantly pumped into the system using a peristaltic 
pump (SLS). The flow was increased to 7 ml/minute to remove the dead cells and 
250 ml were discarded. Cell fractions (200 ml) were collected sequentially after 
increasing the flow-rate from 8 ml/minute. G1-enriched fractions were collected at 
a flow-rate between 9 and 12 ml/minute. The cells in each fraction were pelleted, 
resuspended in 5-10 ml of complete medium (RPMI with 15% FCS, 0.1 U/mL 
penicillin, 0.1 μg/mL streptomycin, 2 mM L-Glutamine and 50 μM beta-
mercaptoethanol), counted and used for downstream applications. The complete 
medium was kept at room temperature to reduce cell stress. Cell cycle stage was 
determined by assessing the DNA content through propidium iodide (PI) staining 
of each fraction. 
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2.3 FACS analyses 
2.3.1 Propidium iodide staining 
For PI staining, 0.5-1x106 cells were washed in PBS supplemented with 2% 
FCS. Fixation was carried out for 10 minutes in 70% ethanol at -20°C. After 2 
washes with 2% FCS/PBS, cells were incubated for 30 minutes at room 
temperature in PBS containing 0.05 mg/ml PI (Sigma), 0.05% Igepal CA-630 and 
1 μg/ml RNase A (Sigma). The samples were analysed for cell cycle distribution 
on a FACS Calibur machine (BD Pharmigen). 
 
2.3.2 Cell surface markers staining 
For determination of the expression of markers on the cell surface, 106 cells 
were washed in PBS supplemented with 2% FCS. The unfixed cells were blocked 
with 5% goat serum and anti-CD16 antibody and incubated for 5 minutes. A 
1:100 dilution was used for each antibody (see section 2.11). After 2 washes with 
2% FCS/PBS, cells were resuspended in PBS and analysed within 30 minutes on 
a FACS Calibur machine. 
2.4 Chromatin immunoprecipitation (ChIP) 
2.4.1 Chromatin preparation 
B or T cells were counted and their concentration was adjusted to 106 
cells/ml in complete medium. Proteins were crosslinked to the DNA by adding a 
37% w/v formaldehyde solution (VWR) directly to the medium to a final 
concentration of 1% and incubating the cells at room temperature for 10 minute 
with gentle tumbling. The reaction was quenched by adding to the medium a 1 M 
glycine solution (Sigma) to a final concentration of 0.125 M and incubating the 
cells for 10 minutes at room temperature with gentle tumbling. 
The crosslinked cells were spun for 7 minutes at 780 g and 4ºC. The 
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supernatant was removed and the cells were washed with 10 ml of ice cold PBS 
three times. Finally, the cells were resuspended in 1.5 ml of swelling buffer/107 
cells (25 mM Hepes pH 7.9 (Sigma), 1.5 mM MgCl2 (Sigma), 10 mM KCl (VWR), 
0.1% Igepal CA-630 (Sigma)) supplemented with Complete MINI, EDTA-free 
protease inhibitors (Roche Diagnostics). The cells were incubated on ice for 10 
minutes and then underwent a 50-stroke homogenization with a tight dounce 
homogeniser on ice. 
The nuclei were pelleted by centrifugation at 3,000 g for 5 minutes at 4ºC 
and snap-frozen. Prior to sonication, the nuclei were resuspended in sonication 
buffer (50 mM Hepes pH 7.5, 140 mM NaCl (Sigma), 0.1% sodium deoxycholate 
(Sigma), 0.1% SDS (Sigma), 1% Triton-X 100 (Sigma), 1 mM EDTA (VWR)) 
supplemented with Complete MINI, EDTA-free protease inhibitors (Roche 
Diagnostics). The final concentration of the cells was 1-3x106 cells/ml and 250 µl-
aliquots were transferred into 1.5 ml low-binding DNA plastic tubes (Eppendorf). 
The tubes were placed in the carousel of a Bioruptor sonicator (Diagenode) 
connected to a water bath (Thermo Scientifics), which kept the temperature of 
the water in the sonicator basin constantly at 4ºC. The nuclei were sonicated at 
30-second on/off intervals for 2 hours at high intensity to obtain a fragment size 
of approximately 500 – 1,000 bp. 
The insoluble fraction was removed from the soluble sonicated chromatin 
by two rounds of centrifugation at 10,000 g for 10 minutes at 4ºC. The purified 
chromatin was quantified after a 5-minute alkaline lysis (1:10 dilution of chromatin 
in 0.1 M NaOH (Sigma)) and measuring the DNA concentration using an ND-
1000 spectrophotometer (Nanodrop). A 2.5-5 µg aliquot of chromatin was saved 
as input material. 
 
2.4.2 Immunoprecipitation 
Antibodies were pre-bound to paramagnetic Protein G Dynabeads 
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(Invitrogen) into conventional 0.5 ml PCR tubes (SLS). For each 
immunoprecipitation (IP), 5 µg of antibody was incubated with 15 µl of beads in 
200 µl of sonication buffer for at least 2 hours at 4ºC with gentle rotation (8 rpm) 
on a rotating wheel. For ChIP experiments with IgM antibodies (see table 2.1), 
the beads were pre-incubated for 1 hour with IgG anti-IgM as a bridging antibody 
and subsequently incubated 4 hours with the IgM antibody of choice. The beads 
were finally washed once with 200 µl of sonication buffer by incubating them for 7 
minutes at 4ºC with gentle rotation (8 rpm) on a rotating wheel. 
For each ChIP assay, 100 µg of chromatin was added to the antibody-
bound beads and the chromatin concentration, when required, was adjusted to 
0.5 µg/µl with sonication buffer. The samples were incubated over night at 4ºC 
with gentle rotation (8 rpm) on a rotating wheel. The beads were sequentially 
washed with 200 µl of each of the following buffers: sonication buffer, high salt 
buffer (50 mM Hepes pH 7.5, 500 mM NaCl, 0.1% sodium deoxycholate, 0.1% 
SDS, 1% Triton-X 100, 1 mM EDTA), LiCl buffer (20 mM Tris pH 8 (Sigma), 250 
mM LiCl (VWR), 0.5% sodium deoxycholate 0.5% Igepal CA-630 (Sigma), 1 mM 
EDTA) and TE buffer (10 mM Tris pH 7.4, 1 mM EDTA).  
Finally, the beads were washed one more time with 100 µl of TE, 
resuspended by gentle pipetting and transferred into a 1.5 ml low-binding DNA 
tube. To elute the chromatin from the beads and reverse the formaldehyde 
crosslink, the beads and the input DNA were resuspended in 150 µl of elution 
buffer (50 mM Tris pH 8, 50 mM NaCl, 1% SDS, 1 mM EDTA, 20 µg/ml DNase-
free RNase (Roche Diagnostics)) and incubated at 68ºC for 6-8 hours with 
vigorous agitation (1200 rpm) on a thermoshaker (Eppendorf). The supernatant 
was collected and the beads were further eluted for 1 hour with 150 µl of elution 
buffer at 68ºC with vigorous agitation (1200 rpm). For input samples, 150 µl of 
elution buffer were added and crosslink reversal was carried out for an additional 
hour as well. 
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The resulting 300 µl of eluted DNA and protein mixture was incubated 
overnight at 42ºC with gentle shaking (300 rpm) in the presence of 200 µg/ml 
Proteinase K (Sigma) to remove proteins. The DNA was further purified using 
QIAQuick PCR purification kit (Qiagen), according to manufacturerʼs instructions. 
The DNA from IP experiments was eluted in 30 µl of AnalaR grade water (VWR), 
while DNA from input samples was eluted in 60 µl of AnalaR water. 
 
2.4.3 DNA quantification and quantitative real-time polymerase chain 
reaction 
The concentration of DNA recovered from each sample was measured with 
a plate reader spectrofluorometer (Gemini) using the Picogreen Quanti-IT kit 
(Invitrogen). The fluorescent excitation and emission wavelengths were 480 and 
520 nm, respectively. A standard curve was prepared using -phage DNA (NEB) 
at standard concentrations (12.8 – 6.4 – 3.2 – 1.6 – 0.8 – 0.4 – 0.2 ng/µl) and the 
DNA concentration of each sample was generated by line interpolation. 
Quantitative real-time polymerase chain reactions (qRT-PCR) were used to 
determine the binding levels of each factor using the same amount of DNA (0.15 
or 0.1 ng) for the immunoprecipitated and input sample. The amount of DNA 
produced in any PCR reaction can be described by the formula X=X02Ct, where X 
and X0 are respectively the final and initial DNA concentration of a sequence and 
Ct is the number of cycles. Since the same threshold value of DNA concentration 
is used, X becomes a constant. The number of cycles required to reach this 
value is inversely related to X0 and, therefore, for a given sequence, X0(IP)2Ct(IP) 
= X0(input)2Ct(input), from which: 
 
Fold enrichment = X0(IP)/ X0(input) = 2Ct(input)-Ct(IP) 
 
For histone modifications, enrichment was calculated relative to 
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immunoprecipitation of the total histone instead of input DNA. qRT-PCR was 
performed either on a Chromo 4 (Biorad) or DNA Engine Opticon system (MJ 
research) under the following conditions: initial denaturation at 95ºC for 10 
minutes followed by 37 cycles at 95ºC for 15 seconds, annealing at 60ºC for 15 
seconds, extension at 72ºC for 15 seconds and final extension 72ºC for 5 
minutes. For each experiment the threshold was set to cross a point at which the 
amplification was linear (usually 0.025). 
For each primer pair, the Ct values for input/total histone DNA were always 
determined in duplicate (technical duplicates), whereas IP samples were 
measured in duplicate only when a sufficient amount of DNA had been 
recovered. Anti-IgG control antibodies (negative control) always yielded 10-100 
fold less DNA than specific antibodies and were diluted to 88 µl with AnalaR 
water. For each primer pair, each well on qRT-PCR plates (Biorad) was loaded 
with 5 µl of DNA and 20 µl of primer mix (5.5 µl of water, 1 µl of 100 µM forward 
primer, 1 µl of 100 µM reverse primer, 12.5 µl of SYBR Green JumpStart Taq 
Ready Mix (Sigma)). 
 
2.4.4 Sequential ChIP (ReChIP) 
For ReChIP analysis, the first ChIP was performed as previously described 
but the beads were eluted for 10 minutes at 68ºC in 100 µl of ReChIP elution 
buffer (50 mM Tris pH 7.5, 1% SDS, 10 mM EDTA) with vigorous shaking (1400 
rpm). One tenth of the eluted material was used to assess the first ChIP as 
previously described, while the remainder was diluted 1:10 with dilution buffer 
(16.7 mM Tris pH 8, 167 mM NaCl, 0.01% SDS, 1.1% Triton-X 100, 1.2 mM 
EDTA). The diluted eluate was divided into equal fractions and the second ChIP 
was performed as previously described. 
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2.5 ChIP-sequencing (ChIP-seq)  
2.5.1 Library preparation 
ChIP-seq libraries were prepared from at least 10 ng of DNA 
immunoprecipitated using the ChIP protocol described above. Multiple IPs from 
the same biological sample were performed in the case of low-DNA yield 
experiments in order to obtain a sufficient amount of DNA. The final DNA was 
first tested by qRT-PCR and then used to prepare ChIP-seq sequencing libraries 
with NEBNext ChIP-seq Library Prep Master Mix Set for Illumina (NEB) with 
minor variations on the manufacturerʼs protocol. Specifically, the protocol was 
tailored to a lower amount of starting material (10 ng rather than the 
recommended 1 mg) with help from Dr. Carmelo Ferrai. 
The quantity of DNA adaptors used was a 1:60 dilution of the recommended 
amount, in order to reduce the presence of unligated adaptors that would 
compete with and reduce the amount of sequenced specific DNA fragments. This 
is due to the fact that short fragments (such as those generated by unligated 
fragments) tend to be sequenced more than long ones. To sequence more than 
one library per lane on the Illumina HiSeq2000 (Illumina), DNA Illumina adapters 
and indexes from the Multiplexing Sample Preparation Oligonucleotide Kit 
(Illumina) were used to allow sample multiplexing. 
Following PCR enrichment of adaptor ligated DNA fragments, the library 
were resolved on a 2% agarose gel to remove primer dimers and gel purified with 
Qiaquick Gel extraction kit (Qiagen) according to manufacterʼs guidelines. The 
purified libraries were analysed on the Bioanalyser (Agilent) with a High 
Sensitivity DNA kit (Agilent) for the determination of the average fragment size 
and concentration and to assess the integrity of the library. ChIP-seq libraries 
were given to the Genomics Laboratory at MRC CSC and run on the Illumina 
HiSeq2000 sequencer. Libraries were always subjected to single ended 
sequencing and the output size was either 50 or 100 bp. Gopuraja Dharmalingam 
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provided post-sequencing bioinformatic analysis of all the output files. 
 
2.5.2 Data analysis  
The overall quality of the sequencing reads including per base quality 
distribution, duplicate level, GC content and adapter contamination etc were 
assessed by 'fastqc' version 0.10.0. The reads were aligned to Mouse genome 
mm9 using Bowtie version 0.12.8 using '-S -n 2 -l 25 -m 1' parameters. Only 
reads aligned uniquely to the genome were retained for further analysis. The 
SAM files generated by Bowtie were converted to BAM files using Samtools 
version 0.1.18, sorted according to chromosomal co-ordinates and indexed. 
Reads with identical chromosomal co-ordinates and orientation (duplicates) were 
filtered using Picard version 1.65. To visualise the genomic coverage of samples 
in UCSC genome browser, the reads were extended to estimated fragment size 
and converted to BigWig format. The fragment size was estimated using SISSR 
method (Jothi et al., 2008). 
 
2.5.3 Density plot generation 
To visualise the ChIP-seq enrichment for each factor/modification around 
TSS, we divided TSS ± 3kb region in to 50 base bins (total 120 bins). Gene co-
ordinates were retrieved from Ensembl version64 using 'biomRt' bioconductor 
package. The genes were ordered by FPKM values of 4 biological replicates of 
resting B cells mRNA-seq that were estimated using Cufflinks version v1.3.0 (see 
section 2.7). For each factor, number of reads overlapping with each bin was 
counted and Reads per Million per bin (RPM) was calculated. MeV version 4.8 
was used to visualise the enrichment and generate the heat map images. 
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2.5.4 Line plot generation 
FPKM values for 4 biological replicates of mRNA-seq in resting B-cells (see 
section 2.7) were estimated using Cufflinks version 1.3.0. Genes with at least 0.5 
FPKM in any one of the biological replicates were classified as active genes 
(13264 genes). Gene co-ordinates were obtained from Ensembl version 64 and a 
window of TSS ± 3kb was constructed for all active genes. ChIP-seq datasets 
were aligned using Bowtie version 0.12.8 with default settings and only uniquely 
aligned reads were used for further analysis. 
Fragment size was estimated using the SISSR method in 'chipseq' 
Biconductor package and reads were extended to fragment size. The number of 
reads overlapping with each base in TSS ± 3kb window was calculated and used 
for computing RPM (Reads Per Million of mapped reads). RPM values are 
averaged for all active genes and plotted using 'plot' function in R. 
2.6 Transcriptional analysis 
2.6.1 Spike-in RNA preparation 
The generation and use of the spike-in RNA used to quantify transcription in 
this study has been previously described (Szutorisz et al., 2006). The sequence 
for the spike-in was chosen for its low homology with the mouse genome, in 
order to allow an accurate quantification. A pBluescript II SK (+) was linearised 
and in vitro transcribed using T7 RNA polymerase (Promega), according to the 
manufacturerʼs instructions. The RNA generated in this reaction was treated with 
DNase I to remove the original DNA template and column purified using the 
RNeasy Mini Kit (Qiagen) according to the manufacturerʼs guidelines for RNA 
clean up. The spike-in RNA was eluted in 60 µl of DEPC-treated water (Ambion), 
quantified on an ND-1000 spectrophotometer and diluted to a final concentration 
of 0.1 ng/µl. 
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2.6.2 Total RNA extraction and cDNA preparation 
Cell lysates were homogenized using QIAshredder spin columns (Qiagen). 
The spike-in RNA was added at this stage at a fixed ratio of 0.2 ng/106 starting 
cells. To obtain an accurate quantification, the number of cells was the average 
of 10 separate counts on a haemocytometer. Total RNA was purified with 
RNeasy Mini Kit (Qiagen), eluted in 30 µl of DEPC-treated water and quantified 
on an ND-1000 spectrophotometer. Using the least abundant sample as a 
limiting factor, the same amount of RNA (usually approximately 500 ng) from 
each sample was diluted to a final volume of 16 µl with DEPC-treated water and 
underwent DNase I (Invitrogen) digestion, according to manufacturerʼs 
instructions. To remove traces of undigested DNA and DNase I that could impair 
downstream applications, the DNase treated RNA was further column purified by 
performing RNA cleanup with the RNeasy Mini Kit, according to the 
manufacturerʼs guidelines. 
The purified RNA was eluted in 30 µl of DEPC-treated water and quantified 
with an ND-1000 spectrophotometer and used for reverse transcription with 
Random Primers and SuperScript II (Invitrogen). Samples were prepared as 
follows: 
 RT+ No RT (negative control) 
RNA (ng) 100 50 
Random Primers (μl) 4 4 
H2O up to 44 μl up to 22 μl 
Incubate 10 minutes at 70ºC   
5x buffer (μl) 16 8 
0.1M DTT  (μl) 8 4 
10 μM dNTPs (μl) 4 2 
1/10 diluted SuperScript II (μl) 4 2 
 
The reverse transcription was carried out as follows: 10 minutes at 20ºC, 50 
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minutes at 42ºC, 10 minutes at 94ºC. Finally, the cDNA was column purified with 
QIAQuick PCR purification kit, according to manufacturerʼs instructions, to 
remove potentially interfering reagents for the downstream qRT-PCR. Samples 
were diluted 1:100 and, for each primer pair, the Ct values for RT+ samples were 
always determined in duplicate (technical duplicates), whereas No RT controls 
were always measured in single. qRT-PCR were performed as previously 
described (section 2.4.3) with the sole difference of doing 40 cycles of 
amplification instead of 37.  
 
2.6.3 RNA quantification 
Specific primers were designed for the spike-in control and they were used 
to measure the abundance of the spike-in RNA in each sample. To calculate the 
relative expression level of each gene (x) with respect to the spike-in control, the 
following formula was used: 
 
Gene X RNA expression = 2Ct(spike-in)-Ct(x)  
2.7 mRNA-sequencing (mRNA-seq) 
2.7.1 Library preparation 
mRNA-seq libraries were prepared using 2 µg of total RNA purified as 
previously described. A total of four libraries were prepared for four independent 
biological replicates. Libraries were prepared using the TruSeq RNA Sample 
Preparation Kits v2 (Illumina) according to the manufacturerʼs protocol. The 
libraries were resolved on a 2% agarose gel to remove primer dimers and gel 
purified with Qiaquick Gel extraction kit (Qiagen) according to manufacturerʼs 
guidelines. The purified libraries were analysed on the Bioanalyser (Agilent) with 
DNA 1000 kit (Agilent) for the determination of the average fragment size and 
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concentration and to assess the integrity of the library. RNA-seq libraries were 
given to the Genomics Laboratory at MRC CSC and run on the Illumina 
HiSeq2000 sequencer. Libraries underwent paired-end sequencing and the 
output size was either 150 or 300 bp. Gopuraja Dharmalingam provided post-
sequencing bioinformatic analysis of all of the output files. 
 
2.7.2 Data analysis and quantification 
RNA-seq sequencing reads were aligned to mm9 using Tophat using 
default parameters. Gene coordinates from Ensembl version 64 was used as 
known gene model. FPKM values for each sample was estimated using Cufflinks 
version 1.3.0 and correlation between replicates assessed using 'Spearman 
correlation'. 
2.8 Proteomics 
2.8.1 Protein extraction and western blotting 
Cells were first washed 3 times in ice cold PBS (Gibco) and then 
resuspended in 10µl/106 cells of lysis buffer (50 mM Hepes pH 7.5, 150 mM 
NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton-X 100, 1 mM EDTA) 
supplemented with Complete MINI, EDTA-free protease inhibitors (Roche 
Diagnostics) and Phosphatase Inhibitors Cocktail I and II (Sigma). Cells were 
placed at 4ºC with vigorous shaking (1400 rpm) for 30 minutes. To improve the 
extraction of chromatin bound proteins, the lysate was frozen in liquid nitrogen 
and thawed by vigorously shaking (1400 rpm) at 37ºC. This procedure was 
repeated three times. Finally the extract was cleared from the insoluble fraction 
by centrifugation at 10,000 g for 10 minutes at 4ºC. The concentration of the 
protein extract was determined by Bradford assay (Biorad) using a Genesys 
spectrophotometer (Thermo). A standard curve was prepared using BSA 
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dissolved in lysis buffer (0.2 – 0.4 – 0.8 – 1.6 – 3.2 – 6.4 – 12.8 µg/µl). 
For western blots, 20-50 µg of whole protein extract was loaded on 
acrylamide/bis-acrylamide gels and transferred onto nitrocellulose membranes 
(GE) using a transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 0.1% SDS) 
supplemented with 20% methanol (VWR). The membranes were blocked over 
night at 4ºC in 5% milk/ 0.1% TBS-Tween-20. The primary and secondary 
antibodies were both diluted in blocking solution and incubated with the 
membrane at room temperature for 60 and 45 minutes, respectively. All 
secondary antibodies were horseradish peroxidase (HRP)-conjugated and the 
chemiluminescent substrate used for visualisation of bands was Western 
Lightning Chemiluminescence Reagent Plus (Perkin Elmer). 
   
2.8.2 Protein co-immunoprecipitation 
For co-immunoprecipitation (Co-IP) experiments, whole cell extracts were 
prepared by resuspending PBS-washed cells in 1% NP-40 lysis buffer (50 mM 
Tris HCl pH 7.5, 150 mM NaCl, 1mM MgCl2, 10% glycerol, 1% Triton-X 100, 5 
mM EDTA, 1mM DTT), supplemented with Complete MINI, EDTA-free protease 
inhibitors and Phosphatase Inhibitors Cocktail I and II. Protein extracts were 
separated from genomic DNA and cell debris by centrifugation at 14,000 rpm at 
4°C for 15 minutes. The extracts were then diluted with 4 volumes of dilution 
buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 1mM MgCl2, 10% glycerol, 0.5 mM 
EDTA) and quantified using the Bradford method. 
1 mg of whole protein extract was incubated for 2 hours with 50 μL of 
protein G Dynabeads, pre-coupled to 2 μg of antibody. The beads were washed 
6 times with 0.1% NP-40 buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 1mM 
MgCl2, 10% glycerol, 0.1% Triton X-100, 0.5 mM EDTA). Immunocomplexes 
were eluted by boiling the beads in 60 μL of 2X Loading buffer and 5X Reducing 
agent (both from Invitrogen), for 10 minutes at 99°C. For western blots, half or 
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one third of the eluted material was diluted 1:2 with water and loaded on 
acrylamide/bis-acrylamide gels. 
 
2.8.3 Calcium phosphate transfection 
For co-IP experiments with tagged proteins, 50% confluent 293T cells were 
co-transfected with plasmids expressing N-terminus FLAG-tagged mouse Aurora 
B and N-terminus HA-tagged mouse Ring1B. The FLAG-Aurora B construct was 
inserted in a pSPORT6 vector (Invitrogen), while the HA-Ring1B construct was 
inserted in a pSG5 vector (Invitrogen) and was a kind gift of Dr. Miguel Vidal 
(CNIO, Madrid). Both vectors (2 µg each) were resuspended in 500 µl of 0.4 M 
CaCl2 (Sigma) to which a volume of 500 µl of HEBS solution (pH 7.05) (1.5 mM 
Na2HPO4.2H2O (Sigma), 280 mM NaCl, 10 mM KCl, 12 mM glucose (Fischer), 
50 mM Hepes) was added dropwise while vortexing the tube. This solution was 
incubated at 37ºC for 15 minutes and then added dropwise to the 9 ml of medium 
covering the cells in a 100mm Petri dish. The cells were returned to the cell 
incubator and, after 24 hours, the medium was changed. After an additional 24 
hours the cells were harvested for protein extraction and co-IP experiments as 
described in section 2.8.2. 
 
2.8.4 Cell labelling for SILAC 
I.29+ cells were gradually adapted to grow in dialysed FBS (Biosera) by 
increasing the percentage of dialysed over normal FBS over 4 passages. The 
adapted cells were switched from normal RPMI to RPMI for SILAC (Thermo 
Scientifics) and supplemented with 0.1 mg/mL of 13C6 15N2 L-Lysine-2HCl and 
13C6 15N4 L-Arginine-HCl (CKGas). After 4 doublings, a small number of cells 
(~105) were lysed and the heavy label incorporation was confirmed by mass 
spectrometry by Dr. Ambrosius Snijders. 
  142 
 
2.8.5 Sample preparation for LC-MS/MS analysis 
Co-immunoprecipitated proteins were spiked with 10 µg of heavy-labelled 
I.29+ whole cell extract. To drastically reduce the concentration of detergents in 
the samples, which could interfere with downstream applications, the samples 
were partly resolved by running them on a 10% acrylamide/bis-acrylamide gel. 
The proteins were fixed and stained with Simplyblue safe stain (Invitrogen), 
according to the manufacturerʼs instructions. A total of 8 bands were excised per 
sample and transferred into clean plastic tubes. The slices were dehydrated by 
adding 250-500 µl of acetonitrile (VWR) and incubating the tubes at 37ºC for 5 
minutes. The acetonitrile was removed and the samples left to air-dry. To 
increase the efficiency of the trypsin digestion, cysteine residues were first 
reduced by incubating the gel for 30 minutes at 55ºC with 100 µl of 100 mM DTT 
(Sigma) in 100mM ammonium bicarbonate (Sigma). After a second wash with 
acetonitrile, the gel was alkylated by incubating it in the dark for 20 minutes in the 
presence of 100 µl of 55mM iodoacetamide (Sigma) in 100mM ammonium 
bicarbonate. 
The samples were washed with acetonitrile as before and destained for 30 
minutes at 37ºC in 500 µl of 200 mM ammonium bicarbonate in 40% acetonitrile. 
In-gel trypsin digestion was performed overnight at 37ºC using 10 ng/µl Trypsin 
(Sigma) in the presence of 10 mM ammonium bicarbonate and 10% acetonitrile. 
The supernatant, containing the digested peptides, was collected and a second 
peptide extraction on the gel slice was carried out using 50 µl of 5% formic acid 
(Fischer) in 50% acetonitrile for 20 minutes. The peptides in the supernatants 
were dried by means of a vacuum centrifuge (Thermo). The dried samples were 
resuspended in 10 µl of 0.1% Trifluoroacetic acid (Sigma) using a sonicator water 
bath and subjected to mass spectrometry analysis by the Proteomics Facility at 
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the MRC CSC.  
 
2.8.6 Mass spectrometry analysis and data processing 
The analysis was performed by Dr. Ambrosius Snijders. Peptide mixtures 
were separated using a 50 cm analytical column on a 3 hour gradient from 3 to 
50 % acetonitrile (0.1% fluoroacetic acid). The data was acquired on the LTQ-
Orbitrap Mass Spectrometer using a top 6 MS/MS collision-induced dissociation 
(CID) method to ensure that each 3D peak is sampled multiple times thereby 
facilitating quantification. The number of MS/MS per cycle was extended to 20 to 
increase the number of peptide identifications. All raw data was analysed using 
MaxQuant. 
Table 2.1 Antibodies 
Antibody Manufacturer Host Application 
Aurora B (ab2254) Abcam Rabbit ChIP, ChIP-seq 
Aurora B (sc-14327) Santa Cruz Goat Co-IP, Western Blot 
Ring1B (D139-3) MBL Mouse 
ChIP, ChIP-seq, Western 
blot 
Cbx7 (ab31765) Abcam Rabbit ChIP, ChIP-seq 
Bmi1 (05-637) Millipore Mouse ChIP, ChIP-seq 
H2A (07-146) Millipore Rabbit ChIP 
H2AK119ubq (05-678) Millipore Mouse (IgM) ChIP 
USP16 (sc-130906) Santa Cruz Rabbit ChIP, ChIP-seq 
H2A.Z (ab4174) Abcam Rabbit ChIP, ChIP-seq 
Suz12 (ab12073) Abcam Rabbit ChIP 
Ezh2 (39875) Active Motif Mouse ChIP, ChIP-seq 
H3 (ab1791) Abcam Rabbit ChIP, Western Blot 
H3S28ph (ab5169) Abcam Rabbit ChIP 
H3K27me3 (ab6002) Abcam Mouse ChIP, ChIP-seq 
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Ser5ph RNA Pol II (MMS-
128P) 
Covance Mouse ChIP, ChIP-seq 
8WG16 (MMS-126R) Covance Mouse 
ChIP, ChIP-seq, Wesetrn 
blot 
MSK1 (M5437) Sigma Rabbit ChIP 
Normal goat IgG (sc-2028) Santa Cruz Goat Co-IP, ChIP 
Normal mouse IgG (12-371) Millipore Mouse Co-IP, ChIP 
Normal rabbit IgG (kch-504-
250) 
Diagenode Rabbit ChIP 
IgM (bridging antibody) (715-
006-020) 
Jackson 
Immunoresearc
h 
Donkey ChIP 
CD43-biotinilated (553269) BD Rat B cell purification 
CD16/CD32 (Fc Block) 
(553141) 
BD Rat B cell purification 
CD69-PE conjugated 
(553237) 
BD Hamster FACS 
B220-APC conjugated 
(553092) 
BD Rat FACS 
CD25-APC conjugated 
(558643) 
BD Rat FACS 
CD4-PE conjugated 
(553050) 
BD Rat FACS 
CD40 (553721) BD Hamster B cell activation 
Ig kappa light chain (559749) BD Rat B cell activation 
NIPP1 (ab5300) Abcam Goat Western Blot 
HA (MMS-101P) Covance Mouse Co-IP, Western Blot 
FLAG (F3165) Sigma Mouse Co-IP, Western Blot 
Mouse IgG-HRP conjugated 
(sc-2031) 
Santa Cruz Goat Western Blot 
Goat IgG-HRP conjugated 
(sc-2020) 
Santa Cruz Donkey Western Blot 
Rabbit IgG-HRP conjugated 
(sc-2030) 
Santa Cruz Goat Western Blot 
 
Table 2.2 Primers for ChIP (promoter region) 
b-Actin FW GCAGGCCTAGTAACCGAGACA 
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b-Actin RV AGTTTTGGCGATGGGTGCT 
Fcrl1 FW TGAACACTGGACAAGGTTGCT 
Fcrl1 RV CTTGAGGTGCCTCTCACCA 
Mapbpip FW GGGCCAGAGCCTCAGTAGAT 
Mapbpip RV GCCTCTTGCTCTCCCTCAGT 
Gba FW TAGGCCTCCCCAAAATTCAC 
Gba RV GGCGGACAGAGTCACATGAT 
Cct3 FW ACATACGCACAGGCAAAACA 
Cct3 RV TAGACGCGCTGGTTTTCTTT 
Prcc FW GCCTCCTGCTCCGTGCTCTA 
Prcc RV AGTGACTCGGCGGCCATTAG 
Nestin FW GGGCTGTCTGGCTGTATCTC 
Nestin RV CCCAGCTCAGCAGAGAAGAA 
InsR FW GCGTAAACCAATCCGTTTCT 
InsR RV GACCTCCTGGACATGCAGAC 
Mtx1 FW GTCTCGGTTCTCGGCAAAG 
Mtx1 RV GAGCTGTTCTGCTGGTCAGG 
Pmf1 FW GCGACTAGCTTCTGGAGGAA 
Pmf1 RV GCTGAGGTGAGCCGAGATAG 
Bcan FW GCAAGATTTCCTACCGACCA 
Bcan RV TGCTTAGCAGGGGAGTCTGT 
Hapln2 FW GGACCCAGGTTTCATTTTCA 
Hapln2 RV CTGTGCGCCATGTCTGTAGT 
Fdx1 FW CACTGTTCCAGGGATCTGGT 
Fdx1 RV TGAGGGTCTATGGCAAAAGG 
Atp5s FW GCTCCTGGTTGGTTGTTCAT 
Atp5s RV CGAGCCGTCTACTTTCATCC 
Arhgef2 FW AGAGCTGAGCTGGGTTACCA 
Arhgef2 RV ATCCCTTACCGGAGCAACTT 
Mef2D FW AGCTTGTCCTGAGTGCCAGT 
Mef2D RV GGAGGAAACTCACACGGGTA 
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Table 2.3 Primers for transcriptional analysis 
Atp5s RT FW TCTGGGAATGGTTGAATACAGTG 
Atp5s RT RV CTCCACACCGAAGTAGCCAC 
Fdx1 RT FW TTTGGTGCGTGTGAGGGAAC 
Fdx1 RT RV GCACAGTCATATTGTCCATAGCC 
Myc  RT FW ATGCCCCTCAACGTGAACTTC 
Myc RT RV GTCGCAGATGAAATAGGGCTG 
Klf2 RT FW GAGCCTATCTTGCCGTCCTTT 
Klf2 RT RV CACGTTGTTTAGGTCCTCATCC 
FoxO4 RT FW CTTCCTCGACCAGACCTCG 
FoxO4 RT RV ACAGGATCGGTTCGGAGTGT 
Klf4 RT FW GGCGAGTCTGACATGGCTG 
Klf4 RT RV GCTGGACGCAGTGTCTTCTC 
b-Actin RT FW GGCTGTATTCCCCTCCATCG 
b-Actin RT RV CCAGTTGGTAACAATGCCATGT 
Rnf2 RT FW GAGTTACAACGAACACCTCAGG 
Rnf RT RV CAATCCGCGCAAAACCGATG 
Aurkb RT FW CAGAAGGAGAACGCCTACCC 
Aurkb RT RV GAGAGCAAGCGCAGATGTC 
Spike RT FW CGAAATCGGCAAAATCCCTTAT 
Spike RT RV TTACGGCACCTCGACCCCAAAAA 
Fcrl1 RT FW TCCTCATCTGCTCGGTTGAT 
Fcrl1 RT RV AGCATCGCTCTGCTTCATGT 
InsrR RT FW AGACCTCTTCCCCAACCTCA 
InsrR RT RV CCAGTCAATGGTGGAGAGA 
Prcc RT FW TGGGTACCACAACCACCACT 
Prcc RT RV CTCAACTCCAGGTGGCTCAG 
Nestin RT FW CGCAGAGGGAGCAGCACCAA 
Nestin RT RV CTTCTCCATCCTCCACCACATCC 
Bcan RT FW CGGGAGGTAGAGGTTCTGGT 
Bcan RT RV ATAGACCCCGGAATCATTGG 
Hapln2 RT FW CCCCATCCACGAGGTCATTCAC 
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Hapln2 RT RV CGGGCTCCACTTTGCTCCAG 
Mef2D RT FW CATGCAGTTCAGCAATCCAA 
Mef2D RT RV GCAAGCCTCGAGAAACACTG 
Cct3 RT FW CCGTGAGATGATGTTGAGCA 
Cct3 RT RV CTGCCATTCTCTTCAAACTGC 
Pmf1 RT FW CTCCTCTCCGGAAGCTGTG 
Pmf1 RT RV CCTGTCGGCGACTAGCTTTT 
Mapbpip RT FW ATAATGAGGGATCGCTGCTG 
Mapbpip RT RV GCTTGGTTCCCGTTCCTATC 
Arhgef2 RT FW CCGGGAAAAGGAGAAGATGA 
Arhgef RT RV TCCTTGGCTGTGATGCTCTT 
Gba RT FW TCCCCAAAAGCTTTGGCTAC 
Gba RT RV AGTGCTCTCGTAACGGCTGA 
Mtx1 RT FW ACCAGCAATCCTTGGCAGA 
Mtx1 RT RV CGAAGATGGGTGATGATCTTG 
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Chapter 3 - Identification of new partners of Aurora B outside 
mitosis 
 
3.1 Introduction 
The Aurora B kinase (henceforth referred to as Aurora B) is a key mitotic 
regulator (Carmena and Earnshaw, 2003). Over the years, however, it has 
become linked to other functions such as regulation of the G1/S transition (Song 
et al., 2007), transcriptional regulation of pituitary genes (Tardáguila et al., 2011) 
and Xist RNA recruitment (Hall et al., 2009). The aim of this PhD project was to 
identify novel functions for Aurora B outside mitosis, in particular in gene 
regulation. The link between Aurora B overexpression and myeloid malignancies 
(Katayama et al., 2003), the relatively good efficacy of Aurora B inhibitors in 
leukaemias (Yang et al., 2007), its role in interphase in T-cells (Song et al., 2007) 
and its expression in terminally differentiated, post-mitotic plasma cells 
(Sabbattini et al., 2007) led to the choice of mature murine B and T cells as the 
cell models for the study. A further advantage of these cells is the fact that they 
are primary non-transformed cells that can be readily isolated and studied. 
The initial strategy was to search for novel binding partners for Aurora B 
outside mitosis. The experimental approach used in this part of the project 
involved co-immunoprecipitation (co-IP) of Aurora B in G1 and control, 
unsynchronized LPS-activated B cells followed by quantitative mass 
spectroscopy. This strategy allowed me to quantify proteins that interact with 
Aurora B mainly in G1.  
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3.2 Isolation of G1 activated B cells by counter-flow centrifugal elutriation  
The expression of Aurora B peaks at the onset of G2 and remains constant 
until the end of cytokinesis (see section 1.5). Therefore, most of the detectable 
Aurora B comes from the G2/M phase in an unsynchronized population of cycling 
cells. In LPS-activated B cells, for example, the levels of Aurora B in an 
asynchronous population are orders of magnitude higher than the amount of 
Aurora B present in the same cells when they are in G1 (Fig. 3.1) In order to 
study Aurora B outside mitosis it is therefore necessary to separate interphase 
from mitotic cells, as the contribution from the G2/M cells in a cycling population 
to the overall amount of Aurora B expressed is so large that it impairs the study 
of Aurora B in interphase. 
 
Figure 3.1: Differential expression of Aurora B in unsynchronized and G1-elutriated B-
cells.  
Whole cell extracts from unsynchronized and G1-elutriated LPS-activated B cells were resolved 
on a 6% acrylamide/bis-acrylamide gel and probed with antibodies against Aurora B and RNA 
Polymerase II.  
 
Several compounds, such as aphidicolin and nocodazole, have been shown 
to reversibly arrest the cell cycle by blocking critical steps during the cell cycle. 
However, attempts to use these drugs in primary, lipopolysaccharide (LPS)-
activated B cells proved unsuccessful or unsatisfactory in terms of cell death 
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(data not shown). I decided therefore to use counter-flow centrifugal elutriation 
(CEE) (Banfalvi, 2008) to obtain pure interphase B cells. This technique 
separates cells based on their size, which varies in direct proportion to their DNA 
content. CEE proved a reliable method for obtaining high numbers of cells in the 
G1 phase of the cell cycle (Figure 3.2 and section 2.2).  
 
Figure 3.2: Cell cycle distribution in unsynchronized and G1-elutriated (fraction 9ml/min) 
LPS-activated B cells.  
CD43-negative cells were isolated from 6- to 8-week old mice and stimulated with 12.5 µg/ml LPS 
for 72 hours. 
3.3 Indirect SILAC-based determination of Aurora B partners in G1 
3.3.1 Introduction to SILAC 
Stable isotopic labelling with amino acid in culture (SILAC) is a powerful tool 
to quantify protein interactions in different samples in vivo (Amanchy et al., 2005). 
Briefly, cells are growth in the presence of amino acids containing stable isotopic 
elements, such as 13C and 15N, so that every peptide will incorporate them over 
time and increase its mass. Heavy-labelled peptides differ from those containing 
natural (light) amino acids only for their higher mass, resulting in distinguishable 
spectra. The relative abundance of each protein is expressed as the ratio of 
relative intensity of heavy- to light-labelled peptides (Fig. 3.3). 
A key requisite for SILAC is the full incorporation of the heavy amino acids. 
For this reason, cells are firstly adapted to grow in dialyzed serum, which is 
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devoid of the natural amino acids present in cell culture sera. Secondly, cells 
must go through at least 5-6 divisions (depending on protein turn-over) in 
medium supplemented with heavy amino acids before every peptide is fully 
labelled. 
 
Figure 3.3: Schematic representation of the SILAC workflow from cell labelling to 
quantification of relative abundance (reproduced with permission from Amanchy et al., 2005, 
Science's STKE 2005, pl2. Reprinted with permission from AAAS). 
3.3.2 Use of an internal standard to perform quantitative mass spec 
analyses in primary cells 
LPS-activated B cells can survive in culture for 3-4 days before entering 
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apoptosis or beginning to differentiate into plasmablasts and plasma cells. During 
this window of time no more than 3-4 divisions are completed, which is not 
enough to allow complete SILAC labelling. To circumvent this problem, 
unsynchronized I.29+ B cell lymphoma cells (I.29) were labelled with heavy 
amino acids. A protein extract from the heavy-labelled I.29 cells was mixed with 
the eluates obtained from co-IPs of Aurora B from primary G1-elutriated and 
unsynchronized LPS-activated B cells (Fig. 3.2). This method has been 
previously described for primary tissues (Ishihama et al., 2005) and allows for 
quantification of “light” samples by means of a heavy internal standard (Fig. 3.4). 
I.29 cells were used to provide the heavy internal standard because of their close 
resemblance to mature B cells (Alberini et al., 1987). This cell line has also used 
as a model to study proteosomal changes during B cell development (Romijn et 
al., 2005). In summary, I reasoned that the repertoire of proteins expressed in 
I.29 cells is likely to be similar to that of primary mature B cells. Therefore 
peptides from both the co-IPs of primary cells should be present in the heavy I.29 
cells extract, making it possible to quantify them. 
A fixed amount of heavy I.29 extract (1% of the input used for each co-IP) 
was added to both co-IP samples. The relative abundance of each heavy peptide 
was considered as a constant value in both the G1 and control (CTL) light 
sample. Hence, the relative abundance of each protein co-immunoprecipitated in 
both samples (G1 and unsynchronized control) could be directly compared and 
assigned a numerical value (ratio G1/CTL). 
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Figure 3.4: Experimental scheme of SILAC in primary B cells using a heavy-labelled 
internal standard.  
I.29 cells were fully labelled with 13C6, 15N4 L-Arginine and 13C6 L-Lysine. The input used or each 
co-IP was 1mg of whole cell extract from either unsynchronized or G1-elutriated LPS-activated B 
cells and was added to anti-Aurora B antibody coupled to protein-G magnetic beads. 
Immunoprecipitated complexes were eluted by boiling the beads in 2x loading buffer. Whole cell 
extract (10 µg) from labeled I.29 cells were added to each eluted fraction. Samples were run on a 
10% acrylamide/bis-acrylamide gel for less than a third of its length to remove traces of 
detergents. A total of 8 bands were excised per sample and in-gel trypsin digestion was 
performed before LC-MS/MS analysis. 
3.4 Quantitative analysis of the partners of Aurora B in G1-elutriated, LPS-
activated B cells 
My analysis focused on peptides that are present primarily in G1 and, as a 
first indication of the type of interactors that co-immunoprecipitate with Aurora B, I 
looked at the annotated function of peptides whose G1/CTL ratio was greater 
than 1. Gene expression, developmental process and chromatin organization 
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were represented among the terms displaying a statistically significant 
enrichment, (Fig. 3.5). This first analysis supported the original hypothesis that, 
outside mitosis, Aurora B interacts with different types of proteins implicated in 
biological processes such as gene regulation. 
 
 
Figure 3.5: Functional annotation of proteins with G1/CTL ratio higher than 1.  
Proteins are grouped according to their annotated biological process. (This analysis as carried 
out by Dr. Tom Carrol). 
 
For the second phase of the analysis I looked at the specific proteins that 
interact with Aurora B mainly in G1. For this purpose, I considered proteins with a 
G1/CTL ratio greater than 0.2. The rationale for this value is based on the 
observation that 83.9% (80% by approximation) of the cells in the 
unsynchronised control sample are in G1 (Fig. 3.2, left panel) and, therefore, 
some of proteins with a G1/CTL ratio between 1 and 0.2 might still interact with 
Aurora B in G1 and, because of different efficiency of the co-IP in the G1 and 
CTL samples, be more represented in the CTL sample. Moreover, the SILAC 
determination was not performed in duplicate, as the aim of this experiment was 
to identify potential partners that would be validated by direct co-IP and western 
blot in at least two independent biological replicates. To validate this approach I 
selected a protein with a G1/CTL value slightly above the cut-off value, NIPP1 
(G1/CTL = 0.28), and analysed its interaction with Aurora B by co-IP in the G1-
elutriated and unelutriated LPS-activated B cells. NIPP1 interacts with PRC2 and 
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is required for its association with target genes (Van Dessel et al., 2010) and, to 
date, it has not been reported as a partner of Aurora B. Western blot detection 
with an anti-NIPP1 antibody confirms that this protein interacts with Aurora B and 
this interaction occurs in both samples (Fig. 3.6). 
 
Figure 3.6: NIPP1 interacts with Aurora B in G1-elutriated cells despite being detected 
with a G1/CTL ratio of 0.2 in the SILAC-based screening for new potential partners of 
Aurora B outside mitosis.  
Magnetic beads were pre-incubated with antibodies against goat IgG (negative control) or Aurora 
B. The input material for each co-IP was 500 µg of whole cell extract from unsynchronized (green, 
left) and G1-elutriated (red, right) B cells. Complexes were eluted by boiling the beads in 2x 
loading buffer and resolved on a 10% acrylamide/bis-acrylamide gel. Membranes were incubated 
with antibodies against NIPP1. Asterisks denote heavy and light chains of the IgG. 
 
Table 3.1 lists some of the most interesting peptides with a G1/CTL ratio 
greater than 0.2. PcG proteins were identified including the PRC1 components 
Ring1B and RYBP and the DNA binding protein YY1. Since no PcG protein has 
been, to date, shown to directly or functionally interact with Aurora B or members 
of the CPC at any stage of the cell cycle, I decided to focus my attention on this 
possibility. 
Other proteins identified in this screening as new partners of Aurora B were 
Dicer and Argonaute 2, members of the RISC complex. Interaction of short, 
centromeric non-coding RNAs with Aurora B has been described and minor 
satellite RNAs have been shown to enhance Aurora B kinase activity, hinting at 
the possibility of a role for short RNAs in Aurora B regulation (see section 1.5.1). 
  156 
Furthermore, Two DNA methyltransferases (DNMT1 and 3A) were also found to 
co-immunoprecipitate with Aurora B (see section 1.4.1). DNA methylation has 
been shown to promote Aurora B recruitment and phosphorylation of serine 10 
on histone H3 (H3S10ph) during the transition from S to G2 phase. Moreover, the 
knockdown of DNMT1 reduces H3S10ph on pericentromeric foci in G2 (Monier et 
al., 2007). However, these proteins have never been identified as potential 
interactors of Aurora B.  
Other previously unknown interactors included members of the 
deadenylation complex CCR4-Not and Forkhead transcription factors. 
Specifically, the Cnot 2, 3, 6, 7, 8 and 10 subunits of the CCR4-Not complex 
immunoprecipitated with Aurora B and presented a G1/CTL value above 0.2. The 
Cnot 1 subunit was also co-immunoprecipitated with Aurora B but with a G1/CTL 
value below 0.2. Among the Forkhead transcription factors, FoxO1A, FoxK1 and 
FoxP1 were identified as interactors with a G1/CTL ratio above 0.2. These 
interactions were validated by other members of our group. 
Table 3.1: Aurora B partners identified by SILAC screening as potential 
interactors during G1. 
Protein name G1/CTL value 
Dicer 3.033033487 
Cnot8 1.464916589 
Cnot3 1.30663808 
HP1β 1.301726626 
Cnot2 1.007795999 
Cnot10 0.977521716 
Dnmt1 0.943904332 
Cnot7 0.919563132 
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mTor 0.902603745 
Argonaute 2 0.875105078 
Ring1B 0.842019574 
Cnot6 0.786866446 
FoxK1 0.768578215 
RYBP 0.698245614 
FoxO1A 0.647821447 
FoxP1 0.624228885 
Dnmt3a 0.621664627 
SUV39H2 0.579021595 
YY1 0.573954217 
NIPP1 0.27945747 
 
The SILAC analysis confirmed that, as has been reported for T cells, Aurora 
B and mTOR interact with one another outside mitosis in B cells (see section 
1.5.5). Aurora B displaces the heterochromatin protein HP1 from trimethylated 
lysine 9 on histone H3 (H3K9me3) at the onset of mitosis by phosphorylating the 
nearby serine 10 (see section 1.5.2). The histone methyltransferase SUV39H2, 
responsible for deposition of the H3K9me3 mark (O'Carroll et al., 2000) was 
detected, as well as HP1β. The CPC proteins INCENP and Borealin and several 
subunits of the APC complex were detected only in the CTL sample or with a 
G1/CTL ratio below the cut-off value of 0.2 (not shown in table 3.1). Interestingly, 
the PRC2 core component Suz12 was also identified in the CTL but not in the G1 
sample, suggesting that this interaction might take place either during S or G2/M. 
3.5 Validation of the Aurora B-Ring1B interaction 
One of the major results of the SILAC analysis was the finding that Aurora B 
and Ring1B interact in G1 activated B cells. As this observation raised the 
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possibility that Aurora B might be involved in PRC1-mediated regulation of gene 
expression, additional experiments were performed to confirm the result. Co-IP 
was carried out on extracts from G1 activated B cells, followed by western blot 
analysis of immunoprecipitated proteins using an anti-Ring1B antibody (Fig. 3.7).  
The western blot detected a band at the predicted molecular weight of Ring1B 
both in the input and Aurora IP lanes but not in the negative IgG control (Fig. 3.7 
bottom panel). A similar analysis carried out using an antibody that recognises 
the catalytic subunit of PRC2 Ezh2 found no evidence of interaction between 
Aurora B and Ezh2 (Fig. 3.7, top panel). 
 
 
Figure 3.7: Aurora B interacts with Ring1B but not with Ezh2 in G1-elutriated LPS-
activated B cells.  
Magnetic beads were pre-incubated with antibodies against goat IgG (negative control) or Aurora 
B. The input material for each co-IP was 500 µg of whole cell extract from G1-elutriated B cells. 
Complexes were eluted by boiling the beads in 2x loading buffer and resolved on a 10% 
acrylamide/bis-acrylamide gel. Membranes were incubated with antibodies against Ezh2 (top 
panel) and Ring1B (bottom panel). Asterisks denote heavy and light chains of the IgG. 
 
To further confirm this result, I transiently co-transfected 293T cells with 
vectors expressing tagged versions of Aurora B (Flag) and Ring1B (HA) (see 
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section 2.8.3). After confirming the efficiency of the co-transfection and the 
expression of the two proteins, I performed co-IP of HA (Ring1B) and assessed 
the presence of Flag-Aurora B among the proteins eluted (Fig. 3.8, top panel) 
and vice versa (Fig. 3.8, bottom panel). This approached confirmed the 
interaction between Aurora B and Ring1B, although it does not establish whether 
the interaction is direct or whether the DNA or other proteins mediate it.  
 
 
Figure 3.8: Co-immunoprecipitation of Aurora B and Ring1B in co-transfected 293T.  
Magnetic beads were pre-incubated with antibodies against IgG (negative control), HA (Ring1B) 
or Flag (Aurora B). The input material for each co-IP was 1 mg of whole cell extract from co-
transfected 293T cells. Complexes were eluted by boiling the beads in 2x loading buffer and 
resolved on 8% acrylamide/bis-acrylamide gels. Membranes were incubated with antibodies 
against Flag-Aurora B (top panel) and HA-Ring1B (bottom panel). Asterisks denote heavy chains 
of the IgG. 
3.6 Summary 
In summary, I used centrifugal elutriation to purify G1 LPS-activated B cells 
from an actively proliferating population. Quantitative MS analysis of Aurora B-
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containing complexes immunoprecipitated from G1 and unsynchronized cells 
demonstrated that Aurora B interacts with epigenetic regulators in interphase. 
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Chapter 4 - Aurora B and Ring1B bind to the regulatory 
elements of active genes in resting lymphocytes 
 
4.1 Introduction 
Co-IP and western blot confirmed that Aurora B interacts with Ring1B. 
Ring1B is an epigenetic regulator responsible for the monoubiquitination of 
histone H2A and Aurora B phosphorylates histone H3 to compact chromosomes 
in mitosis and to promote transcription in G0/G1 pituitary cells. Previous 
chromatin immunoprecipitation (ChIP) and ChIP-on-ChIP data generated in our 
lab by Dr. Marcela Sjoberg had shown that Aurora B, Ring1B and Cbx7 bind to 
promoters of active genes in resting B cells. PRC1 binding is independent of 
PRC2-mediated trimethylation of lysine 27 on histone H3, which decorates silent 
promoters in these cells. Moreover, Ring1B and the H2Aubq mark do not 
colocalise as the latter is detected at high levels only at silent genes. 
On the basis of these findings, I firstly assessed the effects of different 
methods of B cell activation on the binding of Aurora B and Ring1B. Secondly, I 
expanded the analysis to resting CD4+ T lymphocytes. Finally, I used ChIP in 
conjunction with high-throughput DNA sequencing (ChIP-seq) to characterise the 
genome-wide localisation of Aurora B, PRC1 and PRC2 components. 
4.2 Aurora B and Ring1B bind to the promoters of active genes in 
quiescent B cells 
The spleen is the site of B cell maturation and the primary source of resting 
B cells (see 1.3.5). To obtain resting B cells, I followed a published methodology 
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routinely used in our group and described in detail in Section 2.1.1. Although the 
method relies solely on negative selection of CD43+ cells, analysis of the 
proliferation rate and B cell markers shows that more than 95% of the cells 
isolated with this method are mature B cells (B220+), which are also resting 
(CD69-) (Fig. 4.1).  
 
Figure 4.1: Characterization of CD43 negative cells isolated from the spleen of adult mice.  
After isolation from the spleen of adult mice, a proportion of the CD43- cells (typically 1-2x106 
cells) has been routinely used to assess purity (Resting B cells) and compared with activated 
cells from the very same preparation after 3-4 days (CD40- and LPS-activated B cells). Freshly 
isolated cells were left to recover and then stained with CD69 (activation marker) and B220 
(mature B cells) (left panel) and propidium iodide (right panel) and analysed by FACS. CD40- and 
LPS-activated cells were stimulated as described in section 2.1.1 and analysed after 4 and 3 
days in culture, respectively. The results obtained after one representative procedure are 
presented here. 
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Data from Dr. Marcela Sjoberg had shown that Aurora B and Ring1B are 
both bound to chromatin in resting CD43- splenocytes (henceforth referred to as, 
simply, resting B cells). These cells can be activated in culture with LPS to mimic 
a T-independent B cell activation (see section 1.3.7). The results shown in Fig. 
4.2 demonstrate that Aurora B and Ring1B bind to the promoter regions of genes 
that are known to be active in LPS-activated cells (b-Actin, Fcrl1, Mapbpip, Gba, 
Cct3, Mtx1, Prcc, Pmf1) but not to genes that are silent (Nestin, InsrR, Bcan, 
Hapln2). In contrast, Suz12 exhibits opposite behaviour as it binds to the 
promoters of genes that are silent in activated B cells and not to promoters of 
active genes (Fig. 4.2).  
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Figure 4.2: Distribution of Aurora B, Ring1B and Suz12 on the promoters in quiescent B 
cells.  
ChIP experiments were performed with antibodies recognizing Aurora B (red bars), Ring1B (blue 
bars), Suz12 (grey bars) and IgG (negative control, white bars). Chromatin binding was assessed 
using primer pairs covering the promoter region of the indicated genes. Genes were selected 
based on previous ChIP-on-ChIP results (Dr. Marcela Sjoberg). The genes that were analysed 
are located in a gene-dense region of mouse chromosome 3. Their transcriptional status (active 
or silent) had been previously assessed by qRT-PCR by Dr. Svetlana Nikic in LPS-activated B 
cells. The transcriptional status of the genes in quiescent cells was confirmed and is shown in 
Fig. 4.3. Binding is expressed as enrichment relative to input DNA using the same amount of 
DNA in each PCR reaction (see section 2.4.3). A dashed line indicates the threshold value of 
enrichment above which a protein is considered to be bound. Background levels (DNA 
immunoprecipitated with an anti-IgG antibody) are shown as white bars where detected. Error 
bars represent the standard deviation of the mean (n=4 biological replicates) (For this picture, 
data obtained by Dr Marcela Sjoberg has been combined and averaged with data that I obtained). 
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4.3 Genes bound by Aurora B and Ring1B in quiescent B cells are 
transcribed rather than poised 
It is known that some genes are transcribed selectively during quiescence 
but not in activated cells. To determine the transcriptional status of the Aurora B 
and Ring1B target genes shown in Figure 4.2, I compared their transcriptional 
status to that of quiescent and G1-elutriated, LPS-activated B cells by analysing 
total RNA from both stages. To prevent biases caused by genomic DNA, RNA 
was extensively treated with DNase I and four biological replicates were analysed 
(see section 2.6).  
Since the transcriptional activity of quiescent cells is considerably reduced, 
it is impossible to choose a priori, a reference gene whose transcriptional levels 
are not affected by activation. When comparing transcriptional levels in resting 
and proliferating cells, a parameter that can be controlled and used as a 
reference is the number of cells. For this reason, a spike-in RNA was added to 
cell lysates prepared from equal numbers of cells and used as a reference to 
quantify the gene expression in each sample. Unlike a reference gene 
endogenously transcribed in the genome, the quantity of this reference will not be 
affected by the global transcriptional activity of the cell, because it has been 
exogenously added. By keeping the ratio of cells to spike-in constant and 
provided the spike-in RNA is added immediately after lysis of the cells, it is 
possible to quantify differentially expressed transcripts on a per-cell basis in cell 
types with intrinsically different characteristics such as resting versus 
proliferating.  
The analysis of RNA isolated from quiescent and G1-elutriated, LPS-
activated B cells provided two important pieces of information. Firstly, the results 
showed that genes that are bound by Aurora B and Ring1B produce detectable 
levels of transcripts in quiescent and activated cells and are therefore actively 
transcribed rather than being in a poised state (Fig. 4.3). At the same time, the 
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repressed genes that were analysed remained in a silent condition in both cell 
types. The second major observation was that all of the genes analysed (with the 
exception of Fcrl1 and Mtx1) showed substantial increases (ranging from 2- to 
20-fold) in their absolute level of transcription in G1-LPS activated B cells.  
 
Figure 4.3: Comparison of the transcriptional levels of active genes in resting (quiescent) 
and G1-elutriated LPS-activated B cells (G1 LPS-activated).  
Resting B cells were isolated from the spleen and either immediately lysed or stimulated with LPS 
for 3 days and elutriated to obtain a pure G1-population. Total RNA was extracted from both cell 
types and used to produce cDNA (see section 2.6.2). Transcripts were quantitated by qRT-PCR 
and levels were calculated relative to a spike-in RNA (see section 2.6.1), which was added to the 
cell lysate prior to the RNA purification. The ratio of spike-in RNA to the starting number of cells 
was kept constant. This means that the transcript levels measured by qRT-PCR should be a 
measure of the absolute level of transcripts per cell, allowing direct comparison of the levels of 
each transcript in different cell types. Cell numbers were the average of 10 counts using a 
haemocytometer (see section 2.6.2). Error bars represent the standard deviation of the mean 
(n=2 biological replicates) for the qRT-PCR analysis. 
4.4 Aurora B binding is lost upon B cell activation 
If Aurora B binding is mainly a function of transcriptional activity, one might 
expect that during the activation-induced transcriptional burst, Aurora B binding 
will increase proportionally. To test this hypothesis, I measured the binding of 
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Aurora B to target promoters following activation in G1-elutriated cells. The 
presence of high levels of Aurora B on chromosome arms during G2/M made it 
necessary to carry out the analysis using cells in the G1-phase that had been 
purified by elutriation (see section 3.2).  
Cells were activated in vitro by treatment with LPS or with a combination of 
anti-CD40 and anti-Igκ antibodies. The mitogen LPS triggers activation of the 
MAPK/ERK pathway, which has been shown to lead to binding of MSK1/2 to 
promoters, phosphorylation of serine 10 and 28 on histone H3 and consequent 
gene activation (see section 1.4.3). The anti-CD40 antibody, instead, mimics a T-
dependent activation in culture and does not activate the MAPK/ERK pathway 
(see section 1.3.5), thus providing a test of whether any effects observed are 
specifically due to the action of mitogens. An additional consideration is the fact 
that MZ B cells are more sensitive to LPS-stimulation than follicular B cells, which 
are more responsive to anti-CD40 (see section 1.3.6). Therefore, by activating 
two different pathways that lead to B cell activation, it is possible to characterise 
the behaviour of Aurora B relative to activation per se in both types of quiescent 
cells, rather than the response to one particular stimulus in one subtype of resting 
B cells.  
Following the addition of the stimulating agents, the cells were left in culture 
for three to four days (3 for LPS and 4 for anti-CD40 plus anti-Igκ) and then 
elutriated to obtain a purified G1-fraction (see section 2.2). The results of the 
analysis are shown in Figure 4.4 and reveal that both activation methods result in 
displacement of Aurora B from its target promoters as measured by its 
enrichment over input DNA. Indeed, with the possible exception of Fcrl1 in LPS-
activated cells, Aurora B levels are reduced to background level (Fig. 4.4).  
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Figure 4.4: Binding of Aurora B to promoters is lost upon activation.  
Binding of Aurora B kinase was measured in quiescent resting B cells (red bars), G1-elutriated 
LPS-activated B cells (orange bars) and G1-elutriated anti CD40-activated B cells (yellow bars). 
Resting B cells were isolated from the spleen and either immediately lysed or stimulated with LPS 
or anti-CD40 plus anti-Igκ for 3/4 days and elutriated to obtain a pure G1-population. Binding is 
expressed as enrichment relative to input DNA using equal amounts of DNA in the PCR reactions 
(see section 2.4.3). A dashed line indicates the threshold value of enrichment above which a 
protein is considered to be bound. Background levels (DNA immunoprecipitated with an anti-IgG 
antibody) are shown as white bars where detected. Error bars represent the standard deviation of 
the mean (n=4 biological replicates).  
4.5 Distribution of Ring1B in quiescent and activated B cells 
Since Aurora B is removed from target promoters in these cells, I asked 
whether Ring1B follows Aurora B and is also removed from chromatin following 
activation. I performed ChIP experiments for Ring1B in G1-elutriated cells 
activated with either LPS or anti-CD40 plus anti-Igκ. Ring1B binding to active 
target genes is preserved following B cell activation, although on some genes 
(Fcrl1, Mapbpip and Pmf1) it is substantially reduced (Fig. 4.5). In addition to its 
continued presence on active genes, a low level of binding of Ring1B is detected 
on the promoters of the Nestin and Bcan genes following activation, as measured 
by levels of enrichment over input DNA. This hints at different roles for this 
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protein at different genes, possibly as part of different complexes (see section 
1.6.5). In general, the results suggest that any effects that are observed on 
Ring1B binding are a consequence of activation per se, as opposed to a specific 
type of activation.  
 
Figure 4.5: Binding of Ring1B to promoters is maintained following activation.  
Binding of Ring1B was measured in quiescent (blue bars), G1-elutriated LPS-activated (cyan 
bars), G1-elutriated anti CD40-activated B cells (light blue bars). Resting B cells were isolated 
from the spleen and either immediately lysed or stimulated with LPS or anti-CD40 plus anti-Igκ for 
3/4 days and elutriated to obtain a pure G1-population. Binding is expressed as enrichment 
relative to input DNA using the same amount of DNA in the PCR (see section 2.4.3). A dashed 
line indicates the threshold value of enrichment above which a protein is considered to be bound. 
Background levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as white bars 
where detected. Error bars represent the standard deviation of the mean (n=4 biological 
replicates). 
4.6 Cbx7 and Bmi1 both colocalise with Ring1B in quiescent cells but 
exhibit divergent behaviours following activation 
Ring1B associates with a wide spectrum of interactors to form different 
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PRC1 complexes. Preliminary data showed that the binding pattern of Cbx7 in 
resting B cells was identical to that of Ring1B (Dr. Marcela Sjoberg, data not 
shown). PCGF family members are core components of PRC1, which uniquely 
identify the different PRC1 complexes (see section 1.6.5). ChIP analysis showed 
that the PCGF family member Bmi1 binds to the same genes that bind Ring1B 
and Cbx7 in resting B cells. Since these proteins are involved in defining the 
functional properties of PRC1 complexes, I sought to characterise their behaviour 
following B cell activation and to compare it with the binding of Ring1B. 
Following activation, Cbx7 remains bound to the active promoters that bind 
Ring1B and the two proteins display the same pattern at four out of the six active 
genes that were analysed (Fcrl1, Mapbpip, Gba, Cct3) (Fig. 4.6 top panel). 
However, the binding of Cbx7 is reduced on the b-Actin gene and unchanged on 
the Prcc gene, which is the opposite of what is observed for Ring1B. Silent genes 
show no increase in binding of Cbx7, which remains close to background. 
In contrast, Bmi1 is completely removed from 5 out of 6 of the active genes 
analysed, with only Prcc, retaining a low level of binding (Fig. 4.6 bottom panel). 
This result was obtained in G1-elutriated cells and is therefore in agreement with 
the reported displacement of Bmi1 from chromatin during this phase of the cell 
cycle (Voncken et al., 1999). Moreover, these cells were activated using LPS. 
The MAPKAP kinase 3 (3pK), a downstream effector of the signalling cascade 
triggered by LPS, has been shown to remove Bmi1 from chromatin by 
phosphorylating the protein (see section 1.6.5).  
Since the PRC1 complexes isolated to date all contain a PCGF family 
member, it is possible that a switch to another PCGF protein might occur upon 
activation. Further experiments will be required to determine whether this is the 
case and which (if any) PCGF protein substitutes for Bmi1 in G1-elutriated G1 
activated B cells. Mel18 constitutes a good candidate for this role (see section 
1.6.5). Binding of Mel18 was not detected on chromatin in quiescent cells (data 
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not shown). However, in vitro at least, this protein requires phosphorylation by an 
unknown kinase before it can confer substrate specificity to Ring1B. The question 
of whether a phosphorylation-dependent switch governs the association of Bmi1 
and Mel18 with Ring1B/Cbx7 in this context will require further investigation. 
 
 
 
Figure 4.6: Cbx7 binds to active promoters in quiescent and LPS-activated B cells, 
whereas Bmi-1 binds in quiescent cells but not in G1 activated cells.  
Binding of Cbx7 (top panel) and Bmi-1 (bottom panel) to promoters was measured in resting B 
cells (green bars) and G1-elutriated LPS-activated B cells (light green bars). Resting B cells were 
isolated from the spleen and either immediately lysed or stimulated with LPS for 3 days and 
elutriated to obtain a pure G1-population. Binding is expressed as enrichment relative to input 
DNA using the same amount of DNA in the PCR (see section 2.4.3). A dashed line indicates the 
threshold value of enrichment above which a protein is considered to be bound. Background 
levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as white bars where 
detected. Error bars represent the standard deviation of the mean (n=4 biological replicates) (The 
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top panel show the average generated by combining data obtained by Dr Marcela Sjoberg with 
data that I obtained). 
4.7 H2A ubiquitination marks silent genes and does not co-localize with 
PRC1 components in quiescent and activated B cells 
PCGF proteins allow Ring1B to monoubiquitinate histone H2AK119 (see 
section 1.6.5). However, despite the presence of Bmi1, H2AUbq was not 
detectable above background at the active Ring1B-bound genes but was instead 
present at silent genes, where Ring1B binding was not detected. ChIP 
experiments confirm that this pattern is conserved in activated cells, although a 
small increase in the presence of the mark is detected on active promoters (Fig. 
4.7). The H2Aubq mark is also present in quiescent cells on active genes such as 
b-Actin and Fcrl1, albeit at much lower levels than on silent genes. 
Following activation with LPS, H2Aubq increases above background also on 
active genes such as Mapbpip, Gba and Cct3. This reinforces the idea that 
Ring1B is part of a PRC1 complex with some ubiquitination activity in G1-
elutriated, LPS-activated cells and again raises the possibility that Bmi1 is 
substituted by another PCGF protein following activation. A possible way of 
interpreting the acquisition of this repressive mark at the same time as the 
transcriptional burst that accompanies LPS-activation is that Ring1B is fine-tuning 
transcription.  
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Figure 4.7: H2A ubiquitination levels are higher on silent promoters than on active 
promoters in both quiescent and LPS activated cells.  
ChIP experiments with antibodies against total histone H2A and against ubiquitinated lysine 119 
on histone H2A were performed in quiescent and G1-elutriated LPS-activated B cells. Levels of 
ubiquitinated H2A were measured in quiescent resting B cells (dark green bars) and G1-elutriated 
LPS-activated B cells (light green bars). Resting B cells were isolated from the spleen and either 
immediately lysed or stimulated with LPS for 3 days and elutriated to obtain a G1-population. 
Levels of H2Aubq are expressed as enrichment relative to DNA immunoprecipitated by an anti 
H2A antibody that recognises total H2A using the same amount of DNA in the PCR. A dashed 
line indicates the threshold value of enrichment above which a protein is considered to be bound. 
Background levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as white bars 
where detected. Error bars represent the standard deviation of the mean (n=4 biological 
replicates). 
4.8 The histone H2A deubiquitinase USP16 is present at Aurora B target 
genes and is displaced following B cell activation 
The deubiquitinase USP16 removes the H2Aubq mark from chromosomes 
at the onset of mitosis thereby allowing Aurora B to bind and phosphorylate 
histone H3 (see section 1.5.2). Since H2Aubq is absent from Aurora B target 
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genes in quiescent B cells, I asked whether USP16 is also present at these 
promoters. ChIP analysis of the distribution of USP16 shows that the 
deubiquitinase binds to promoters that are bound by Aurora B (b-Actin, Fcrl1, 
Mapbpip, Gba, Cct3) but not to active genes that are devoid of the kinase (Fdx1 
and Atp5s) (Fig. 4.8, dark green bars). Binding of USP16 to active promoters is 
no longer observed in G1-elutriated, LPS-activated B cells (Fig 4.8 light green 
bars), consistent with its reported cytoplasmic localization in interphase (Cai et 
al., 1999). This observation raises the possibility that loss of the deubiquitinase 
allows Ring1B to ubiquitinate histone H2A at active promoters in G1 cells. 
 
 
Figure 4.8: USP16 binds to promoters that bind Aurora B and Ring1B in quiescent B cells 
but not in G1 activated B cells.  
The binding of USP16 to promoters was measured in quiescent (green bars) and G1-elutriated 
LPS-activated (light green bars) B cells. Resting B cells were isolated from the spleen and either 
immediately lysed or stimulated with LPS for 3 days and elutriated to obtain a pure G1-population. 
Binding is expressed as enrichment relative to input DNA using the same amount of DNA in the 
PCR (see section 2.4.3). A dashed line indicates the threshold value of enrichment above which a 
protein is considered to be bound. Background levels (DNA immunoprecipitated with an anti-IgG 
antibody) are shown as white bars where detected. Error bars represent the standard deviation of 
the mean (n=4 biological replicates). 
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4.9 Aurora B and Ring1B co-occupy the same promoters  
An important question is whether Aurora B and Ring1B are colocalised at 
the same active promoters within the same cell. Moreover, it is also possible that 
they occupy different alleles within the same cell. To test whether they physically 
co-occupy the same target promoter, I performed Re-ChIP (also known as 
sequential ChIP) for Aurora B and Ring1B in resting B cells isolated from mouse 
spleen. 
Chromatin from resting B cells was first immunoprecipitated with anti-Aurora 
B antibody and the precipitated chromatin was then used as the input for ChIP 
with anti-Ring1B antibody (Fig. 4.9 top panel). The results confirmed that Aurora 
B and Ring1B co-occupy the same promoters in the same cell. To validate this 
result, I performed Re-ChIP for Aurora B using chromatin immunoprecipitated 
with anti-Ring1B as the input (Fig. 4.9 bottom). 
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Figure 4.9: Sequential ChIP demonstrates co-occupancy of Aurora B and Ring1B at active 
promoters in quiescent B cells.  
Chromatin was immunoprecipitated with an anti-Aurora B antibody (red bars) and the precipitated 
chromatin was then re-immunoprecipitated with an anti-Ring1B antibody (blue bars) (top panel) 
and vice versa (bottom panel). These experiments show that Aurora B and Ring1B co-occupy the 
same DNA fragments. For the first ChIP (top and bottom left), binding is expressed as enrichment 
relative to input DNA using the same amount of DNA in the PCR (see section 2.4.3). For the 
second ChIP (top and bottom right), the input DNA is obtained from the first ChIP. A dashed line 
indicates the threshold value of enrichment above which a protein is considered to be bound. 
Background levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as white bars 
where detected. Error bars represent the standard deviation of the mean (n=2 biological 
replicates). 
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4.10 Aurora B and Ring1B bind to active genes in quiescent resting T cells 
To test whether the co-localization of Aurora B and Ring1B at the promoters 
of active genes is a common trait of resting lymphocytes or, alternatively, is 
restricted to B cells, I looked at their distribution in quiescent T cells 
(CD4+/CD25-), purified from subcutaneous and mesenteric lymph nodes (see 
section 2.1.2). I chose to perform a double purification with a positive enrichment 
(CD4+) to avoid the risk of obtaining a cell population that was too 
heterogeneous, particularly due to the presence of follicular B cells in lymph 
nodes. The assessment of the purity of the population shows that 93.4% of these 
cells are positive for CD4 and negative for CD25 and only 0.5% result positive for 
both marks (Fig. 4.10, left panel). The analysis of the cell cycle distribution of the 
cells shows that 99.6% of the purified cells are in G0/G1 (Fig. 4.10, right panel). 
The isolated T cells present therefore a satisfactory level of purity similar to the 
CD43 negative resting cells used so far. 
 
 
Figure 4.10: Analysis of the composition of the cell population after CD25 negative 
selection and CD4 positive selection.  
CD4+/CD25- cells were isolated from the subcutaneous and mesenteric lymph nodes and stained 
with antibodies against CD4 and CD25 and analysed by FACS (left panel). The cells in the top left 
panel (CD4+/CD25-) represent resting T cells and constitute 93.4% of the total population. The 
cell cycle distribution of the isolated cell was also assessed by PI staining and FACS (right panel). 
This analysis shows that 99.6% of the cells are in G0/G1. 
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To assess the transcriptional status of these genes, I firstly measured the 
RNA levels of a group of genes largely overlapping with those that I had 
previously analysed in resting B cells (Fig. 4.11). Similar to the analysis of resting 
B cells, total RNA was analysed by qRT-PCR and levels of specific transcripts 
were compared with an exogenously added spike-in RNA control. This made it 
possible to identify active and silent promoters in resting CD4+ cells. Secondly, I 
looked for the presence of Aurora B and Ring1B on these promoters using ChIP. 
The results are shown in Fig. 4.12 and demonstrate that Aurora B and Ring1B 
bind to all active promoters tested and are absent from silent genes. 
 
 
Figure 4.11: Determination of the transcriptional levels of active genes in resting CD4+ 
cells.  
Total RNA was extracted from CD4+ T cells isolated from subcutaneous and mesenteric lymph 
nodes and was used to produce cDNA (see section 2.6.2). Gene expression was calculated as a 
percentage relative to a spike-in RNA (see section 2.6.1), which was added to the cell lysate prior 
to the RNA purification. The ratio of spike-in RNA to the starting number of cells was kept 
constant. Cell number was the average of 10 counts using a haemocytometer (see section 2.6.2). 
Error bars represent the standard deviation of the mean (n=2 biological replicates). 
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Figure 4.12: Distribution of Aurora B and Ring1B on the promoters of active and silent 
genes in quiescent resting T cells.  
ChIP experiments were performed with antibodies recognizing Aurora B (red bars), Ring1B (blue 
bars) and IgG (negative control, white bars). Chromatin binding was assessed using primer pairs 
covering the promoter region of the indicated genes. The transcriptional status of the genes 
encompassed in that region (active or silent) had been previously assessed by qRT-PCR (Fig. 
4.11). Binding is expressed as enrichment relative to input DNA using the same amount of DNA 
in the PCR (see section 2.4.3). A dashed line indicates the threshold value of enrichment above 
which a protein is considered to be bound. Background levels (DNA immunoprecipitated with an 
anti-IgG antibody) are shown as white bars where detected. Error bars represent the standard 
deviation of the mean (n=2 biological replicates). 
4.11 Genome-wide analysis of the distribution of Aurora B and Ring1B in 
quiescent B cells 
4.11.1 Quantification of absolute expression levels in resting and activated 
B cells 
 ChIP-seq has now replaced ChIP-on-ChIP in the study of the genomic 
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distribution of chromatin-bound factors as it yields a genome-wide view and also 
provides quantitative results. Therefore, the analysis of the distribution of Aurora 
B, Ring1B and other important factors in quiescent B cells was extended 
genome-wide by performing ChIP-seq. In order to be able to relate the presence 
of a factor with the transcriptional status mRNA sequencing (mRNA-seq) was first 
carried out on mRNA extracted from freshly purified CD43- mouse resting B cells.  
Four independent biological samples were paired-end sequenced using a 
next-generation high throughput sequencer. Figure 4.13 shows that the four 
samples exhibit a good degree of correlation as measured by Spearman 
correlation (see section 2.7). A total of 37,158 genes were analysed based on the 
Ensembl annotation. Of these, for 19,749 of them, at least one copy of the mRNA 
was found, while for the remaining 17,409 genes no mRNA was detected in any 
of the samples. A value of 0.5 FPKM (fragments per kilobase of exon per million 
fragments mapped) in all four samples was chosen as the cut-off value, above 
which a gene was considered active. A total of 12,251 genes had FPKM values 
above this threshold with the most highly expressed gene (the H-2 class II 
histocompatibility antigen gamma gene CD74) exhibiting a value of 8,087 FPKM.  
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Figure 4.13: Correlation plot of the mRNA-seq samples. 
Four biological samples were used to prepare a total of four mRNA sequencing libraries as 
described in section 2.7.1. The libraries were paired-end sequenced on a next-generation high 
throughput sequencer and Gopuraja Dharmalingam provided post-sequencing bioinformatic 
analysis of all the output files. FPKM values for each sample was estimated using Cufflinks 
version 1.3.0 and correlation between replicates assessed using 'Spearman correlation. This 
picture was generated by Gopuraja Dharmalingam. 
4.11.2 Aurora B and Ring1B bind to the promoters and enhancers of active 
genes  
Having obtained information regarding the transcriptional status of resting B 
cells, I performed ChIP followed by DNA sequencing (ChIP-seq) for Aurora B and 
Ring1B to study their distribution across the genome in quiescent B cells. Both 
proteins were subjected to single-strand sequencing on a next-generation high 
throughput sequencer (see section 2.5). The sequencing of the Aurora B library 
generated 86,082,547 reads with a Phred quality score of 94%. The Ring1B 
sequencing library generated 89,377,580 reads with a quality score of 94.95%. 
The results of the ChIP-seq are shown in Fig. 4.13 and Appendix A, (red and 
  182 
blue tracks). Aurora B and Ring1B display a high degree of overlap on a 
genome-wide scale. 
DNase hypersensitivity can be used to identify candidate regulatory 
elements (see section 1.4.1). Comparison of Aurora B and Ring1B tracks with the 
publicly available DNase I hypersensitivity dataset generated in CD43- B cells 
(Fig. 4.13 and Appendix A, top track) confirms that Aurora B and Ring1B bind 
almost exclusively to regulatory elements, such as promoters and enhancers. For 
example, both proteins bind strongly to the known enhancer of the CD19 gene, 
whose tight transcriptional control is fundamental during B cell development 
(Walter et al., 2008) (Fig. 4.13).  
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Figure 4.14: Genome-wide analysis in quiescent B cells.  
Snapshots representative of ChIP-seq analysis of the distribution of Aurora B (red), Ring1B 
(blue), H2A.Z (purple), Ezh2 (dark grey), H3K27me3 (black), Cbx7 (green) and USP16 (orange). 
Data view scaling (y-axis) for each single library was selected based on the signal to noise ratio 
of each individual track and kept constant (25 for Aurora B and USP16; 50 for Ezh2, H3K27me3 
and Cbx7; 100 for Ring1B and H2A.Z). RPKM values representing the expression of each gene 
are reported next to the gene name and were defined by RNA-seq analysis of mRNA in freshly 
isolated resting B cells (table 2). DNase I sensitivity data are shown through the publicly available 
dataset generated in CD43-, CD11b- B cells from 8-week old male mice (M. Benderʼs laboratory). 
See also Appendix A for more examples. These pictures were generated in collaboration with 
Gopuraja Dharmalingam (see section 2.5.2 for details). 
 
In collaboration with Gopuraja Dharmalingam, density maps were generated 
for Aurora B and Ring1B to assess the relationship between their genome-wide 
distribution and the amount of mRNA of genes in resting B cells (Fig. 4.15). The 
generation of these maps is described in detail in section 2.5.3. Briefly, active 
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genes were ranked in descending order based on the FPKM value obtained from 
the mRNA-seq analysis. In order to include silent genes (RPKM=0), 2,000 genes 
(PRC2-repressed) were selected based on the decreasing density of tags for 
H3K27me3 around the TSS ±3 kb region (see below) and another 2,000 genes 
(silent) were randomly selected among the silent genes with low H3K27me3 tag 
density.  
The distributions of Aurora B and Ring1B were analysed in a window of 
±3kb around the annotated TSS. By summarising the genome-wide distribution of 
Aurora B and Ring1B in these density maps it is possible to appreciate that the 
binding of both proteins clusters around the TSS of active genes and are absent 
from both PRC2-repressed and silent groups of genes. Moreover, the signal for 
both proteins is particularly strong at highly transcribed genes and lower at genes 
with FPKM values close to 0.5. 
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Figure 4.15: Heat maps showing the distribution of Aurora B (red), Ring1B (blue), H2A.Z 
(purple), Ezh2 (black), H3K27me3 (black), Cbx7 (green) and USP16 (orange) within 3kb of 
the transcriptional start site (TSS) in quiescent B cells.  
Active genes were ranked based on their transcriptional level as assessed by mRNA-seq analysis 
(see section 2.7). A total of 2,000 genes (PRC2-repressed) were selected based on the highest 
density of tags for H3K27me3 around the TSS and ranked in decreasing order (top to bottom). 
Another 2,000 genes (silent) were randomly selected among the silent genes with low H3K27me3 
tag density. This image was generated by Gopuraja Dharmalingam. 
4.12 Genome-wide distribution of other key factors in quiescent B cells  
4.12.1 Genome-wide analysis of the distribution of the histone variant 
H2A.Z 
The histone variant H2A.Z has been shown to mark a wide range of 
promoters and enhancers in resting human cells (Barski et al., 2007). To further 
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analyse the extent to which Aurora B and Ring1B are localised to these types of 
elements in quiescent resting B cells from mouse, I analysed the distribution of 
the histone variant H2A.Z in these cells.  
The pattern of H2A.Z deposition is shown in Fig. 4.14 (purple track). The 
distribution of H2A.Z was found to correspond closely to the locations of DNA HS 
regions. Moreover, the localization of H2A.Z across the genome is very similar to 
the binding pattern of Aurora B and Ring1B, with an abundant presence around 
the TSS of highly expressed Aurora B target genes (Fig. 4.15, purple heat map). 
Similar to Aurora B and Ring1B, the signal for H2A.Z disappears from PRC2-
repressed and silent genes. This could simply stem from the absence of the 
histone variant around the TSS of these genes and/or from the 
monoubiquitination of the C-terminal tail that has been reported to impair the 
antibody from binding to the epitope, such as monoubiquitination (Sarcinella et 
al., 2007). Indeed, the monoubiquitination of H2A.Z has been shown to be a 
mechanism to silence some genes in mammals (Draker et al., 2011).  
4.12.2 Genome-wide analysis of the distribution of Ezh2 and the histone 
mark H3K27me3 
Since our previous ChIP analyses in resting B cells had suggested a 
mutually exclusive binding of PRC1 and PRC2 to active and silent promoters 
respectively, I expanded the analysis of the distribution of Ezh2 and H3K27me3 
relative to Ring1B using ChIP-seq analysis. mRNA-seq data showed that, despite 
resting lymphocytes being non-dividing cells, the Ezh2 gene is transcribed to 
comparable levels with Ezh1. Nevertheless, the ChIP-seq data shows that Ezh2 
binding is largely absent from the active genes that bind Ring1B and is mainly 
restricted to repressed genes. H3K27me3 marks broad domains across the 
whole body of silent genes such as the silent genes in the HoxA locus (Fig. 4.14, 
black track). This binding profile is completely different from the sharp peaks of 
Aurora B, Ring1B and H2A.Z binding that are observed around the TSS. Ezh2 
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and the H3K27me3 mark are present only at silent genes PRC2-repressed 
genes, such as the silent genes in the HoxA locus (Fig. 4.14). In agreement with 
previous reports in ES cells (Brookes et al., 2012) and Drosophila (Schwartz et 
al., 2010), some silent genes are regulated by other mechanisms and devoid of 
Ezh2 and H3K27me3, as well as the other analysed proteins (see Robo1 in 
Appendix A).  
4.12.3 Genome-wide analysis of the distribution of Cbx7 
Our ChIP data had shown that Cbx7 is present with Ring1B at active 
promoters in resting and activated cells. I decided to perform ChIP-seq in order to 
test the degree of association genome-wide between Ring1B and Cbx7 at active 
promoters in resting B cells. Cbx7 exhibits a striking overlap with Aurora B and 
Ring1B at the same targets genes and no overlap with H3K27me3 (Fig. 4.15, 
green heat map). This is particularly surprising as, among the different Cbx 
proteins that can be present in PRC1 complexes, Cbx7 shows the highest degree 
of overlap with H3K27me3 (Vincenz and Kerppola, 2008). Moreover, unlike other 
Cbx proteins, Cbx7 has been associated almost exclusively with the repression 
of developmental genes in ES cells (Morey et al., 2012).  
Nevertheless, the recruitment of Cbx7 to promoters has also been shown to 
depend on ncRNAs and to be reduced by the inhibition of transcription obtained 
following treatment with α-amanitin (Yap et al., 2010). The observation that Cbx7 
binds to the promoters of active genes together with Ring1B and Aurora B might 
therefore reflect an alternative recruitment mechanism of this protein where 
RNAs or other components play a major role and the H3K27me3 mark is not 
read as a recruiting signal for the protein. Finally, the correlation in the binding 
patterns of Ring1B and Cbx7 indicates that Ring1B binds to active promoters in 
these cells as part of a PRC1 complex. Other Ring1B-containing complexes (see 
section 1.6.8), such as E2F6.com-1, do not feature Cbx7 among their members. 
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4.12.4 Genome-wide analysis of the distribution of USP16 
Finally, I examined the genome-wide distribution of the USP16 
deubiquitinase (Fig. 4.14, orange track). The results show that USP16 binds 
together with Aurora B, Ring1B and Cbx7 exclusively at active genes. These 
regions also include the histone variant H2A.Z, a target for Ring1B-mediated 
monoubiquitination. USP16 is the most effective deubiquitinase for both H2A and 
H2A.Z in vitro (Draker et al., 2011) and the antibody used for the ChIP of H2A.Z 
does not recognize the epitope in its monoubiquitinated form (Sarcinella et al., 
2007). The strong signal obtained for H2A.Z using this antibody provides indirect 
evidence that these regions are devoid not only of H2Aubq but also of H2A.Zubq, 
although the lack of a commercially available antibody for H2A.Zubq prevented 
me from directly testing this hypothesis. 
Since Aurora B requires USP16 to remove the H2Aubq mark in order to 
bind to mitotic chromosomes, the colocalization of these proteins at active 
promoters (Fig. 4.15, orange heat map) might explain the binding of Aurora B in 
concomitance with Ring1B, as these regions have probably been deubiquitinated 
by USP16. It is possible therefore that USP16 recruitment constitutes a 
prerequisite for the recruitment of Aurora B to its target genes. 
4.13 Summary 
The results presented in this Chapter show that Aurora B binds to a high 
proportion of active promoters and to at least some enhancers in resting B cells. 
The highest levels of Aurora B binding are observed at highly transcribed genes 
and binding is absent from some genes that are transcribed at a low level.  
Aurora B binding is specific for quiescent cells as its binding is lost upon 
activation. Ring1B is present at active promoters in quiescent cells in a PRC1 
complex that includes Cbx7 and Bmi1. Both Ring1B and Cbx7 are retained on 
active promoters following B cell activation, whereas Bmi1 binding is lost. In 
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resting B cells, PRC1 is recruited in a non-canonical manner as the PRC2 
component Ezh2 and PRC2-mediated H3K27me3 are detected on silent genes 
only. The H2Aubq mark decorates silent promoters both in quiescent and LPS-
activated cells. In quiescent cells, the histone deubiquitinase USP16 is present 
on Aurora B and Ring1B target genes and USP16 association with promoters is 
lost upon activation with LPS and cell cycle re-entry. Genome-wide analysis 
showed that regions that bind Aurora B and Ring1B are also characterised by the 
presence of the histone variant H2A.Z (a marker of promoters and enhancers in 
mammals), Cbx7 and USP16. The PRC2 component Ezh2 and the repressive 
histone mark H3K27me3 show mutual exclusivity with Aurora B and Ring1B at 
the majority of silent and active genes. However, at some low-expressing genes 
that lack Aurora B, there is a degree of overlap between Ring1B and PRC2 and it 
is possible that PRC1 and PRC2 cooperate at these genes to fine-tune gene 
expression. 
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Chapter 5 - Aurora B and Ring1B are involved in regulating 
transcription in quiescent lymphocytes 
 
5.1 Introduction 
The results described in Chapter 4 show that Aurora B and Ring1B co-
occupy the regulatory elements of active genes in quiescent B and T cells. 
Aurora B binding is lost upon activation and cell cycle re-entry. In resting B cells, 
Ring1B is part of a PRC1 complex that contains Cbx7 and Bmi1 and is recruited 
to active target genes in the absence of PRC2 members and H3K27me3, which 
are detected (together with the H2Aubq mark) on silent genes. Since both Aurora 
B and Ring1B bind to regulatory elements and are known to regulate 
transcription, I studied their effect on gene expression. For Aurora B, I took 
advantage of a specific inhibitor of its kinase activity (AZD1152) and of a 
conditional knockout (cKO) mouse model.  
5.2 Use of conditional knockout models to study of the functions of Aurora 
B and Ring1B in resting lymphocytes 
5.2.1 Aurora B cKO system 
To determine the role of Aurora B in gene expression in resting B cells, I 
investigated the effect of Aurora B ablation in quiescent lymphocytes using a 
knockout model. Germline knockout of Aurora B is embryonically lethal due to 
problems with chromosomal segregation (Fernández-Miranda et al., 2011). 
Therefore, I used an Aurora B cKO mouse model in which a floxed Aurora B 
allele (Aurkbfl) has been crossed with a tamoxifen-inducible cre-ERT2 gene under 
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the control of the constitutive Rosa26 promoter (see section 2.1.3).  Resting B 
cells were isolated from mice that were homozygous for both the Aurkbfl and cre-
ERT2alleles were treated with tamoxifen for 48 hours and the level of Aurora B 
was determined by western blotting. The results show a dramatic reduction in the 
level of Aurora B protein, indicating that the Aurora B gene (Aurkb) has 
undergone recombination, giving an efficient knockout of the Aurora B protein 
(Fig. 5.1). 
 
Figure 5.1: Analysis of Aurora B cKO resting B cells.  
CD43- B cells were extracted from the spleen of 6-8 weeks old WT (CreERT2 +/+) and AurB KO 
(CreERT2/Aurkb flx +/+) mice. To induce the conditional knockout of the Aurora B gene, resting B 
cells were incubated for 48 hours in the presence of 250nM 4-OHT. Under these conditions, the 
level of Aurora B was drastically reduced (left panel) and resting B cells were not spontaneously 
activated (right panel).  Equal amounts of whole protein extract from WT and AurkB KO resting B 
cells were resolved on a 5-20% acrylamide/bis-acrylamide gel and probed with antibodies against 
Aurora B and histone H3 (loading control). AurkB KO cells were stained for B220 (mature B cells 
marker) and CD69 (lymphocytes activation marker) by FACS. Numbers of stained cells are 
shown as mean  standard deviation from the mean (n=2 biological duplicates). One 
representative experiment is shown.  
5.2.2 Ring1B cKO system 
To study the effect of the ablation of Ring1B in resting lymphocytes I 
employed the same strategy used to study the function of Aurora B: a conditional, 
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tamoxifen-dependent knockout model. The knockout mice were kindly provided 
by Dr. Miguel Vidal, CIB, Madrid. Since the knockout of the Rnf2 gene (which 
encodes for the protein Ring1B) is embryonically lethal (Voncken et al., 2003), a 
conditional knockout mouse model made it possible to remove Ring1B from 
purified resting B cells. A near complete knockout of Ring1B was achieved after 
48 hours of 4-OHT treatment and staining for CD69 showed that the Rnf2 
knockout does not trigger B cell activation (Fig. 5.2). 
 
Figure 5.2: Analysis of Ring1B cKO resting B cells.  
CD43- resting B cells were isolated from spleens of 6-8 weeks old WT (CreERT2 +/+) and Ring1B 
KO (CreERT2/Rnf2 flx +/+) mice. To induce the nuclear relocalization of CreERT2 and homologous 
recombination, B cells were incubated for 48 hours in the presence of 250nM 4-OHT. Under 
these conditions, the presence of Ring1B was almost completely abrogated (left panel) and 
resting B cells were not spontaneously activated (right panel).  Equal amounts of whole protein 
extract from WT and Ring1B KO B cells were resolved on a 5-20% acrylamide/bis-acrylamide gel 
and probed with antibodies against Ring1B and histone H3 (loading control). Ring1B KO cells 
were stained for B220 (mature B cells marker) and CD69 (lymphocytes activation marker) by 
FACS. Error represents the standard deviation from the mean (n=2 biological replicates). One 
representative experiment shown. 
5.2.3 Validation of the Aurora B and Ring1B ChIP-seq libraries 
The cKO systems were used to validate the ChIP-seq tracks presented in 
chapter 4. ChIP experiments were carried out on Aurora B and Ring1B cKO 
resting B cells and ChIP-seq libraries were prepared from the 
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immunoprecipitated DNA and subjected to high-throughput sequencing. The 
results are shown in figure 5.3 and clearly demonstrate that the respective 
knockouts result in strong reductions in binding of Aurora B and Ring1B to 
promoters and neighbouring sequences compared with the binding observed in 
wild-type resting B cells.  
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Figure 5.3: Genome-wide validation of the signal specificity of the Aurora B and Ring1B 
binding analysed by ChIP.  
Aurora B and Ring1B were immunoprecipitated in their respective cKO resting B cells and the 
resulting ChIP-seq are lined up against the tracks obtained for freshly isolated WT resting B cells. 
Representative examples were selected for the data sets. To allow direct comparison of the 
intensities, the same y-axis scales were used for each WT and knockout pair. RPKM values 
representing the expression of each gene are reported next to the gene name and were defined 
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by RNA-seq analysis of mRNA in freshly isolated CD43- B cells. TSS are derived from the UCSC 
dataset. Images in this figure were generated in collaboration with Gopuraja Dharmalingam (see 
section 2.5.2). 
5.3 Aurora B promotes transcription of target genes in quiescent 
lymphocytes 
The presence of Aurora B on regulatory elements prompted the question of 
whether this kinase has an activating or a silencing effect on transcription. Aurora 
B has been shown to promote transcription of thyroid hormone responsive genes 
by phosphorylating serine 10 on histone H3 following hormonal stimulation (see 
section 1.5.6). However, in resting B cells Aurora B is lost from promoters 
following B cell activation (Fig. 4.2), when transcriptional levels increase (Fig. 
4.3). In addition, histone phosphorylation by Aurora B triggers chromosomal 
condensation at the onset of mitosis, although in this case Aurora B is distributed 
all over the chromosome arms and not localised at promoters (see section 1.5.2). 
Thus, it was equally possible that Aurora B might have an activating or a 
silencing effect on transcription in resting B cells. 
The resting B cells used as the control for the experiment were isolated 
from wild type (WT) mice homozygous for CreERT2 but not containing any floxed 
allele. Use of the CreERT2 cells means that the experiment is controlled for 
possible effects caused by Cre in response to 4-OHT. Freshly isolated 
lymphocytes from both WT and AurkB KO mice were exposed to the same dose 
(250nM) of 4-OHT for the same amount of time (48 hours). In both WT and KO 
cells, 4-OHT induces nuclear localization of CreERT2 but only in the latter cells 
this promotes homologous recombination and knockout of the expression of the 
Aurkb gene. After 48 hours resting cells do not spontaneously activate, as 
measured by CD69 expression on their surface (Fig. 5.1).  
As described in section 4.3, total RNA was analysed using primers pairs 
located within the same exon, in order to assess the levels of both primary and 
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processed transcript. Instead of selecting a gene within the cell, I used a spike-in 
RNA as the reference in each sample, since it was impossible to predict a priori 
which genes will be unaffected (directly or indirectly) by the inhibition. cDNA was 
prepared from total RNA extracted from equal numbers of WT and KO resting B 
cells and spike-in RNA was added in a standard proportion to the number of 
cells.  
The results of the analysis are shown in Fig. 5.4 and demonstrate that 
Aurora B targets (b-Actin, Fcrl1, Gba, Cct3, Mtx1, Prcc, Pmf1) are reduced by 
approximately 50% in the KO cells. This transcriptional phenotype appears to be 
specific for Aurora B target genes, as it is not observed on Fdx1, Atp5s and Rnf2 
(which encodes the Ring1B protein). qPCR -ChIP and ChIP-seq analysis showed 
that these genes lack strong binding of Aurora B to their promoters. 
 
Figure 5.4: Knockout of Aurora B in resting B cells results in a reduction of transcription 
from Aurora B-bound genes.  
Total RNA was extracted from WT (CreERT2 +/+) (blue bars) and AurkB KO (CreERT2/Aurkb flx 
+/+) (red bars) resting B cells treated with 250nM 4-OHT for 48 hours. Gene expression was 
calculated relative to a spike-in RNA (see section 2.6.1), added to the cell lysate prior to the RNA 
purification. Cell number was the average of 10 counts using a haemocytometer. Differential 
expression (DE) was calculated relative to transcript levels in WT cells (DE=1). Error bars 
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represent the standard deviation of the mean (n=4 biological replicates). 
 
To study the role of the kinase activity of Aurora B in this transcriptional 
phenotype, I treated freshly purified resting B cells with a specific Aurora B 
inhibitor, AZD1152, frequently used to study the partners and activity of Aurora B 
(Kettenbach et al., 2011). qRT-PCR analysis of the cDNA extracted from resting 
B cells treated for 24 hours with 200nM AZD1152 shows a reduction of the 
transcripts of Aurora B target genes (Fig. 5.5). The treatment results in a more 
dramatic reduction in the levels of transcript than the reduction observed in the 
cKO model. Treatment with AZD1152 also reduces transcription of non-Aurora B 
target genes such as Fdx1 and Atp5s, albeit to a lesser extent. This could be due 
to more general effects of Aurora B inhibition on the transcriptional or RNA 
processing machinery or it could be caused by off-target effects of the drug, 
which cannot be completely excluded, despite the relatively high specificity of 
AZD1152 for Aurora B. In summary, these results show that Aurora B promotes 
the transcription of its target genes in resting B cells and demonstrate that its 
kinase activity is required for this role. 
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Figure 5.5: Inhibition of the kinase activity of Aurora B in resting B cells results in a 
dramatic reduction in the level of transcription of Aurora-bound genes.  
Total RNA was extracted from resting B cells treated with 200nM AZD1152 (an inhibitor of the 
kinase activity of Aurora B, red bars) or DMSO (vehicle, blue bars) for 24 hours. Gene expression 
was calculated relative to a spike-in RNA (see section 2.6.1), added to the cell lysate prior to RNA 
purification. Cell number was the average of 10 counts using a haemocytometer. Differential 
expression was calculated relative to transcript levels in WT cells (DE=1). Error bars represent 
the standard deviation of the mean (n=4 biological replicates). 
5.4 Ring1B cKO results in reduced transcription of target genes in 
quiescent B cells    
Genome-wide data had shown that Ring1B is bound to a high proportion of 
the active promoters in resting B cells (Fig. 4.11). These promoters are however 
also devoid of detectable levels of H2Aubq, the canonical mark associated with 
PRC1 activity as a repressor. Nevertheless, a Ring1B point-mutant that cannot 
ubiquitinate histone H2A has been reported to be sufficient for transcriptional 
repression of Hox genes (Eskeland et al., 2010). I asked whether Ring1B is 
counterbalancing the stimulatory effect of Aurora B providing a mechanism to 
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keep the overall low transcriptional levels that characterise quiescent cells. 
Total RNA was extracted from wild type (homozygous for Cre-ERT2) and 
Ring1B knockout (homozygous for Cre-ERT2 and floxed Rnf2 allele) quiescent B 
cells and differential expression of genes was calculated by means of a spike-in 
reference RNA. Surprisingly, Ring1B knockout resulted in a substantial reduction 
in expression of the Aurora B target genes analysed. A small reduction in Fdx1 
was observed but Atp5s was not affected (Fig. 5.6). It should be noted that Fdx1 
and Atp5s are both transcribed at a low level and it is therefore necessary to be 
cautious about inferring a biological meaning to changes in their expression. 
 
 
Figure 5.6: Knockout of Ring1B in resting B cells leads to a substantial reduction in 
transcription of Aurora B-bound genes.  
Total RNA was extracted from resting B cells from WT (CreERT2 +/+) mice (blue bars) and Ring1B 
KO mice (CreERT2/Rnf2 flx +/+) (red bars) treated with 250nM 4-OHT for 48 hours. Gene 
expression was calculated relative to a spike-in RNA (see section 2.6.1), added to the cell lysate 
prior to the RNA purification. Cell numbers were the average of 10 counts using a 
haemocytometer. Differential expression was calculated relative to WT (DE=1). Error bars 
represent the standard deviation of the mean (n=3 biological replicates). 
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The transcriptional phenotype following Ring1B cKO is stronger in terms of 
reduction, with genes such as b-Actin, Gba, Cct3 and Pmf1 becoming almost 
silent. The promoter of the Aurora B gene itself (Aurkb) appears is bound by 
Aurora B and Ring1B and is downregulated following Ring1B cKO, which raises 
the possibility that the observed transcriptional reductions might stem from a 
combined effect of reducing Ring1B and Aurora B protein levels. The Rnf2 gene, 
which encodes Ring1B, does not seem to be regulated by Aurora B and levels of 
expression of the gene are not reduced in Aurora B cKO cells (Fig. 5.4). This 
might explain why the effect of Aurora B cKO on transcription was less 
pronounced than that of the Ring1B cKO. 
 
5.5 Aurora B and Ring1B cKO resting T cells display reduced transcription 
of target genes 
As Aurora B and Ring1B bind to the promoter region of active genes in 
quiescent T cells as well as in B cells, I assessed the impact of knocking out 
each protein in resting CD4+ T cells. WT (CreERT2++), Aurora B cKO 
(CreERT2/Aurkb flx +/+) and Ring1B cKO (CreERT2/Rnf2 flx +/+) cells were 
incubated for 72 hours in 4-OHT and knockout was assessed by measuring the 
RNA levels of Aurkb and Rnf2. RNA was extracted from WT and both KO cells 
and differential expression of a set of active genes that bind Aurora B and 
Ring1B was quantified by qRT-PCR using the spike-in RNA as an internal 
standard. The knockout of both genes was confirmed by qRT-PCR, which 
showed that a 72-hour incubation with 4-OHT is necessary to achieve a 
satisfactory knockout of both proteins (Fig. 5.7).  
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Figure 5.7: The knockouts of Aurora and Ring1B in naïve T cells result in a reduction of 
total RNA produced from Aurora B-bound genes.  
Total RNA was extracted from WT (CreERT2 +/+) (black bars), AurB KO (CreERT2/Aurkb flx +/+) 
(red bars) and Ring1B KO (CreERT2/Rnf2 flx +/+) (blue bars) mice treated with 500nM 4-OHT for 
72 hours. Gene expression was calculated as relative to a spike-in RNA (see section 2.6.1), 
added to the cell lysate prior to the RNA purification. Cell number was the average of 10 counts 
using a haemocytometer. Differential expression is expressed as relative to the WT (DE=1). Error 
bars represent the standard deviation of the mean (n=2 biological replicates). 
 
The results obtained from analysing the knockout cells are shown in Fig. 
5.7. The Aurora B cKO resulted in a 30-50% reduction in the levels of total 
transcripts from a panel of active target genes (Fig. 5.7 red bars). Of the active 
genes tested, only Klf4 and FoxO4 were upregulated following the knockout of 
the kinase. It is notable that both of these are transcribed at relatively low levels 
in naïve CD4+ cells. Ring1B cKO resulted in a more pronounced reduction (50-
80%) in expression of active genes, particularly at genes such as Gba (Fig. 5.6 
blue bars). Moreover, both Klf4 and FoxO4 were downregulated. It is possible 
that, as in resting B cells, Aurora B and Ring1B differentially regulate a subset of 
active but poorly transcribed genes. Interestingly, both proteins have a positive 
effect on transcription of the KLF2 gene a master regulator of T cell quiescence 
and survival (see section 1.2.3).  
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5.6 Aurora B and Ring1B cKOʼs affect different steps in the RNA Pol II cycle 
at the promoter of active target genes 
The finding that Aurora B and Ring1B bind to promoters and enhancers and 
that knockout of either protein leads to a reduction in transcription of their target 
genes, raises the possibility that they regulate binding of RNA Pol II to regulatory 
elements (see sections 1.4.2 and 1.4.3). To test this hypothesis, I quantified and 
compared the binding of the unphosphorylated and serine 5-phosphorylated RNA 
Pol II by ChIP in WT, Aurora B KO and Ring1B KO resting B cells. The 
unphosphorylated RNA Pol II binds to promoters as part of the PIC (see section 
1.4.2). Phosphorylation of serine 5 of the RNA Pol II CTD allows promoter 
clearance and marks transcriptional initiation (see section 1.4.2). S5p Pol II is 
also often found at pausing sites and is progressively lost during elongation (see 
section 1.4.2). 
 
5.6.1 Aurora B regulates the levels of S5p Pol II at target genes 
I looked first at the levels of unphosphorylated (8WG16) and phospho-
serine 5 RNA Pol II (S5p) at the promoters of active and silent genes following 
the knockout of Aurora B. The results are shown in Figure 5.8 and demonstrate 
that both forms of the polymerase are present at active promoters and completely 
absent from silent promoters in WT cells (Fig. 5.8, blue bars). In general, both 
types of RNA Pol II seemed to bind with the same affinity to each gene and the 
enrichments of both forms were particularly high at the promoters of two highly 
transcribed genes (b-Actin and Fcrl1). Interestingly, S5p Pol II was not detected 
at the promoter of any of the two silent genes. This indicates that these 
promoters are not in the poised state observed in ES cells, possibly due to a 
particularly compacted chromatin structure that blocked the recruitment of the 
PIC.  
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Figure 5.8: Aurora B cKO resting B cells exhibit reduced levels of S5p Pol II at promoters 
but the unphosphorylated RNA Pol II is less affected.  
The binding of S5p Pol II and unphosphorylated RNA Pol II (8WG16) was measured in resting B 
cells isolated from mice that were homozygous Cre-ERT2  (WT, blue bars) or homozygous Cre-
ERT2/Aurkb floxed allele (Aurb KO, red bars). Cells were treated with 250nM 4-OHT for 48 hours. 
Binding is expressed as enrichment relative to input DNA using equal amounts of DNA in the 
PCR reactions (see section 2.4.3). A dashed line indicates the threshold value of enrichment 
above which a protein is considered to be bound.  Background levels (DNA immunoprecipitated 
with an anti-IgG antibody) are shown as white bars where detected. Error bars represent the 
standard deviation of the mean (n=2 biological replicates for both experiments). 
 
Following the knockout of Aurora B, however, S5p Pol II was strongly 
reduced and in some instances (Mapbpip, Gba, Cct3) the levels of enrichment 
are down to background levels (Fig. 5.8, top panel). The effect of the knockout on 
the levels of unphosphorylated RNA Pol II is milder and the signal is not reduced 
to background for any of the genes analysed (Fig. 5.8, bottom panel). These 
  205 
results strongly suggest that Aurora B promotes transcription of its target genes 
by favouring promoter clearance and transcriptional initiation. To test whether the 
kinase activity of Aurora B is required for these activities, I looked at the effect of 
a 48-hour treatment of resting B cells with 200nM AZD1152 on the levels of S5p 
Pol II at promoters. The results shown in Fig. 5.9 show that Aurora B kinase 
activity is required for efficient binding of S5p Pol II as the levels of this form of 
the polymerase were dramatically reduced compared to cells treated with DMSO. 
 
 
Figure 5.9: The kinase activity of Aurora B is required to maintain high levels of S5p Pol II 
at its target promoters.  
Binding of S5p Pol II was measured in resting B cells treated with 200nM AZD1152 (an inhibitor 
of the kinase activity of Aurora B, red bars) or DMSO (vehicle, blue bars) for 48 hours. Binding is 
expressed as enrichment relative to input DNA using equal amounts of DNA in the PCR reactions 
(see section 2.4.3). A dashed line indicates the threshold value of enrichment above which a 
protein is considered to be bound.  Background levels (DNA immunoprecipitated with an anti-IgG 
antibody) are shown as white bars where detected. Error bars represent the standard deviation of 
the mean (n=3 biological replicates). 
5.6.2 Ring1B cKO resting B cells have reduced levels of RNA Pol II at target 
genes 
The analyses of the binding of the two types of RNA Pol II to promoters are 
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shown in Fig. 5.9. The results show a near complete loss of both forms of the 
polymerase in Ring1B KO resting B cells with the levels of S5p Pol II reduced to 
near-background values in 4 of the 5 Aurora B target genes analysed (Fig. 5.10, 
top panel). The results also show that binding of unphosphorylated RNA Pol II 
(8WG16) to promoters was abolished or drastically reduced at all of the 
promoters (Fig. 5.10, bottom panel). 
 
Figure 5.10: Knockout of Ring1B reduces the levels of both types of promoter-bound RNA 
Pol II.  
Binding of S5p Pol II and unphosphorylated RNA Pol II (8WG16) was measured in homozygous 
Cre-ERT2  (WT, blue bars) and homozygous Cre-ERT2/Rnf2 floxed allele (Ring1B KO, red bars) 
quiescent B cells. Binding is expressed as enrichment relative to input DNA using equal amounts 
of DNA in the PCR reactions (see section 2.4.3). A dashed line indicates the threshold value of 
enrichment above which a protein is considered to be bound.  Background levels (DNA 
immunoprecipitated with an anti-IgG antibody) are shown as white bars where detected. Error 
bars represent the standard deviation of the mean (n=2 biological replicates for both 
experiments). 
 
Since RNA Pol II is unphosphorylated in the PIC, when it is recruited to 
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regulatory elements and therefore appears on promoters before S5p Pol II (see 
section 1.4.2), the observed reduction in the levels of S5p Pol II might be due to a 
reduced recruitment of the enzyme per se. Moreover, as the knockout of Ring1B 
reduces transcription of the Aurora B gene, this partial knockdown of Aurora B 
could directly affect the levels of S5p Pol II. Indeed, upon close inspection, the 
degree of reduction of S5p Pol II at promoters is almost identical in both 
knockouts. 
5.6.3 Genome-wide effect of Aurora B and Ring1B cKOʼs on binding of 
unphosphorylated and serine 5-phosphorylated RNA Pol II 
In order to assess the scale of the effects of the Aurora B and Ring1B cKOs 
on RNA Pol II on the whole genome, DNA immunoprecitated in the ChIP of S5p 
Pol II in WT and Aurora B cKO cells and the unphosphorylated RNA Pol II in WT 
and Ring1B KO cells was analysed by high-throughput sequencing (ChIP-seq). 
One of the advantages of ChIP-seq over ChIP-on-ChIP is that, like conventional 
ChIP- qRT-PCR, it allows quantification, but on a genome-wide scale. ChIP-seq 
type of analysis showed a global reduction in binding of both forms of RNA Pol II 
around the TSS of Aurora B and Ring1B target genes, particularly at highly 
transcribed genes (Fig. 5.11).  
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Figure 5.11: Genome-wide comparison of the distribution and binding intensities of S5p 
Pol II and 8WG16 by ChIP-seq in WT, Aurora B and Ring1B cKO cells.  
Representative examples were selected for the data sets. To allow direct comparison of the 
intensities, the same y-axis scale was used for WT cells (blue) and KO cells (red) tracks . RPKM 
values representing the expression of each gene are reported next to the gene name and were 
defined by mRNA-seq analysis of freshly isolated resting B cells. Positions of the TSS are derived 
from the UCSC dataset. DNase I sensitivity data were obtained from the publicly available dataset 
generated using CD43-, CD11b- B cells from 8-week old male mice (M. Benderʼs laboratory) This 
image was generated in collaboration with Gopuraja Dharmalingam (see section 2.5.2). 
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Figure 5.12 shows line plots that summarise the ChIP-seq results for the 
analysis of S5p Pol II in the Aurora B cKO and unphosphorylated RNA Pol II 
(8WG16) in the Ring1B cKO. The line plots show the average binding distribution 
each type of RNA Pol II in a window of ±3kb around the TSS. There is no change 
in the binding profile of either S5p Pol II or 8WG16 in the cKOʼs, but the average 
amount of bound enzyme is affected. Average levels of binding of S5p Pol II are 
halved in the Aurora B KO (Fig. 5.12, left plot) and average levels of the 
unphosphorylated RNA Pol II showed a 2.6-fold reduction in the Ring1B cKO 
(Fig. 5.12, right plot). 
 
Figure 5.12: Line plots depicting the average reduction in binding of S5p Pol II following 
the knockout Aurora B (left) or Ring1B (right).  
Blue lines indicate the average signals for RNA Pol II in WT cells, while the red lines represent 
the average signal in the AurKB and Ring1B cKO samples. The binding is assessed in a window 
covering 6 kb and centered on the TSS (based on RefSeq data). This image was generated by 
Gopuraja Dharmalingam (see section 2.5.4 for details). 
5.7 The knockouts of Aurora B or Ring1B reduce the viability but not the 
responsiveness of quiescent lymphocytes to activating stimuli 
The analysis of the effect of Aurora B and Ring1B cKO in resting B and T 
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cells revealed global reductions in the binding of RNA Pol II and the transcription 
of highly expressed genes. These results raise the important question of what 
specific roles are played by Aurora B and Ring1B in generating and maintaining 
the quiescent phenotype. One possibility is that maintenance of transcription of 
many of the affected genes is required for survival of quiescent lymphocytes. To 
test whether this is the case, in collaboration with Dr. Monica Roman Trufero, I 
measured the viability of both resting B and T cells in both cKO models. 
Freshly isolated resting B and T cells were incubated for 72 hours with 4-
OHT and trypan blue exclusion was then used as a measure of lymphocyte 
viability. The percentage of viable wild type resting B and T cells after this period 
of culture was 84% ± 2.5% for B cells and 80.75% ± 2.5% for T cells. (Fig. 5.13, 
black lines).  The value for B cells agrees well with published data (Dayal et al., 
2011) At 72 hours, the Aurora B cKO resting B and T cell cultures had a lower 
percentage of viable cells (67% ± 4.2% for B cells and 69% ± 1.4% for T cells) 
(Fig. 5.13, red lines). The knockout of Ring1B has, on average, a slightly greater 
impact on cell viability (59% ± 1.4% for B cells and 61% ± 1.4% for T cells) (Fig. 
5.13, blue lines). This difference mirrors the differences in transcriptional 
phenotype observed by the analysis of total RNA in between the two cKOʼs in 
both B and T cells and might also stem from the possible dual reduction in 
Ring1B and Aurora B levels observed in Ring1B cKO cells (see section 5.4). 
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Figure 5.13: Resting lymphocytes display reduced viability following knockout of Aurora B 
or Ring1B.  
Viable cells were scored as the percentage of cells not stained with Trypan Blue. WT (CreERT2 
+/+) (black line), AurB KO (CreERT2/Aurkb flx +/+) (red line) and Ring1B KO (CreERT2/Rnf2 flx 
+/+) (blue line) naive cells were cultured for the indicated times in the presence of 250nM (B cells, 
top panel) or 500nM (CD4+ T cells, bottom panel) 4-OHT for 72 hours. Error bars represent the 
standard deviation of the mean (n=3 biological replicates for all experiments). 
 
To test whether Aurora B and Ring1B are required for B cell activation, I 
stimulated homozygous CreERT2 (WT) and AurB and Ring1B cKO cells with LPS 
or anti-CD40 after 48 hours of incubation with 4-OHT. I then assessed the 
activation of these three cell types by measuring the levels of CD69 expressed 
on their surface, as this marker appears rapidly following activation. Because 
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Aurora B ablation in cycling cells results in mitotic disruption (see section 1.5), I 
looked at activation before entry into G2/M and, therefore, within a relatively short 
window of time (14 hours for LPS and 24 for anti-CD40).  
Aurora B KO resting B cells exhibit no changes in their responsiveness to 
either LPS or anti-CD40, as the percentages of CD69 positive cells are identical 
to WT cells (Fig. 5.14, left and central panels). Ring1B KO resting B cells do not 
display an altered responsiveness to anti-CD40 and a slightly reduced response 
to LPS (approximately 10% less than WT cells). It is possible that such a small 
difference is merely a reflection of the reduced viability of resting B cells in the 
absence of Ring1B. Overall, however, the results of these experiments seem to 
suggest that both proteins are more important for the homeostasis rather than the 
responsiveness of resting B cells.  
 
 
Figure 5.14: Aurora B and Ring1B cKO does not affect activation of resting B cells.  
Analysis of the responsiveness to LPS and anti-CD40 of resting B cells isolated from WT 
(CreERT2 +/+) (left panel), AurB KO (CreERT2/Aurkb flx +/+) (central panel) and Ring1B KO 
(CreERT2/Rnf2 flx +/+) (right panel) mice. Cells were treated for 48 hours with 250nM 4-OHT and 
then stimulated either for 14 hours with 12.5 µg/mL of LPS or 24 hours with 5 µg/mL anti-CD40 
antibody. The cells were then stained with anti-B220 (mature B cell marker) and anti-CD69 
(lymphocyte activation marker) and analysed by FACS. Values represent mean standard 
deviation from the mean (n=2 biological replicates). One representative experiment is shown. 
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. 
5.8 Summary 
The results presented in this Chapter show that Aurora B promotes 
transcription of a subset of highly transcribed genes in quiescent lymphocytes. 
Treatment of resting B cells with an Aurora B inhibitor results in reduced 
transcription of a high proportion of the genes analysed. Conditional knockout of 
Aurora B in quiescent B and T cells confirms that the kinase promotes 
transcription in both cell types.  
In contrast to its repressive role in ES cells, Ring1B knockout results in a 
transcriptional reduction of active target gene in quiescent B cells. As Ring1B 
knockout reduces Aurora B expression (but not vice versa), this very strong effect 
could be due to the proteins acting in synergy to regulate transcription in 
quiescent lymphocytes. Ring1B also induces a stronger transcriptional phenotype 
than Aurora B in resting T cells. 
qPCR-ChIP and ChIP-Seq analysis shows that ablation of Aurora B and 
Ring1B proteins reduces the presence of S5p Pol II and the unphosphorylated 
RNA Pol II around the TSS of active genes in resting B cells. Ring1B knockout 
affects both forms of the polymerase whereas Aurora B knockout has a stronger 
effect on the S5p Pol II form. This result matches the reductions observed by 
qRT-PCR analysis of total RNA. Finally, loss of either protein negatively impacts 
on the viability of resting lymphocytes but not on their responsiveness to 
activating stimuli. 
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Chapter 6 - Aurora B phosphorylates histone H3S28 and 
modulates Ring1B-mediated H2A ubiquitination at active 
promoters 
 
6.1 Introduction 
Aurora B and Ring1B promote transcription in resting lymphocytes as their 
conditional knockout leads to transcriptional repression of active genes and 
reduced recruitment to promoters of RNA Pol II (in its unphosphorylated form) 
and transcriptional initiation (serine 5-phosphorylated). In this section of the 
project, I sought to understand the molecular mechanism through which Aurora B 
exerts its function as a transcriptional co-activator. I examined whether Aurora B 
is responsible for phosphorylating H3S28 at active promoters since H3S28 
phosphorylation is known to be a marker of transcriptional activation. I also 
tested whether Aurora B affects mono-ubiquitination of H2A at active promoters 
and binding of the USP16 deubiquitinase. Finally, I investigated the functional 
role of Aurora B in quiescent lymphocytes by testing the effect of the conditional 
knockout of Aurora B on resting B cell survival and activation.  
6.2 Aurora B controls phosphorylation of histone H3S28 at active 
promoters 
Aurora B phosphorylates both histone H3S10 and H3S28 at gene 
promoters and this post-translational modification has generally been associated 
with transcriptional activation at promoters (see section 1.4.3). Published ReChIP 
experiments have shown that the H3S28ph histone mark, but not H3S10ph, 
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physically co-occupies active promoters with S5p Pol II (Lau and Cheung, 2011). 
Therefore, I asked whether the levels of H3S28ph are also reduced in Aurora B 
cKO cells. For this purpose, I performed ChIP analysis for H3S28ph in resting B 
cells isolated from mice that were either WT (homozygous for Cre-ERT2) or 
Aurora B cKO (homozygous for Cre-ERT2 and the floxed Aurkb allele). 
The results of this analysis are shown in Fig. 6.1. In the wild-type cells, the 
ChIP analysis detected the H3S28ph mark both at Aurora B target genes and at 
silent promoters (Fig. 6.1, blue bars). This is in agreement with unpublished data 
generated in our lab that describe the presence of H3S10ph and H3S28ph in 
conjunction with H3K9me3 and H3K27me3 at silent genes in resting B cells  
(Sabbattini et al., manuscript in revision). However, the conditional knockout of 
Aurora B only affects the levels of H3S28ph on active target genes (Fig. 6.1). 
This result indicates that the presence of Aurora B is required to maintain the 
levels H3S28ph modification at active promoters, whereas its loss has little 
impact on the levels of H3S28ph at repressed genes in quiescent B cells. 
 
Figure 6.1: Aurora B cKO resting B cells have reduced levels of H3S28ph at the promoters 
of Aurora B target genes.  
Enrichment of H3S28ph over the total histone H3 at promoters was measured in homozygous 
Cre-ERT2  (WT, blue bars) and homozygous Cre-ERT2/Aurkb floxed allele (Aurb KO, red bars) 
resting B cells after incubation with 4-OHT for 48 hours. Levels of H3S28ph are expressed as 
enrichment relative to DNA immunoprecipitated by the anti-total H3 antibody using equal amounts 
  216 
of DNA in the PCR reactions (see section 2.4.3). A dashed line indicates the threshold value of 
enrichment above which a protein is considered to be bound. Background levels (DNA 
immunoprecipitated with an anti-IgG antibody) are shown as white bars where detected. Error 
bars represent the standard deviation of the mean (n=2 biological duplicates). 
 
H3S28 phosphorylation by MSK1/2 has been shown to be involved in 
displacing PRC2 from repressed promoters (Lau and Cheung, 2011) and 
(Gehani et al., 2010). Since Aurora B targets are devoid of Ezh2 and H3K27me3, 
I tested whether Aurora B prevents the deposition of the H3K27me3 mark via 
phosphorylation of H3S28. However, although the conditional knockout of Aurora 
B reduces the levels of H3S28ph, ChIP experiments show that this event does 
not coincide with an increase of H3K27me3 above the background value of 1 and 
does not affect the high levels of this mark at silent promoters (Fig. 6.2). 
Therefore, PRC2-mediated silencing seems to be regulated by a different 
mechanism in resting B cells.  
 
 
Figure 6.2: Reduction of the levels of H3S28ph is not accompanied by an increase in the 
levels of PRC2-mediated H3K27me3 in Aurora B cKO resting B cells.  
Enrichment of H3K27me3 over total histone H3 at promoters was measured in homozygous Cre-
ERT2  (WT, blue bars) and homozygous Cre-ERT2/Aurkb floxed allele (Aurb KO, red bars) resting 
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B cells. Levels of H3K27me3 are expressed as enrichment relative to DNA immunoprecipitated 
by anti-total H3 antibody using equal amounts of DNA in the PCR reactions (see section 2.4.3). A 
dashed line indicates the threshold value of enrichment above which a protein is considered to be 
bound.  Background levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as 
white bars where detected. Error bars represent standard deviation of the mean (n=2 biological 
replicates). 
6.3 Aurora B regulates the levels of H2A ubiquitination at active promoters 
6.3.1 Loss of Aurora B is accompanied by acquisition of the H2Aubq mark 
at promoters 
Since Aurora B and PRC1 co-occupy the same promoters, I assessed 
whether Aurora B influences deposition of the H2Aubq mark. This mark is 
detectable at silent promoters but almost completely absent from active 
promoters (Fig. 4.7, green bars). In cKO cells, the levels of H2Aubq (as 
measured by enrichment over total histone H2A) increase dramatically at Aurora 
B target genes and to a level similar to what observed on silent genes (Fig. 6.3). 
In the latter group, little increase in H2Aubq is observed, on 3 out of 4 promoters 
with only the Bcan gene showing any increase. Moreover, Fdx1, which is not 
bound by either Aurora B or Ring1B, maintains background levels of H2Aubq. 
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Figure 6.3: The histone mark H2Aubq marks Aurora B target genes in Aurora B cKO 
resting B cells.  
In Aurora B cKO resting B cells the levels of H2Aubq at Aurora B/Ring1B-bound promoters 
increase to the same level observed on silent genes. Enrichment of H2Aubq over total histone 
H2A was measured in homozygous Cre-ERT2  (WT, blue bars) and homozygous Cre-ERT2/Aurkb 
floxed allele (Aurb KO, red bars) resting B cells following a 48-hour treatment with 4-OHT. Levels 
of H2Aubq are expressed as enrichment relative to DNA immunoprecipitated by the anti-total H2A 
antibody using the same amount of DNA in the PCR (see section 2.4.3). A dashed line indicates 
the threshold value of enrichment above which a protein is considered to be bound. Background 
levels (DNA immunoprecipitated with an anti-IgG antibody) are shown as white bars where 
detected. Error bars represent the standard deviation of the mean (n=4 biological replicates). 
6.3.2 USP16 binding to promoters is lost following knockout of Aurora B  
Aurora B binding to mitotic chromosomes requires H2A deubiquitination by 
USP16 (Joo et al., 2007). Moreover, ChIP-seq analysis revealed a high degree of 
overlap of Aurora B and USP16 at target genes (Chapter 4, Figs. 4.11 and 4.12). 
In addition, USP16 association with promoters is lost in G1-elutriated, LPS-
activated cells (Chapter 4, Fig. 4.8), where levels of H2Aubq slightly increase 
(Chapter 4, Fig. 4.7). qPCR-ChIP was used to analyse binding of Aurora B in 
resting B cells following conditional knockout of Aurora B. The results of the ChIP 
experiments show that binding of USP16 to active promoters is severely reduced 
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and in some instances is almost completely lost from promoters following the 
knockout of Aurora B (Fig. 6.4).  
 
 
Figure 6.4: USP16 no longer associates with active promoters in Aurora B cKO resting B 
cells.  
The binding of USP16 was measured in homozygous Cre-ERT2  (WT, blue bars) and 
homozygous Cre-ERT2/Aurkb floxed allele (Aurb KO, red bars) resting B cells. Binding is 
expressed as enrichment relative to input DNA using equal amounts of DNA in the PCR (see 
section 2.4.3). A dashed line indicates the threshold value of enrichment above which a protein is 
considered to be bound. Background levels (DNA immunoprecipitated with an anti-IgG antibody) 
are shown as white bars where detected. Error bars represent the standard deviation of the mean 
(n=2 biological replicates). 
 
These results suggest that Aurora B and USP16 co-operate to regulate the 
levels of H2Aubq at promoters. Moreover, binding of both proteins is lost from the 
active promoters that I have analysed following activation (see Chapter 4). 
However, Aurora B and USP16 both associate with chromatin at the onset of 
mitosis, with USP16 required to deubiquitinate H2A to allow the binding and 
activity of Aurora B (see section 1.5.2). It would therefore be interesting to test 
whether USP16 has a role in Aurora B recruitment at active gene promoters, 
similar to its role during mitosis.  
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6.3.3 Binding and composition of PRC1 at active promoters is independent 
of the presence of Aurora B or USP16 
USP16 has been shown to promote transcription of the HoxD10 gene in 
HeLa cells via deubiquitination of H2A at the promoter but without affecting 
binding of Bmi1 (Joo et al., 2007). When Aurora B is knocked out in resting B 
cells, more PRC1 (or another complex) could bind to active promoters and 
monoubiquitinate histone H2A. Alternatively, PRC1 could be recruited by an 
Aurora B-dependent pathway and, in cKO cells, another complex with E3 ligase 
activity could substitute for PRC1 To test whether any of these hypotheses is 
correct or whether Aurora B and USP16 simply control the activity, but not the 
recruitment of PRC1, I compared the binding of Ring1B and Bmi1 (the core 
components of PRC1 that are responsible for the E3 ligase activity) in WT and 
Aurora B cKO cells. 
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Figure 6.5: In the absence of Aurora B, Ring1B binding increases at some active 
promoters, whereas Bmi1 and Cbx7 binding is largely unaltered.  
The binding of Ring1B, Bmi1 and Cbx7 were measured in homozygous Cre-ERT2  (WT, blue 
bars) and homozygous Cre-ERT2/Aurkb floxed allele (Aurb KO, red bars) resting B cells. Binding 
is expressed as enrichment relative to input DNA using the same amount of DNA in the PCR (see 
section 2.4.3). A dashed line indicates the threshold value of enrichment above which a protein is 
considered to be bound. Background levels (DNA immunoprecipitated with an anti-IgG antibody) 
are shown as white bars where detected. Error bars represent the standard deviation of the mean 
(n=2 biological duplicates, for all experiments). 
 
The results of the analysis are shown in Fig. 6.7 The level of enrichment 
over input of Ring1B increases substantially at three promoters (Gba, Cct3 and 
Mtx1) out of eight active genes analysed by qRT-PCR, whereas it remains 
unaltered on the remaining ones. On the other hand, Bmi1 and Cbx7 association 
with promoters appears unchanged following the removal of Aurora B, with the 
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exception of Mapbpip where a 3-fold decrease is observed in the Cbx7 ChIP (Fig. 
6.5).  
While recruitment of other PRC1 components cannot be excluded, the 
analysis shown here does not support the idea that the increased ubiquitination is 
due to a change in the composition of the PRC1 complex at promoters that bind 
Aurora B. Therefore, the main change in protein binding that can be related to the 
change in ubiquitination levels in Aurora B knockout cells is decreased binding of 
USP16, which would be expected to lead to increased H2A ubiquitination.  
Data generated by Dr. Monica Roman Trufero supports the hypothesis that, 
rather than regulating the binding of PRC1 components to promoters, Aurora B 
counteracts Ring1B-mediated monoubiquitination of histone H2A. Firstly, Aurora 
B phosphorylates USP16 in vitro and this increases the activity of the 
deubiquitinase towards nucleosomal substrates in vitro. Secondly, Aurora B 
phosphorylates in vivo the E2 ligase specific for Ring1B, UbcH5c, and this 
reduces the ubiquitin ligase of PRC1 in vitro (data not shown). 
 
6.3 MSK1 replaces Aurora B on active promoters after B cell activation 
6.3.1 B cell-activation induces a rapid exchange of Aurora B with MSK1 at 
transcriptionally active promoters 
Finally, I sought to understand the role played by Aurora B in resting B cells 
and B cell activation. The binding of Aurora B to promoters is lost in B cell 
activated with LPS or anti-CD40 (Fig. 4.3) and Aurora B cKO B and T cells 
activate normally (Fig. 5.14). These observations suggest that Aurora B does not 
play a major role in B cell activation pathways. 
The mitogen LPS induces B cell activation and initiates the Ras/ERK/MAPK 
signalling pathway. One of the downstream effectors of this signalling cascade is 
MSK1, which activates transcription through histone H3 phosphorylation on 
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serine 10 and 28 (see section 1.4.3). I decided to test whether Aurora B is 
replaced at its target promoters by MSK1 in activated B cells. ChIP analysis of 
Msk1 binding was carried out on resting B cells and ChIP G1-elutriated LPS-
activated B cells. The results show that MSK1 does not bind to active promoters 
in resting B cells whereas enrichment for the kinase was observed at these 
promoters in G1 activated b cells. These results indicate that that MSK1 replaces 
Aurora B on gene promoters during B cell activation (Fig. 6.6). 
 
Figure 6.6: MSK1 replaces Aurora B at active target genes following LPS activation.  
Binding of MSK1 to promoters was measured in quiescent (dark green bars) and G1-elutriated 
LPS-activated (light green bars) B cells. A dashed line indicates the threshold value of enrichment 
above which a protein is considered to be bound. Background levels (DNA immunoprecipitated 
with an anti-IgG antibody) are shown as white bars where detected. Error bars represent the 
standard deviation of the mean (n=2 biological replicates). 
 
MSK1 has been shown to bind rapidly to the promoters of its target genes 
and phosphorylate histone H3S10 and S28 (Drobic et al., 2010) (see section 
1.4.3). These phosphorylations can occur within less than 30 minutes, depending 
on the stimulus used to trigger MSK1 activation and the type of cell. I decided to 
analyse the kinetics of binding of MSK1 and Aurora B to the promoters of active 
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genes during LPS activation of resting B cells. 
I selected three promoters (Fcrl1, Mapbpip and Gba) and measured the 
binding to their promoter at 30, 60 and 120 minutes after the addition of LPS (see 
section 2.1.1). MSK1 binds rapidly to both Fcrl1 and Mapbpip, with respective 4- 
and 2-fold increases observed within 30 minutes of adding of LPS to the cells 
(Fig. 6.7, top and middle graphs, blue lines). A similar type of kinetics has been 
described for immediate early response genes in LPS-stimulated fibroblasts 
(Drobic et al., 2010).  
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Figure 6.7: MSK1 and Aurora B rapidly exchange at active promoters following LPS 
stimulation of resting B cells.  
The binding dynamics of exchange of MSK1 (blue line) and Aurora B (red line) were measured on 
the promoters of Fcrl1 (top panel), Mapbpip (middle panel) and Gba (bottom panel). Naive resting 
B cells were freshly purified from the spleen of adult (6-8 weeks old) mice analysed at 0, 30, 60 
and 120 minutes after the addition to the culture of 25 µg/ml LPS as an activating stimulus. 
Binding is expressed as enrichment relative to input DNA using the same amount of DNA in the 
PCR (see section 2.4.3). Error bars represent the standard deviation of the mean (n=3 biological 
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replicates for both MSK1 and Aurora B). 
 
Aurora B shows, instead, a slower but progressive removal up to 120 
minutes after stimulation when its association with chromatin has been almost 
completely lost (Fig. 6.7, red line). This pattern of exchange between the two 
kinases is observed on the promoter of Gba, although at a slower pace (Fig. 6.7, 
bottom chart). MSK1 binding becomes apparent only after 120 minutes of 
activation (blue line), whereas Aurora B is removed from the promoter after 60 
minutes (red line). In summary, MSK1 rapidly replaces Aurora B at active 
promoters following activation suggesting that Aurora B plays a role in gene 
regulation in the quiescent state and then switches to its canonical role in 
regulating mitosis in activated, proliferating cells. 
6.3.2 MSK1 recruitment following stimulation with LPS is independent of 
the presence of Aurora B 
Since Aurora B cKO cells respond normally to LPS stimulation, it is possible 
that gene activation programmes are not compromised by the loss of Aurora B. 
This includes the activation of ERK/MAPK pathway and, ultimately, the binding of 
MSK1 to promoters. To test this idea, I performed ChIP experiments to quantify 
the binding of MSK1 to active genes following the knockout of Aurora B and, 
subsequently, a 14-hour stimulation with LPS (Fig. 6.8). MSK1 binding is not 
abolished by the prior knockout of Aurora B, although the levels appear to be 
halved in the case of b-Actin and Mapbpip. The fact that binding of MSK1 
following B cell activation is not lost in the genes analysed indicates that cKO are 
still able to respond to LPS stimulation via the ERK/MAPK signalling pathway.  
This could provide a partial explanation for why Aurora B cKO B cells activate 
normally despite their reduced transcription of active genes and reduced viability. 
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Figure 6.8: LPS-induced binding of MSK1 to promoters is not compromised in resting B 
cells where Aurora B as been previously knocked out.  
Homozygous Cre-ERT2  (WT, blue bars) and homozygous Cre-ERT2/Aurkb floxed allele (Aurb KO, 
red bars) resting B cells were treated for 48 hours with 4-OHT to knock out Aurora B and then 
stimulated for 14 hours with LPS. Binding of MSK1 was measured in both cell types as a measure 
of the responsiveness of the cells to T-independent activation. The binding of MSK1 is expressed 
as enrichment relative to input DNA using the same amount of DNA in the PCR (see section 
2.4.3). A dashed line indicates the threshold value of enrichment above which a protein is 
considered to be bound. Background levels (DNA immunoprecipitated with an anti-IgG antibody) 
are shown as white bars where detected. Error bars represent the standard deviation of the mean 
(n=2 biological replicates). 
6.4 Summary 
The conditional KO of Aurora B is associated with a stronger reduction of 
the H3S28ph histone mark at active rather than silent promoters in resting B 
cells. This modification could be involved in enhancing the levels of S5p Pol II at 
active promoters. In Aurora B conditional knockout cells, the loss of H3S28ph is 
not accompanied by PRC2-mediated trimethylation of H3K27. However, upon 
loss of Aurora B, PRC1-mediated monoubiquitination of histone H2A is observed 
on target genes and USP16 binding is substantially reduced. The increase in the 
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levels of H2Aubq does not depend on an increased binding of Ring1B or Bmi1, 
No change in Cbx7 binding is observed in Aurora B knockout cells, suggesting 
that the composition of the PRC1 complex on active promoters is unaffected.  
MSK1 replaces Aurora B on active promoters in G1-elutriated, LPS-
activated B cells. The rapid kinetics of the substitution following LPS stimulation 
indicates that it precedes cell cycle re-entry and Aurora B commitment towards 
its role as a mitotic regulator. Aurora B does not seem to regulate B cell 
activation, as its knockout does not impair the binding of MSK1 to promoters 
following stimulation. 
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Chapter 7 - Discussion 
7.1 Aurora B and Ring1B as new players in the quiescence programme 
Cellular quiescence requires a specific transcriptional programme that 
allows the cells to reduce its size and metabolic activity and, at the same time, to 
rapidly resume proliferation upon stimulation. In the mammalian immune system, 
quiescence ensures that an adequate response will be triggered against virtually 
any pathogen, without compromising the energy balance of the organism. 
Quiescent mature B and T cells can remain in this condition throughout their 
lifespan, unless they encounter the specific antigen that can trigger their 
activation. This makes the study of how these cells regulate the expression of 
their genes of particular interest for understanding the correct functioning of the 
immune system and the pathogenesis of leukaemias and autoimmune disease. 
Several transcription factors have been shown to regulate the expression of 
genes that mediate the acquisition and maintenance of a quiescent state in 
mature B and T cells. This study has uncovered previously unknown roles for 
Aurora B and Ring1B in this context. These proteins bind to a high proportion of 
active genes, particularly the highly transcribed ones. The knockout of either 
protein results in a dramatic reduction of RNA Pol II bound to most of the active 
genes. This in turn leads to downregulation of a large proportion of active genes 
and a reduced viability. Some of this effect could be due to downregulation of 
expression of RNA Polymerase subunits, but the widespread binding of Aurora B 
and Ring1B suggest that a large part of it is direct.  
Despite the strong effects on RNA Pol II binding and transcription, our initial 
experiments indicate that B cell activation is not blocked in either of the two 
knockouts. These results suggest that Aurora B and Ring1B are recruited to 
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promoters in order to maintain expression of proteins that are necessary for the 
viability of mature lymphocytes in the resting state. The implication is that Aurora 
B and Ring1B are necessary for the maintenance of active transcription within 
the quiescent state but not for the early response to activation stimuli and exit 
from quiescence. 
The association of Aurora B with regulatory elements in quiescent cells is 
lost following B cell activation and cell cycle re-entry. This suggests that Aurora B 
has different functions depending on the context, with the kinase acting as a 
transcriptional co-activator in quiescent lymphocytes and as a cell cycle regulator 
in activated cells. Ring1B, on the other hand, remains bound to active promoters 
in G1 activated B cells. Despite this difference, Aurora B and Ring1B show a 
remarkable functional interdependence in quiescent lymphocytes. On the one 
hand Ring1B promotes expression of Aurora B in resting B cells and, on the 
other, Aurora B regulates the activity of Ring1B as an E3 ligase by blocking the 
activity of the associated E2 ligase. These results suggest a model where Aurora 
B converts Ring1B from a repressor (histone H2A monoubiquitinating enzyme) 
into an activator (promoting the recruitment of RNA Pol II) (Fig. 7.1).  
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Figure 7.1: Model to explain the role of Aurora B and Ring1B in resting B cells.  
Based on the results presented in Chapters 3 – 6, the model proposes that Aurora B operates 
downstream of signalling pathways that ensure the viability and responsiveness of resting 
lymphocytes. Aurora B promotes the phosphorylation of serine 28 on histone H3 and of USP16, 
which, in this form, can bind to chromatin and exert its deubiquitinating function. Ring1B, Cbx7 
and Bmi1 would be recruited by transcription factors (TF1 and TF2) and promote the formation of 
the pre-initiation complex at promoters. The H3S28ph mark would also act as a recognition signal 
that promotes recruitment of the PIC. 
 
An important question is whether Aurora B and Ring1B play a role in 
enhancing the transcription of key genes in other quiescent cell types. 
Preliminary experiments did not detect Aurora B or Ring1B on active promoters 
in serum-starved fibroblasts. This could imply that their role as transcriptional 
activators is a unique feature of resting lymphocytes. However, serum starvation 
is only one type of in-vitro induced quiescence. Therefore, before drawing any 
conclusion on the generality of the mechanisms identified in this study, it will be 
necessary to test other cell types where quiescence is actively induced as part of 
the developmental programme, rather than an adaptive response to lack of 
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nutrients or mitogens (serum starvation) 
To date, Aurora B has been shown to promote transcription only of thyroid 
hormone-inducible genes in pituitary cells via the deposition of the H3S10ph 
mark. Ring1B is, on the other hand, a widely studied histone modifier that 
promotes silencing, but this study presents evidence that it can function as a 
transcriptional activator in quiescent lymphocytes. Whether this behaviour occurs 
in other cell types is a question left unanswered by this study. Bmi1 and Suz12 
have been shown to respectively promote and restrict HSC/progenitor functions 
(Majewski et al., 2010), raising the interesting possibility that PcG proteins have 
different functions and regulatory roles in different cell types and that the 
haematopoietic system in particular might represent an exception to the 
canonical role of PRC1 as a repressor. 
7.2 Two new functions for Aurora B in transcriptional regulation outside 
mitosis 
7.2.1 Aurora B phosphorylates serine 28 on histone H3 in quiescent B cells 
The results presented in this thesis provide evidence that Aurora B 
promotes transcription via two mechanisms in resting B cells: through 
phosphorylation of serine 28 on histone H3 and regulation of H2A ubiquitination 
(Fig. 7.1). The H3S28ph mark is being increasingly linked to transcriptional 
activation because of its antagonistic effect on PRC2-mediated silencing, its 
binding affinity for 14-3-3 proteins and its physical colocalization with S5p Pol II. 
Several kinases activate transcription via this mechanism and, for example, 
MSK1 promotes the transcription of target genes by depositing the H3S28ph 
mark upon stimulation with mitogens, such as LPS. My results show that MSK1 
substitutes for Aurora B following LPS-driven stimulation of resting B cells, where 
Aurora B no longer binds to the active promoters that I have analysed. It is 
possible that, following cell cycle re-entry, Aurora B no longer functions as a 
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transcriptional regulator and that other kinases take over this role. Similarly, upon 
cell cycle exit and engagement of the quiescent programme, Aurora B 
phosphorylates histone H3, a function known to be carried out by this protein at 
the onset of mitosis. In this respect, an interesting observation from the genome-
wide ChIP analysis is that Aurora B specifically binds to promoters and 
enhancers in resting B cells, whereas at the onset of mitotsis, it spreads all over 
the chromosome arms. An important question is what mediates the contrasting 
distribution and function of histone phosphorylation in interphase and mitosis. In 
the case of Aurora B, the answer might be in the different protein interactors in 
the two stages, as this is also what determines the different localizations and 
targets of Aurora B during mitosis. In this respect, my SILAC-based screening of 
Aurora B might prove useful, with different transcription factors (such as YY1, the 
Forkhead proteins and members of the CCR4-not complex) being identified as 
potential G1-partners. Additional work in the group has validated the CCR4-Not 
complex member Cnot3 as a genuine interactor with Aurora B, both in vitro  and 
in resting and activated B cells (M. Martufi and M. Roman-Trufero, personal 
communication)  
7.2.2 Aurora B negatively regulates the levels of monoubiquitination of 
histone H2A in quiescent B cells 
A second function for Aurora B uncovered by this study is the indirect 
control of the levels of the repressive H2Aubq mark at promoters. The ablation of 
Aurora B by conditional knockout coincides with an increase in the levels of H2A 
ubiquitination, although the levels of PRC1 binding do not change. This, in turn, 
points to a role for Aurora B in regulating the ubiquitinating activity rather than in 
the recruitment of PRC1 to promoters (Fig. 7.1). The binding of Aurora B to 
mitotic chromosomes requires H2A deubiquitination by USP16 and ChIP-seq 
analysis has revealed a high degree of overlap of Aurora B and USP16 at target 
genes in resting B cells. Indeed, the two proteins exhibit a remarkable similarity in 
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their binding to chromatin, as the levels of USP16 at promoters decrease 
dramatically following the knockout or the displacement of Aurora B in LPS-
activated cells. 
The evidence suggests that USP16, like Aurora B, changes its functions 
following cell cycle exit and binds to the promoters of highly transcribed genes 
following cell cycle exit. The association of USP16 with chromatin and its 
deubiquitinase activity are dependent on USP16 phosphorylation. Cdk1 has been 
shown to be able to generate this modification on USP-16 in-vitro. However, the 
only identified phosphorylation site on USP16 in-vivo is an Aurora B consensus 
site (Zanivan et al., 2008) and in-vitro data generated in our group shows that 
Aurora B can phosphorylate USP16 and, in turn, promote its histone 
deubiquitinase activity (Dr. Monica Roman-Trufero, personal communication). 
Moreover, in-vivo data produced by Dr. Monica Roman-Trufero shows that 
Aurora B phosphorylates the E2 ligase responsible for Ring1B-mediated 
monoubiquitination of histone H2A (UbcH5c). This phosphorylation reduces the 
E3 activity of Ring1B towards nucleosomal substrates in vitro. 
7.3 Interaction of Aurora B and Ring1B in quiescent and activated 
lymphocytes 
The analysis of the Aurora B interactome in G1-elutriated, LPS-activated B 
cells shows that Aurora B interacts with proteins implicated in gene regulation, 
developmental processes and chromatin organization such as Ring1B. The 
interaction with Ring1B has been validated in this cell type and in transfected 
293T cells by direct Co-IP and western blot. However, the ChIP data indicates 
that Aurora B and Ring1B physically co-occupy the same promoters in resting but 
not G1-elutriated, LPS-activated B cells. The Aurora B-Ring1B interaction 
detected in the co-IP experiments might occur in the soluble portion of the 
nucleus or cytoplasm or, alternatively, at an untested subset of genes where 
  235 
Aurora B and Ring1B bind in interphase. Unfortunately, the low amount of DNA 
recovered in ChIP experiments of Aurora B in G1-elutriated cells has meant that 
it was not possible to test this hypothesis. Nevertheless, the possibility cannot be 
formally ruled out that Aurora B is still affecting the E3 ligase activity of Ring1B at 
some target genes in activated B cells. It is possible that Aurora B no longer 
binds directly to chromatin in G1-elutriated, LPS-activated cells as it no longer 
phosphorylates histone H3 and that, as a result, it cannot be immunoprecipitated 
by ChIP because its interaction with Ring1B is too dynamic. 
A further consideration is the fact that even in activated cells, the presence 
of Ring1B on promoters does not correlate with acquisition of the H2Aubq mark 
on promoters or on repression. Ring1B-bound genes exhibit a transcriptional 
increase following activation and, therefore, it is possible that Aurora B is still 
preventing Ring1B from ubiquitinating histone H2A via phosphorylation of the E2 
ligase or the recruitment of a histone deubiquitinase. The genome-wide 
distribution of USP16 in resting B cells closely resemble that of Aurora B and 
several USP proteins were detected in my SILAC analysis of the Aurora B G1-
interactome: USP 7, 34, 47 and 48. USP7, in particular, represents an interesting 
candidate as its knockout results in the derepression of Polycomb regulated 
genes (Maertens et al., 2010) and it deubiquitinates Ring1B, effectively stabilizing 
but also depriving it of its E3 ligase function (de Bie et al., 2010). The histone 
H2A deubiquitinase MYSM1, in addition, has been shown to play a key role in B 
cell development by preventing the ubiquitination and repression of key target 
genes such as Ebf1 and Pax5 (Jiang et al., 2011). This makes MYSM1 a 
potential candidate for a role as a transcriptional regulator in activated B cells 
through deubiquitination of histone H2A.  
7.4 Ring1B promotes transcription in quiescent mature lymphocytes 
The observation that conditional knockout of Ring1B results in a global 
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reduction of the levels of unphosphorylated RNA Pol II recruited at active 
promoters and strongly reduces transcription is not easily reconciled with the 
known role of Ring1B as a transcriptional repressor. Independently of the 
composition of the complex it belongs to, Ring1B has generally been considered 
to act as a silencer (Wang et al., 2004) and knockout of the gene in ES cells 
leads to derepression of its target genes (Endoh et al., 2008). Recently, however, 
the paradigm of PRC1 and PRC2 being exclusively repressive co-factors is 
starting to be undermined. For instance, ChIP experiments have shown that 
PRC1 and PRC2 bind to the promoters of active genes in T helper cells and that 
their knockdown leads to transcriptional repression (Jacob et al., 2011). 
Moreover, in megakaryocytes and thymocytes, Ring1B is recruited to target 
genes by the transcriptional factors Runx1 and CBF and its knockdown results in 
the upregulation of 152 and downregulation of 345 genes (Yu et al., 2012). It is 
becoming increasingly accepted that Polycomb-repression represents a middle-
ground between complete repression and the transcriptionally active state. In ES 
cells, although Polycomb-repressed genes show very low but detectable 
transcriptional activity, they have the S5p form of RNA Pol II bound at their 
promoters, where it is thought to be poised to initiate productive transcription 
upon stimulation of the appropriate developmental pathway (Brookes et al., 
2012). The promoters of such genes are different from other silent genes, such 
as those marked by H3K9me3, which are usually found at particularly compacted 
regions. 
Studies in Drosophila have also shown that Polycomb blocks transcriptional 
initiation but does not impair recruitment of RNA Pol II to Polycomb-repressed 
genes by the pre-initiation complex (Dellino et al., 2004). In light of these 
observations, it is possible to speculate that Ring1B might be able promote 
recruitment of RNA Pol II to the genes to which it binds, independently of the 
transcriptional status (active or poised/silenced) of the gene.  
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These findings lead us to propose a model where Ring1B would exert its 
RNA Pol II recruitment function independently of its E3-ligase activity in quiescent 
lymphocytes, because Aurora B prevents the deposition of H2Aubq on active 
promoters in these cells (Fig. 7.1). In Aurora B cKO cells, Ring1B operates as a 
transcriptional repressor by monoubiquitinating histone H2A, in the absence of 
Aurora B and USP16 (Fig. 7.1). This would, in turn, poise the gene but, at the 
same time, keep it silenced. It is possible that Ring1B is involved in recruiting 
RNA Pol II in both quiescent and activated lymphocytes, which would explain 
why it is retained on promoters following cell cycle re-entry. Testing of this 
hypothesis and identification of molecular mechanisms and partners that mediate 
such a function will require further investigation.  
7.5 PRC1 and PRC2 display opposite localizations in quiescent 
lymphocytes 
Several papers have now presented experimental evidence for a PRC2-
independent recruitment of PRC1 to promoters. The analysis of the genome-wide 
distribution of Ring1B and H3K27me3 presented in this thesis provides another 
example of this phenomenon. One possible mechanism for the recruitment of 
PRC1 in the absence of PRC2 is through the binding of transcription factors. In 
this respect, YY1 and RYBP would represent good candidates. RYBP has been 
shown to permit the recruitment of PRC1 to Polycomb repressed genes in the 
Eed KO ES cells (Tavares et al., 2012). However, attempts at co-
immunoprecipitating YY1 with RYBP-containing  PRC1 complexes have so far 
proved unsuccessful (Gao et al., 2012) and (Tavares et al., 2012). Interestingly, 
the transcription factors Runx1 and CBF have been shown to associate with 
Ring1B and Bmi1 at active promoters.  However, because of the large number of 
promoters bound by Ring1B in quiescent B cells, it is difficult to imagine a single 
transcription factor promoting the binding of a protein to so many different genes.  
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 Experiments in the Aurora B cKO mouse show no involvement of this 
kinase in the recruitment of PRC1 to promoters, as the level of Ring1B binding 
(together with those of Cbx7 and Bmi1) are largely unaffected by the knockout. 
Cbx7 has been shown to interact with the ANRIL ncRNA and participates in 
repression of the INK4b/ARF/INK4a locus  and its binding is reduced when 
transcription is reduced by treatment with -amanitin (Yap et al., 2010). It is 
possible to speculate that Cbx7 recognizes short ncRNAs originating around the 
TSS of active genes and, in turn, recruits PRC1 to their promoter, in a fashion 
similar to what has been reported for Suz12 and PRC2 recruitment (Kanhere et 
al., 2010).  The determination of whether RNAs play a role in the recruitment of 
PRC1 to active promoters or whether PRC1 binding is a pre-requisite for 
transcription will require further study. 
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Appendix A 
 
Genome-wide distribution of Aurora B, Ring1B and other components of the 
transcriptional network operating in naïve B cells 
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reproduce 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reproduce 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